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The NOW Trial: A Pragmatic Randomized Controlled Trial of
Personalized, Genetic-Based Lifestyle Advice

Abstract
Background: The impact of nutrigenomics and lifestyle genomics interventions on health
outcomes and behaviours remains controversial and under-explored.
Objectives: To determine the short-term (3-month), moderate-term (6-month) and long-term
(12-month) impact of providing personalized, genetic-based lifestyle information and advice on
anthropometric measures, as well as dietary intake and adherence.
Methods: The nutrigenomics, overweight/obesity and weight management trial (NOW Trial) is a
pragmatic randomized controlled trial that was incorporated into the Group Lifestyle Balance™
(GLB) program (N=140). Inclusion criteria: overweight or obesity (BMI ≥ 25 kg/m2), ≥ 18 years
of age, English-speaking, having access to internet at least one day per week, willing to undergo
genetic testing, and not seeing another healthcare provider outside of the study for weight-loss
advice. Exclusion criteria: Pregnancy and lactation. Twelve-month GLB weight management
program groups were randomized 1:1 to receive either the standard GLB program or a modified
nutrigenomics-based GLB program (GLB+NGx). Data collection occurred at baseline, 3-, 6- and
12-month follow-up. The predetermined primary outcome was change in body fat percentage
(BFP). Dietary intake and adherence were secondary outcome measures.
Statistical Analysis: Statistical tests conducted using SPSS (version 26.0) included: repeated
measures analyses of variance (ANOVAs), split-plot ANOVAs, two-way ANOVAs, chi-square
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and Fisher’s exact tests and logistic regression. Key components of the Theory of Planned
Behaviour were considered in the dietary intake analyses.
Results: After 3- and 6-month follow-up, the GLB+NGx group improved (reduced) their BFP to
a significantly greater extent (p<0.05) than the standard GLB group. There were no statistically
significant differences in BFP between groups after 12 months. Furthermore, the GLB+NGx
group significantly reduced their total fat intake after 12 months; the standard GLB group did
not. Dietary adherence to saturated fat and total fat recommendations were significantly (p<0.05)
greater in the GLB+NGx group compared to the standard GLB group at 12 months.
Conclusion: Genetically-tailored lifestyle advice can lead to improvements in body composition
over the short-term and moderate-term, and motivate long-term dietary changes and adherence to
nutrition recommendations. Biological mechanisms may challenge long-term weight loss, even
with genetically-tailored advice that motivates long-term dietary changes.

Keywords: nutrigenomics, nutritional genomics, nutrigenetics, lifestyle genomics, genetics,
nutrition, overweight, obesity, Theory of Planned Behaviour, Theory of Planned Behavior
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Summary for Lay Audience
Nutrigenomics is a science that explores how our genes impact the way our bodies respond to the
foods, beverages and nutrients we consume. For example, one person may lose more weight by
following a lower saturated fat nutrition plan compared to someone else. Nutrigenomics can be
used to provide more personalized nutrition advice. Some studies have shown that giving
personalized, genetic-based information and advice can help motivate individuals to make
dietary changes. Very few studies have assessed the effectiveness of nutrigenomics-based weight
loss interventions. Therefore, the studies included in this dissertation aimed to build upon past
research and provide new insights into whether providing people with genetic-based lifestyle
advice results in improvements in dietary intake, weight and body fat. To study this, we
randomly assigned people to receive either standard advice for weight management or geneticbased advice for weight management and then followed up with them after 3, 6 and 12 months.
The study participants also participated in a 12-month intervention. Overall, people who received
the genetic-based advice experienced a decrease in body fat, more so than the people who
received the standard advice after 3 and 6 months. After 12 months, there was no major
difference in body fat between these two groups. When we looked at changes to their nutritional
intake, people who received the genetic-based advice significantly reduced their overall intake of
dietary fat after 12 months, whereas those who received the standard advice did not.
Additionally, after 12 months, people who received the genetic-based advice better adhered to
the recommendations for total fat and saturated fat compared to those who received the standard
intervention. Overall, we found that nutrigenomics interventions can motivate long-term (12month) dietary changes and can lead to improvements in body fat over the short-term (3-month)
and moderate-term (6-month) to a greater extent than standard advice. Previous research shows
that over time, the body tries to compensate for weight loss with physiological mechanisms
promoting weight regain. This may help to explain why we found that after 12 months, the group
receiving the standard advice had lost a similar amount of body fat as the group receiving
genetic-based advice, despite the genetic intervention group improving their diet to a greater
extent.
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CHAPTER 1: INTRODUCTION

1

1.1 Introduction
Nutrigenomics is a science that seeks to explore interactions between genetic variation,
nutritional intake, and subsequent health outcomes (Gibney and Walsh 2013). The terms
nutrigenomics and nutritional genomics are often used interchangeably. Recently, the more
broad definition lifestyle genomics has been coined, which is used to describe the study of
interactions between genetic variation, lifestyle habits (such as nutrition, physical activity,
smoking, etc.) and subsequent health and disease outcomes (Karger 2019). Table 1.1 provides an
overview of key terms and definitions which appear throughout this dissertation and are related
to the field of genetics.
Table 1.1: Key terms and definitions
Term
Gene

Variant (Genotype)

SNP

Allele
rs#
Linkage
Disequilibrium

Nutrigenomics
(Nutritional
Genomics,
Nutrigenetics)
Lifestyle Genomics

Definition
A section of DNA, which forms part of the chromosome. It is the
functional unit of heredity. Everyone has the same genes, but
individuals differ in their genetic variants (see definition below).
A set of two alleles, typically making a single nucleotide
polymorphism (SNP) (e.g. a “TT” variant/genotype).
Variants/genotypes can also exist in the form of copy number variants.
When one allele is replaced by a different allele (e.g. a “T” replacing
an “A”). This is the most common type of variation within the genetic
code.
One of two variant forms of a genotype (e.g. a “T” allele).
A number used to identify a specific location on a gene. The letters
“rs” stand for Reference SNP.
The association between alleles in different locations on the genome,
whereby having a specific genetic variant at one location, predicts a
strong likelihood of having a certain genetic variant at another, nearby
genetic location.
Terms used to describe the study of the interaction between genetic
variation, nutritional intake, and subsequent health outcomes.

The study of the interaction between genetic variation, lifestyle habits
(e.g. physical activity, sleep, smoking, nutrition, etc.), and subsequent
health outcomes.
2

From a weight management perspective, lifestyle genomics and nutrigenomics help to
explain why some individuals lose more weight or improve their body composition to a greater
extent than others, even when they are following the same nutrition and physical activity plan.

1.2 Research Purpose, Objectives and Hypotheses
The overarching aim of this dissertation is to provide new insights into whether providing
people with genetic-based nutrition advice can improve nutrition- and health-related outcomes.
Overall, it is hypothesized that when patients enrolled in a genetically-tailored weight
management program receive genetic-based lifestyle information and advice, this will reduce
weight and positively impact body composition, dietary intake, and dietary adherence to a
greater extent than population-based lifestyle information and advice over the short-term (3
months), moderate-term (6 months) and long-term (12 months).
Objectives:
•

To review and summarize the literature on the impact of providing genetic-based lifestyle
information and advice on weight-related outcomes and lifestyle changes

•

To determine if the provision of genetic-based lifestyle information and advice is more
effective than population-based lifestyle advice for improving: 1) anthropometric
measures [body fat percentage (BFP) as the predetermined primary outcome; weight and
BMI as predetermined secondary outcomes], 2) dietary intake, and 3) dietary adherence.

•

To compare the short-term (3 month), moderate-term (6 month) and long-term (12
month) impact of providing personalized lifestyle advice on: 1) anthropometric measures,
2) dietary intake, and 3) dietary adherence.

3

1.3 The Science of Nutrigenomics and Lifestyle Genomics
1.3.1 Background Information
There are numerous examples of gene-diet-health outcome interactions reported in the
literature (Zhang et al. 2012; Grau et al. 2010; Corella et al. 2009; Cornelis et al. 2006). At the
same time, consumer interest in nutrigenetic testing continues to grow. In response, genetic
testing companies now offer several different nutrigenetic and lifestyle genomics tests to
consumers. While systematically reviewing the quality of the evidence to support the
information included in commercially available consumer nutrigenetic tests is beyond the scope
of this dissertation, a brief summary of nutrigenomics and lifestyle genomics interactions
relevant to the present dissertation is provided below. Details on how this science can be
translated and incorporated into clinical practice is further outlined in Chapter 5 (section 5.4.12
and Supplementary Table 5.4).
1.3.2 Nutrigenomics and Lifestyle Genomics Examples
Genetic-based information and/or recommendations which are related to weight
management can be provided to patients for: calories, protein, total fat, monounsaturated fat,
polyunsaturated fat, saturated fat, appetite, and physical activity. The goal of providing these
personalized lifestyle recommendations and information is to motivate health behaviour change
and/or optimize health outcomes by providing advice that is tailored towards the individual. As
such, several consumer genetic testing services offer information related to one or more of these
gene-nutrient interactions (Nutrigenomix 2019; Athletigen 2018; MyDNA 2019). Genes
included in these consumer tests include, but are not limited to: UCP1, FTO, TCF7L2, APOA2,
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PPARγ2, MC4R, ADRB3, NRF2, GSTP1, NFIA-AS2 and ACTN3. Each of these will be further
discussed below.
UCP1 and Calories
The uncoupling protein 1 (UCP1) gene plays a role in separating oxidative
phosphorylation from ATP synthesis, while producing heat as a result of this metabolic process
(Gene Cards n.d.). This particular gene is expressed almost exclusively in brown adipose tissue,
which is more metabolically active than white adipose tissue (Jorge et al. 2017). Research has
demonstrated that individuals with GG or GA genotype at UCP1 rs1800592 have lower
metabolic rates than those with the AA genotype (Nagai et al. 2011) and therefore calorie intake
can be targeted based on individual genetic variation. In addition, the presence of at least one G
allele has also been associated with obesity (Hayakawa et al. 1999; Heilbronn et al. 2000; Ramis
et al. 2004).
FTO and Protein
Common variants within the fat-mass and obesity-associated (FTO) gene have been
consistently linked to overweight and obesity whereby A allele carriers are at an increased risk of
obesity and obesity-related conditions (Yang et al. 2017). FTO genetic variation is associated
with differences in hunger/satiety and food intake, likely caused by FTO genetic variation
affecting leptin and ghrelin levels. There does not appear to be a link between resting energy
expenditure and FTO variation (Speakman 2015). In terms of weight loss, results from a 2-year
randomized controlled trial (RCT) demonstrated that individuals with the risk allele of FTO
rs1558902 (in strong linkage disequilibrium with rs9939609) had greater improvements in body
composition and greater weight loss when following a higher protein diet (25% of calories from
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protein) (Zhang et al. 2012). This protective effect of protein intake on obesity in high-risk FTO
genotypes was recently replicated in a cross-sectional study (Merritt et al. 2018).
TCF7L2 and Total Fat
Transcription factor 7 like 2 (TCF7L2) plays an important role in the synthesis of
glucagon-like peptide 1, which contributes to body weight via appetite, adipose tissue
metabolism and insulin signalling (Flint et al. 1998; Verdich et al. 2001; Azuma et al. 2008;
Boschmann et al. 2009; Gao et al. 2007). The release of glucagon-like peptide 1 is stimulated
differently by fat and carbohydrate whereby there is a greater release after ingesting dietary fat,
therefore altering intakes in these dietary components could impact weight-loss response (Eller et
al. 2008; Paniagua et al. 2007). Results from a 2-year RCT found that consuming a diet lower in
total fat (20% of calories) can reduce body adiposity in those with high-risk genetic variants in
TCF7L2 rs12255372 (Mattei et al. 2012) [in strong LD with rs7903146 in some ethnicities
(Humphries et al. 2006)]. Another RCT demonstrated the effectiveness of following a dietary
pattern low in total fat (20-25% of calories) for weight loss in individuals with the TT genotype
of TCF7L2 rs7903146 (Grau et al. 2010).
APOA2 and Saturated Fat
Apolipoprotein A-II (APOA2) is a major component of high-density lipoprotein particles
and regulates both triglyceride and postprandial metabolism (Delgado-Lista et al. 2018; Julve et
al. 2010). There is an association between APOA2 genetic variation, saturated fat intake, and
obesity. Individuals who carry the CC variant of the APOA2 gene (rs5082) are at an increased
risk of obesity when their intake of saturated fat is high. Consuming a diet low in saturated fat
(<22 g per day) is associated with a lower body mass index (BMI) in individuals with the risk
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variant (Corella et al. 2010; Corella et al. 2011). While the mechanism for this nutrigenomics
interaction is not well-understood, individuals with the CC variant of APOA2 (rs5082) have
demonstrated low ghrelin levels when consuming a low saturated fat diet, thus demonstrating a
proposed mechanism for the association between saturated fat intake, obesity, and APOA2
genetic variation via regulation of a hormone involved in hunger signalling (Smith et al. 2012).
FTO, Saturated and Unsaturated Fat
As indicated above, FTO genetic variation is linked to risk of obesity and obesity-related
conditions (Yang et al. 2017), likely due to the effects on leptin and ghrelin levels leading to
differences in hunger/satiety and food intake (Speakman 2015). FTO genetic variation at
rs9939609 impacts individual responses to dietary unsaturated fat intake whereby a diet high in
saturated fat (≥15.5% of calories) and low in polyunsaturated fat (polyunsaturated fat: saturated
fat ratio <0.38) accentuates the risk of obesity (Phillips et al. 2012). Another study found that A
allele carriers following a hypocaloric diet high in polyunsaturated fat (6% of calories; 7 grams
omega-6; 2 grams omega-3 per day) had a lower BMI, weight and fat mass compared to
individuals with TT genotypes following the same dietary pattern (De Luis et al. 2015).
PPARγ2 and Monounsaturated Fat
The peroxisome proliferator-activated receptor gamma 2 (PPARγ2) plays an important
role in regulating adipogenesis – a process in which pre-adipocytes become adipocytes (fat cells,
which make up adipose tissue) (Memisoglu et al. 2003). Memisoglu et al. (2003) were the first to
discover an interaction between PPARγ2 genetic variation, monounsaturated fat intake, and body
mass index BMI (Memisoglu et al. 2003). Later research discovered that a higher intake of
monounsaturated fat (comprising approximately 50% of total fat) was associated with
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significantly lower body fat and BMI in individuals with high risk genotypes of PPARγ2
(Garaulet et al. 2011).
ACE and Sodium
The angiotensin-converting enzyme (ACE) is part of the renin-angiotensin-aldosterone
system (RAAS), which plays a role in blood pressure regulation. Within the RAAS system, ACE
is responsible for cleaving angiotensin I to form angiotensin II (Lifton 1996). It is postulated that
salt-sensitive individuals experience a blunted RAAS response to high dietary sodium, thus
increasing the risk of salt-sensitive hypertension (Poch et al. 2007). Salt-sensitive hypertension
can be measured by monitoring ambulatory blood pressure following high sodium intake.
Research demonstrates that individuals with high-risk genetic variants in the ACE gene are more
prone to high blood pressure when consuming a high intake of sodium (approximately 2300 mg
daily). Those with low-risk genetic variants are less likely to present with high blood pressure in
response to a high sodium intake (Poch et al. 2007; Giner et al. 2012).
MC4R and Snacking (Appetite)
Individual genetic variation can also have an impact on eating behaviours. The
melanocortin 4 receptor (MC4R) gene codes for a receptor found in the hypothalamus region of
the brain where hunger and appetite are controlled (Adan et al. 2006). Studies have demonstrated
that individuals with the CC or CT variant (C allele carriers) of MC4R (rs17782313) are more
likely to eat more frequently during the day and have an intensified appetite (Stutzmann et al.
2009). On the contrary, those with the TT variant are less likely to eat frequently through the day
(Stutzmann et al. 2009). Research further demonstrates that individuals with the CC or CT
variant at rs17782313 of the MC4R gene are more likely to be overweight/obese (Srivastava et
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al. 2014; Loos et al. 2008; Zobel et al. 2009). MC4R variants have also been linked to higher
intakes of calories and fat, binge eating, excessive hunger, hyperphagia, and food-seeking
behaviours (Adan et al. 2006; Qi et al. 2008; Branson et al. 2003).
FTO and Physical Activity
While dietary strategies exist to mitigate obesity-risk associated with FTO genetic
variation, it has also been well-established that physical activity can attenuate the obesityassociated effects in high risk FTO genotypes. Numerous studies have demonstrated this
association and results from the current body of literature have been highly consistent (Sonestedt
et al. 2011; Q. Yang et al. 2017; Celis-Morales et al. 2016; Andreasen et al. 2008; Zou et al.
2015; Speakman 2015; Corella et al. 2012; Lee et al. 2010; Kilpeläinen et al. 2011; Sonestedt et
al. 2009; Ahmad et al. 2010; Rampersaud et al. 2008; Vimaleswaran et al. 2009; Scott et al.
2010; Xi et al. 2011; Zhu et al. 2014). The attenuating effects of physical activity on FTO-related
overweight and obesity provide an example of a lifestyle genomics interaction.
ADRB3, NRF2, GSTP1, NFIA-AS2 and Endurance
Several genes have been demonstrated to impact genetic predisposition to excel at
endurance/aerobic-based activities. Studies have assessed associations between certain genetic
variants and elite endurance performance, running economy, maximal oxygen uptake, and
maximum ventilation. The following genes appear to play a significant role in this endurance
athletic predisposition: adrenergic receptor beta 3 (ADRB3), nuclear factor erythroid 2-related
factor 2 (NRF2), glutathione S-transferase pi 1 (GSTP1), and nuclear factor I A antisense RNA 2
(NFIA-AS2) (Santiago et al. 2011; He et al. 2007; Zarebska et al. 2014; Ahmetov et al. 2015).
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ACTN3 and Strength
The alpha-actinin-3 (ACTN3) gene encodes for a protein that is expressed almost
exclusively in type 2 (fast twitch) muscle fibres (North et al. 1999). The CC and TC genotypes in
the ACTN3 gene (rs1815739) have been significantly associated with speed and power
phenotypes across numerous studies (Ahmetov et al. 2011; Kikuchi et al. 2016; N. Yang et al.
2003; Ma et al. 2013; Eynon et al. 2009). As such, ACTN3 has been referred to as “a gene for
speed” (Pickering and Kiely 2017).
In summary, there are several lifestyle genomics interactions relevant to weight
management and available through consumer genetic testing services. It is plausible that
personalizing weight management strategies through genetically-guided nutrition and physical
activity advice could result in improved health-related outcomes.

1.4 Consumer Nutrigenetic and Lifestyle Genomics Testing
1.4.1 The Current State of the Canadian Industry
Canadians have expressed great interest in nutrigenetic testing (Nielsen et al. 2014;
Vallée Marcotte et al. 2019). With increasing scientific knowledge, coupled with significant
consumer interest in genetic testing for personalized nutrition, there are several companies
offering nutrigenetic testing services to consumers. Many of these companies offer information
and advice related to both physical activity and nutrition, based on the results of their genetic
test. Questions have been raised about the scientific validity and clinical utility of such tests,
given the lack of regulatory industry oversight (San-Cristobal et al. 2013; Grimaldi et al. 2017).
Indeed, there is variable scientific validity and clinical utility among currently available
consumer genetic tests, and this has led researchers to develop proposed guidelines to assess the
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scientific validity of such tests (Grimaldi et al. 2017). Overall, the current Canadian industry
allows for the widespread consumer availability of nutrigenetic and lifestyle genomics testing to
those willing and/or able to pay between approximately $90 - $450 CDN (23andMe n.d.;
MyDNA 2019; Pathway Genomics n.d.; Nutrigenomix Inc n.d.). Consumers can purchase such
tests via direct-to-consumer (DTC) services, or through a healthcare provider.

1.4.2 The Nutrigenetic and Lifestyle Genomics Testing Process
The complete nutrigenetic testing process moves from science through to consumers
(Horne et al. 2020). Scientific knowledge provides the basis for developing consumer genetic
tests and reports. Industry’s responsibilities include reviewing and interpreting science and
collaborating with genetic testing laboratories for the genetic analyses. Consumers provide a
saliva sample or buccal swab to the company [or to the healthcare provider (HCP) offering the
services], which is sent to the laboratory for analysis. In DTC genetic testing, the company sends
the genetic report directly to the consumer. When such testing is offered through a HCP, the
genetic testing company sends the genetic report to the HCP, who then sets up a meeting with the
patient to review their report. Notably, the vast majority of companies offer their genetic testing
services to consumers via DTC pathways; it is less common for a company to offer their services
exclusively through HCPs (Horne et al. 2020). It has been suggested that many ethical concerns
exist with DTC genetic testing (Trent 2013) and as such, offering genetic testing exclusively
through a HCP could be superior to DTC genetic testing. Because of widespread ethical
concerns, several American states have banned DTC genetic testing altogether (Hogarth et al.
2008). The process for genetic testing via DTC services and via a HCP are outlined in Figures
1.1 and 1.2, respectively.
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Figure 1.1: The DTC process for genetic testing
1.
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saliva sample
or buccal
swab

2.
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3.
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Company
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Figure 1.2: The process for genetic testing through a HCP
1.
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saliva sample
or buccal
swab with
HCP

2.

Sample sent
to lab

3.
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sample and
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company

4.
Company
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sends report
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5.

HCP reviews
the report
with patient

6.

Follow-up
booked as
needed

1.5 The Missing Link Between Science and Consumer Services
There is scientific evidence to support several gene-lifestyle-health outcome interactions
(Zhang et al. 2012; Stutzmann et al. 2009; Phillips et al. 2012; Yang et al. 2017; Corella et al.
2010; Grau et al. 2010; Ma et al. 2013). With advancing scientific knowledge, consumer genetic
testing companies are offering personalized nutrition and physical activity recommendations to
consumers. Given that consumers express great interest in DNA-based personalized nutrition
(Nielsen et al. 2014; Vallée Marcotte et al. 2019), and some studies demonstrate that patients are
more motivated to change health behaviours when they receive personalized, DNA-based dietary
advice (Vernarelli et al. 2010; Egglestone et al. 2013; Nielsen and El-Sohemy 2014; HietarantaLuoma et al. 2014; Kaufman et al. 2012), nutrigenomics and lifestyle genomics certainly warrant
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further investigation. To date, minimal research has assessed the impact of the pragmatic
incorporation of personalized, genetic-based weight management interventions in clinical
practice, yet such interventions are used by numerous HCPs globally. Furthermore, significant
methodological flaws limit the small body of knowledge that exists in this area; this is further
discussed in Chapter 4. More broadly, research on the effectiveness of the variety of consumer
lifestyle genomics tests available on the market is lacking. With respect to lifestyle changes
resulting from genetic testing, several studies have been conducted, but there has been minimal
consideration of established behaviour change theories within the existing body of literature
(Horne et al. 2018); Chapter 3 provides more detail on this. Thus, there are several important
research gaps to be filled in this niche area of personalized nutritional sciences and human
behaviour.

1.6 Outline of Dissertation
This dissertation is organized into an integrated manuscript format. As such, there may be
some repetition among the chapters. Additionally, abstract formatting varies throughout this
dissertation as each abstract style is specific to the journal that the manuscript was published in,
or that the manuscript was submitted to.

The purpose of this introductory chapter was to provide a brief overview of the science of
nutrigenomics and lifestyle genomics, including a review of genetic variants that were used on
the Nutrigenomics, Overweight/Obesity and Weight Management (NOW) trial intervention. An
overview of consumer nutrigenetic and lifestyle genomics testing was also presented. Moreover,
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this chapter introduced the overarching objectives and hypotheses of the present dissertation,
which are further detailed in later chapters.

Chapter 2 presents a call to action for personalized healthcare behaviour change
researchers to incorporate the Theory of Planned Behaviour (TPB) into their work. This chapter
additionally provides a thorough overview of the TPB and proposes a possible theoretical
expansion to include personalization in the model. This manuscript has been published in the
journal Personalized Medicine.

In Chapter 3, we systematically reviewed and summarized the current body of literature
on the impact of genetic testing on lifestyle behaviour change. This chapter further assesses the
quality of the genetic interventions provided to participants and whether researchers have
considered established theories of human behaviour in their work. This manuscript has been
published in the journal Lifestyle Genomics.

Chapter 4 critically reviews and summarizes the literature on the effectiveness of
pragmatic lifestyle genomics interventions on weight management. This manuscript has been
submitted for publication.

Following the literature review chapters, Chapter 5 provides a detailed overview of the
study design for the NOW trial, which builds on past research. This chapter has been published
in the journal BMC Public Health.
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The results chapters start with Chapter 6, which gives an overview of dietary change and
adherence in the NOW trial, and then moves to Chapter 7, which details the resulting weight and
body composition outcomes. Chapter 6 provides an analysis and summary of the dietary intake
and adherence results from the NOW trial, and is followed by Chapter 7, which provides an
analysis and summary of weight-related outcomes of the NOW trial. These chapters have been
submitted for publication.

Finally, Chapters 8 and 9 wrap up the dissertation with an integrated discussion and
conclusion on the key findings of the NOW trial. These chapters discuss how the NOW trial
findings relate to past work and how the results can be used to inform future research
endeavours.
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CHAPTER 2: THE THEORY OF PLANNED BEHAVIOUR AND
PERSONALIZED HEALTHCARE BEHAVIOUR CHANGE
RESEARCH
As published* in Personalized Medicine:
Horne J, Madill J, Gilliland J. 2017 “Incorporating the ‘Theory of Planned Behavior’ into
personalized healthcare behavior change research: A call to action.” Personalized Medicine
14(6): 521-29.
*Reference formatting, table numbers, spelling (Canadian) and figure numbers have been revised for consistency with the present
dissertation.
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2.1 Title: Incorporating the ‘Theory of Planned Behaviour’ into personalized
healthcare behaviour change research: A call to action
2.1.1 Abstract
The ‘Theory of Planned Behaviour’ (TPB) has been tested and validated in the scientific
literature across multiple disciplines and is arguably the most widely accepted theory among
behaviour change academics. Despite this widespread acceptability, the TPB has yet to be
incorporated into personalized healthcare behaviour change (PHBC) research. Several prominent
personalized healthcare researchers suggest that personalizing healthcare recommendations have
a positive impact on changes in lifestyle habits. However, research in this area has demonstrated
conflicting findings. We provide a scientific and theoretical basis to support a proposed
expansion of the TPB to include personalization and call to action personalized healthcare
behaviour change researchers to test this expansion. Specific recommendations for study designs
are included.

2.1.2 Background
The ‘Theory of Reasoned Action’, developed in the late 1960s, focused on attitudes and
subjective norms as key predictors of human behaviour. In 1991, Ajzen published a seminal text
in Organizational Behavior and Human Decision Processes where he proposed an important
expansion of Ajzen and Fishbein’s ‘Theory of Reasoned Action’ (Ajzen 1991). He coined this
new expanded theory, the ’Theory of Planned Behaviour’ (TPB; see Figure 2.2) (Ajzen 1991).

The TPB posits that there are three main factors contributing to one’s intention to
perform a behaviour, as well as the resulting actual behaviour. These three independent factors
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include: attitudes, subjective norms and perceived behavioural control (Figure 2.2). The reasoned
action approach (RAA) (Fishbein and Ajzen 2010) further breaks down these main categories
into more descriptive subcategories. Attitudes can be classified as either experiential attitudes or
instrumental attitudes. The former refers to affective attitudes such as pleasant–unpleasant,
whereas the latter refers to cognitive attitudes such as health–unhealthy (Mceachan et al. 2016).
Subjective norms refer to perceived social pressures to perform a behaviour, as well as the
individual’s weighting on the importance of the opinions of others, which leads to behavioural
intention through social reward/punishment. This is referred to as the subcategory of injunctive
norms. Descriptive norms is the second subcategory for this key construct, and simply refers to
the perceived behaviours of others (Mceachan et al. 2016). Perceived behavioural control refers
to the perceived extent to which an individual has access to the appropriate resources and
opportunities to perform a given behaviour and comprises the subcategories of capacity and
autonomy. Capacity refers to the perceived ease/difficulty of a given behaviour, whereas
autonomy refers to one’s perception of control over a given behaviour (Mceachan et al. 2016).
An individual’s intention (motivation) to perform a behaviour is central to the TPB and can be
influenced by these three independent factors and six related subcategories (Ajzen 1991;
Fishbein and Ajzen 2010; Mceachan et al. 2016). Overall, the TPB/RAA identifies key proximal
determinants of behaviour change, which should be considered in intervention studies aimed
toward assessing behaviour change.

Ajzen’s work has been distinguished as having the highest scientific impact score of all
Canadian and American social psychology research (Ajzen 2011). Meta-analyses have found that
the TPB can be used to predict behaviours from behavioural intention or perceived behavioural
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control with mean correlations ranging from 0.4 to 0.53 (Rivis and Sheeran 2003; Armitage and
Conner 2001). Meta-analyses have further found that attitudes, subjective norms and/or
perceived behavioural control can be used to predict intentions with mean multiple correlations
ranging from 0.59 to 0.66 (Rivis and Sheeran 2003; Armitage and Conner 2001; Cheung and
Chan 2000; McEachan et al. 2011; Notani 1998; Schulze and Wittmann 2003). Moreover, with
the exception of autonomy, all subcategories of the RAA (outlined above) were found to be
significant predictors of behavioural intention in recently completed regression analyses
(Mceachan et al. 2016). Meta-analyses of the TPB in relation to specific health-related
behaviours including alcohol consumption, diet, sexual health behaviours and treatment
adherence in chronic illness have also been recently conducted (Cooke et al. 2016; Andrew et al.
2016; Rich et al. 2015; Mcdermott et al. 2015). Notably, the vast majority of these meta-analyses
consistently demonstrated medium to large associations between the key constructs of the TPB
and behavioural intention as well as actual behaviour engagement, with the exception of
treatment adherence in chronic illness whereby intention-behaviour effect sizes were small
(Cooke et al. 2016; Andrew et al. 2016; Rich et al. 2015; Mcdermott et al. 2015). While the TPB
has proven to be a strong predictor of behaviour change, and is widely used by behaviour change
researchers, it is clear that there are other factors contributing to behaviour change that have not
yet been identified and validated within the context of this theory.

With recent advances in personalized healthcare technology, there has been a
considerable increase in research pertaining to personalization of healthcare information and
recommendations. Personalized healthcare, for the purposes of this paper, refers to healthcare
information and recommendations, based on an individual’s blood work results and/or individual
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genetic profile. Several prominent researchers in the field of personalized healthcare suggest that
individualizing lifestyle recommendations based on genetics or blood work could have a
favorable impact on motivation (behavioural intention) and behaviour change (Nielsen, Shih, and
El-Sohemy 2014; Nielsen and El-Sohemy 2014; Celis-Morales et al. 2015). To date, changes in
several behaviours have been studied in personalized healthcare research including alcohol,
nutrition, physical activity, smoking and health-screening behaviours (Nielsen and El-Sohemy
2014; Hendershot et al. 2010; Marsaux et al. 2016; Hishida et al. 2010; Bloss, Schork, and Topol
2011; Roke et al. 2017). Despite the widespread validation and acceptance of the TPB among
academics, the use of this theory in personalized healthcare research is lacking. Notably, a
PubMed search of ([‘Theory of Planned Behavior’ AND ‘personaliz*’ AND ‘health’] OR
[‘Theory of Planned Behavior’ AND ‘personalis*’ AND ‘health’] OR [‘Theory of Planned
Behaviour’ AND ’personaliz*’ AND ’health’] OR [‘Theory of Planned Behaviour’ AND
’personalis*’ AND ’health’]), conducted in April 2017 yielded only two results, neither of which
would be considered personalized healthcare research (Middlemass et al. 2012; Denison et al.
2015).

Based on the current state of knowledge pertaining to behaviour change and personalized
healthcare, this paper calls to action PHBC researchers for the incorporation of the TPB into
scientific research methods. Furthermore, this paper is the first of its kind to propose a potential
expansion of the TPB, based on personalization. It is recommended that this expansion be tested
in robust personalized healthcare research to determine if the TPB should be revised to
incorporate personalization as a significant predictor of behavioural intention and actual
behaviour, alongside attitudes, subjective norms and perceived behavioural control. In particular,
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within the TPB, it is hypothesized that personalization will have a significant impact on attitudes
and subjective norms (Figure 2.2).

2.1.3 Attitudes Towards Personalized Healthcare
Prior to delving further into PHBC research conducted to date, it is important to
understand the attitudes of healthcare professionals, students in post-secondary health programs
and consumers toward personalized healthcare, as these individuals will largely affect the uptake
and acceptability of personalized healthcare in society. Most studies assessing attitudes toward
personalized healthcare have focused on personalization based on genotyping.

A recent randomized clinical trial found that consumers had favorable attitudes toward
participating in genetic testing for personalized healthcare, and those who underwent genetic
testing were more likely to recommend it to friends and family (Kattel et al. 2017). Another
recent study found that ‘perceived personalization benefit’ played a larger role in consumers’
intention to utilize personalized nutrition services than ‘perceived personalization risk’
suggesting that attitudes toward personalized healthcare based on genetics were overall positive
(Berezowska et al. 2014). Additionally, a review article concluded that extensive research has
demonstrated consumers’ keen interest to undergo genetic testing for personalized healthcare
(Gibney and Walsh 2013). Given these findings, it is not surprising that significant economic
growth of genetic testing has been predicted (Vickery and Cotugna 2005).

For healthcare professionals and students in health programs (many of whom will
become healthcare professionals), attitudes have been variable with some expressing skepticism
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and others expressing more positive attitudes toward genetic testing (Bouwman, Molder, and
Hiddink 2009; Collins et al. 2013; Cormier et al. 2014; Horne, Madill, and O’Connor 2016).
Overall, the availability of genetic testing in clinical practice is growing rapidly (Downie,
Donoghue, and Stutterd 2017). With increasing uptake in clinical practice, the question of
whether or not personalized healthcare impacts behaviour change is an important one to consider
and is proving to be a priority area of research, with at least four review articles published on this
topic over the past year alone (O’Donovan et al. 2017; Li et al. 2016; Hollands et al. 2016;
French et al. 2017).

2.1.4 Current State of PHBC Research
Over the past decade, there has been a considerable amount of research conducted
examining the impact of providing personalized healthcare recommendations on motivation and
behaviour change. One of the largest projects currently underway is the ‘Food4Me’ project,
which commenced its research activities in 2011. ‘Food4Me’ is a EU funded, large-scale
research initiative, which aims to improve scientific knowledge pertaining to personalized
healthcare, including motivation and behaviour change resulting from the provision of
personalized nutrition and physical activity recommendations (Food4Me 2011). We reviewed the
29 peer-reviewed publications posted on the ‘Food4Me’ website (Food4Me n.d.) and found eight
unique articles pertaining to the impact of personalized nutrition and physical activity
recommendations on one or more of the following components of the TPB: attitudes and
behaviour (Berezowska et al. 2014; Marsaux et al. 2016; Fallaize et al. 2013; Marsaux et al.
2015; Poinhos et al. 2014; Stewart-Knox et al. 2013; Stewart-Knox et al. 2009). However, none
of the eight manuscripts specifically referred to the TPB, therefore, it is possible that one or more
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components of the TPB were included unintentionally. No study from the ‘Food4Me’ project
was designed based upon the TPB specifically.

Despite the lack of consideration of the TPB in the ‘Food4Me’ project and other
personalized healthcare research projects assessing behaviour change, several components of the
TPB can be found within PHBC research methods. Of the 29 articles published on the
‘Food4Me’ website, five studies assessed attitudes related to genetic testing and personalized
healthcare, which tended to be positive (Berezowska et al. 2014; Fallaize et al. 2013; Poinhos et
al. 2014; B. Stewart-Knox et al. 2013; Stewart-Knox et al. 2009). Two ‘Food4Me’ studies
analyzed behaviour change, and each article found no significant impact on behaviour change
with the provision of personalized healthcare reports and/or recommendations (Marsaux et al.
2016, 2015).While these studies did not find an impact on behaviour change, a recent
randomized controlled trial (RCT) found significantly greater reductions in sodium intake when
individuals were provided with personalized nutrition advice based on genetics, in comparison to
those who were provided with population-based health recommendations (Nielsen and ElSohemy 2014). Similarly, a study assessing changes in lifestyle following a genetic-based
hypertension intervention also found significant changes in sodium intake among participants
provided with DNA-based advice (Taylor and Wu 2010). Furthermore, an RCT found that the
provision of personalized nutrition advice enhances motivation (behavioural intention) to change
lifestyle behaviours (Nielsen and El-Sohemy 2014).

The inconsistent findings of PHBC research suggest that there are confounding factors
influencing behaviour change, which are not being considered in the scientific methods. This is
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likely due to the minimal use of validated theoretical underpinnings to inform study design.
While the current body of knowledge appears to have unintentionally addressed one or more
components of the TPB, a more comprehensive and intentional approach to the incorporation of
the TPB in study design and methodology is required. This would allow for an improved
understanding of the extent to which personalized healthcare recommendations, based on
genetics and/or blood work, may affect behavioural intention and actual behaviour performance.
Studies assessing motivation and behaviour change should include an analysis of attitudes,
subjective norms, perceived behavioural control and actual behavioural control to determine how
these factors may alter study outcomes.

2.1.5 A Call to Action for PHBC Research
It is well known that nutrition, physical activity and wellness strategies can be used to
improve health and well-being and decrease the risk for chronic disease, but despite this
knowledge, rates of obesity and chronic disease continue to climb (Arena et al. 2017). Behaviour
change (or lack thereof) is a key contributor to the increasing rates of obesity and chronic disease
despite our increased knowledge of methods to improve health through lifestyle modification
(Arena et al. 2017). As such, innovative strategies are needed to enhance both intention to
change lifestyle habits as well as actual change in lifestyle habits, and personalized healthcare is
garnering considerable attention as an innovative healthcare strategy to help combat current
global health crises. This paper calls to action PHBC researchers to test the potential expansion
of the TPB to include ‘personalization’ as a possible novel component of the TPB (Figure 2.2).
We propose that personalization may have a significant impact on attitudes and normative beliefs
and therefore has the potential to significantly influence behaviours.
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In order to incorporate the TPB into personalized healthcare research, it is first important
to understand the different components of the theory, including attention to key constructs such
as behavioural beliefs, attitude toward the behaviour, normative beliefs, subjective norms,
control beliefs, perceived behavioural control, actual behavioural control, intention and
behaviour (Figure 2.1). In brief, in the TPB, behavioural beliefs are seen to influence attitudes,
normative beliefs to influence subjective norms and control beliefs to influence perceived
behavioural control. Attitudes, subjective norms and perceived behavioural control all have a
significant impact on one’s behavioural intention and actual behaviour. However, it is also
important to note that factors influencing actual behavioural control, such as the social
determinants of health (Public Health Agency of Canada, 2016), strongly predict behaviours
regardless of attitudes and subjective norms. Describing each component of the TBP in detail is
beyond the scope of this paper and has been accomplished elsewhere (Ajzen 1991, 2006;
Fishbein and Ajzen 2010). Several key resources and seminal texts provide a solid background
for deepening understanding of the TPB (Ajzen 1991, 2006; Fishbein and Ajzen 2010).

We contend that this theoretical background could be translated into a more practical
application to inform the development of assessment tools with theoretical and practical utility
for research in the field. Instructions on completing a TPB questionnaire are available on the
University of Massachusetts website (Ajzen 2006). This resource provides a step-by-step
guideline to develop a TPB questionnaire, which includes defining the behaviour, specifying the
research population, formulating items for direct measures and administering a pilot
questionnaire. Sample TPB questionnaires are also available on the website and can be used for
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guidance in the development of assessment tools to be used in the field (Ajzen 2006). Ajzen
suggests that multiple regression or structural equation modeling analyses can be used to
establish the extent to which attitudes, subjective norms and perceived behavioural control may
have contributed to intentions. These methods of statistical analyses can also be used to
determine the extent to which intentions and perceived behavioural control may have predicted
actual behaviour(s) (Ajzen 2006).

To test the proposed addition of personalization within the TPB, we further advise that an
assessment of attitudes toward genetic testing and/or blood work (depending on the method of
personalization within the study) be included within the TPB questionnaire. Attitudes toward
personalization can be measured on a Likert scale, similar to other questions on Ajzen’s sample
TPB questionnaire (Ajzen 2006). Ideally, a randomized clinical intervention trial study design
could be used for this research, whereby participants are randomly selected to either receive
personalized healthcare advice or general population-based healthcare advice. While blinding
typically enhances the quality of an RCT, for PHBC research blinding may actually diminish the
quality of the results; knowing that one’s recommendations are based on their genetics or blood
work could influence several aspects of the TPB including behavioural beliefs, attitudes,
normative beliefs and subjective norms, thus impacting behavioural intention and behaviours.
Therefore, we do not recommend the blinding of participants. Through the use of repeated
measures analysis of variance and multiple regression, comparisons can then be made within and
between groups to determine the extent to which personalized healthcare advice may have
impacted attitudes and subjective norms, and thus behavioural intention as well as actual
behaviour. To further enhance study design, consideration of the social determinants of health
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(Public Health Agency of Canada, 2016) could additionally be incorporated within the study
questionnaire to determine if factors such as income, education level, housing and employment,
for example, influenced perceived behavioural control and thus behavioural intention and actual
behaviour.

In addition to testing the proposed expansion of the TPB, several hypotheses could be
tested in PHBC research, which incorporate the key constructs of the TPB. Perhaps receiving
genetic testing or blood work results could lead to more positive attitudes toward a behaviour
such as exercising. This may translate into greater intentions to participate in physical activity
and actual engagement in physical activity. Or rather, perhaps personalized healthcare only has a
significant impact on behaviour change in those with a baseline negative attitude toward the
behaviour of interest; personalized healthcare may significantly alter attitudes and thus lead to
greater behaviour change but only in those with baseline negative attitudes. These hypotheses
have yet to be tested in PHBC research, and should be tested in future studies to advance our
understanding of determinants of behaviour change in relation to personalized healthcare.

Furthermore, it would be beneficial to conduct a systematic review of PHBC research
with a focus on assessing how the (likely unintentional) incorporation of components of the TPB
may have impacted the findings of studies conducted to date. While several reviews have been
published on the topic of behaviour change resulting from personalized healthcare, no review has
evaluated studies within the context of the TPB (O’Donovan et al. 2017; Li et al. 2016; Hollands
et al. 2016; French et al. 2017). Based on the information presented in this paper, it is evident
that there is a need for researchers in the field of personalized healthcare and behaviour change
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to incorporate the TPB into their work as a key theoretical underpinning of study design. Past
research in other disciplines can be used to guide research methods (McEachan et al. 2011;
Cooke et al. 2016; Andrew et al. 2016; Rich et al. 2015; Mcdermott et al. 2015).

2.1.6 Conclusion
The lack of consideration of validated theory in the design of studies assessing PHBC can
have a significant impact on the results, as these studies fail to consider key factors that have
been shown to affect behaviour change. This paper calls to action PHBC researchers to
incorporate the TPB in their methods in order to provide a more accurate and thorough
assessment of whether personalized healthcare advice, based on genetics and/or blood work, has
a significant impact on behaviour change. This paper suggests that the next expansion of Ajzen’s
TPB may be the addition of personalization (Figure 2.2). Future research should seek to test the
addition of personalization within the TPB through robust research methods such as RCTs. This
call to action is timely in light of the increased focus on innovative healthcare strategies to
address the myriad of health concerns arising globally, whereby interventions facilitating
behaviour change could have a significant impact on global health.

2.1.7 Future Perspective
Based on the current body of knowledge, in addition to the authors’ clinical and academic
experience, we predict that testing the proposed expansion of the TPB will yield positive
findings toward personalization of healthcare recommendations significantly impacting
behaviour change within some limits. While we predict that personalization will significantly
influence behaviour change, the ability to change one’s behaviour must still remain within the
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individual’s actual and perceived behavioural control. In addition, we predict that the method of
communicating genetic information will play into one’s likelihood of changing, whereby the use
of gain-framed messages and actionable advice may have a more favorable impact on one’s
likelihood of altering their lifestyle habits. Comprehension of the results of personalized
healthcare testing and recommendations will also play into likelihood of behaviour change. As
an example, the results of a nutrigenomics test may inform an individual that they have an
increased risk for cardiovascular disease, but by limiting caffeine intake this elevated risk could
be reduced. This personalized genetic result and consequent gain-framed, actionable
recommendation will likely alter one’s attitudes toward changing the behaviour. If the individual
was to inform their family and/or friends about the results of the genetic test, it is likely that they
would feel pressure from their social circle to abide by the recommendation. While
personalization of healthcare will likely impact attitudes and subjective norms, it is unlikely that
it will be a strong enough force to impact perceived and actual behavioural control. If the
pressures of work and home life do not allow for adequate sleep and lead to increased stress, one
may continue to consume a high quantity of caffeine, regardless of their genetic test. Thus,
perceived and actual behavioural controls remain unchanged. It is for this reason that Figure 2.2
depicts an influence of personalization on attitudes and subjective norms, but not perceived
behavioural control. Considering the above-mentioned points, if the individual was sleeping
adequately and consumed caffeine for the simple enjoyment of the taste of the caffeinated
beverages, the results of the genetic test would likely motivate them to stop drinking caffeinated
beverages.
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It is further predicted based on clinical experience and our review of the literature that
specific aspects of personalized healthcare interventions facilitate behaviour change to a greater
extent than others. For example, providing genetic testing through a trained healthcare
professional rather than using direct-to-consumer methods will likely facilitate behaviour change
to a greater extent. Moreover, providing actionable recommendations rather than disease risk
estimates is likely to result in greater behaviour change. We posit that future research will be
able to identify similar factors in PHBC research that have been shown to facilitate behaviour
change and will use this knowledge to design an algorithm for effective personalized healthcare
results and recommendations. To our knowledge, this hypothesis has yet to be tested in scientific
research.

Overall, we predict that personalization of healthcare will be added to the TPB as a key
factor influencing attitudes and subjective norms and thus intention and behaviour. Achieving
behaviour change when it comes to lifestyle habits is arguably one of the most challenging
aspects of clinical practice. We further predict that the field of genetic testing will continue to
grow as more robust PHBC research is conducted and published. These predictions stem from
clinical and academic experience, our review of the literature and theoretical perspectives.
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2.1.8 Figures and Executive Summary
Figure 2.1: The ‘Theory of Planned Behaviour’

Figure 2.2: Personalization: A proposed expansion of the ‘Theory of Planned Behaviour’

31

Figure 2.3: Executive summary
Executive summary
The ‘Theory of Planned Behaviour’ (TPB)
• The TPB is a widely accepted and validated behaviour change theory, which suggests that
there are three main factors contributing to behaviour change: attitudes, subjective norms
and behavioural control (perceived and actual).
Consideration of theory in personalized healthcare behaviour change research
• To date, consideration of theory (especially the TPB) is limited in personalized healthcare
behaviour change (PHBC) research.
• This lack of consideration of theory helps to explain the heterogeneity of current PHBC
research findings.
Predictions for the future
• We predict that robust research will demonstrate that personalization will significantly
influence behaviour change and thus personalization will be added to the TPB.
• The impact of personalization on behaviour change will be limited to a significant influence
on attitudes and subjective norms.
Call to action
• This paper calls to action PHBC researchers to test the proposed expansion of the TPB to
include personalization.
Conclusion
• Present research demonstrates a lack of consideration of theoretical underpinnings to
inform study design, yet the results of several articles demonstrate that personalization is
likely a key component to be added to behaviour change theory.
• Future research should seek to inform study design using the TPB and determine the extent
to which personalization influences key components of the TPB.
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CHAPTER 3: A SYSTEMATIC REVIEW OF GENETIC TESTING
AND LIFESTYLE BEHAVIOUR CHANGE
As published* in Lifestyle Genomics:
Horne J, Madill J, O ’Connor C, Shelley J, Gilliland J. 2018 “A systematic review of genetic
testing and lifestyle behaviour change: Are we using high-quality genetic interventions and
considering behaviour change theory?” Lifestyle Genomics 11(1): 49-63.
*Reference formatting, table numbers and figure numbers have been revised for consistency with the present dissertation.
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3.1 Title: A systematic review of genetic testing and lifestyle behaviour change:
Are we using high-quality genetic interventions and considering behaviour
change theory?
3.1.1 Abstract
Background: Studying the impact of genetic testing interventions on lifestyle behaviour change
has been a priority area of research in recent years. Substantial heterogeneity exists in the results
and conclusions of this literature, which has yet to be explained using validated behaviour
change theory and an assessment of the quality of genetic interventions. The theory of planned
behaviour (TPB) helps to explain key contributors to behaviour change. It has been hypothesized
that personalization could be added to this theory to help predict changes in health behaviours.
Purpose: This systematic review provides a detailed, comprehensive identification, assessment,
and summary of primary research articles pertaining to lifestyle behaviour change (nutrition,
physical activity, sleep, and smoking) resulting from genetic testing interventions. The present
review further aims to provide in-depth analyses of studies conducted to date within the context
of the TPB and the quality of genetic interventions provided to participants while aiming to
determine whether or not genetic testing facilitates changes in lifestyle habits. This review is
timely in light of a recently published “call-to-action” paper, highlighting the need to incorporate
the TPB into personalized healthcare behaviour change research.
Methods: Three bibliographic databases, one key website, and article reference lists were
searched for relevant primary research articles. The PRISMA Flow Diagram and PRISMA
Checklist were used to guide the search strategy and manuscript preparation. Out of 32,783 titles
retrieved, 26 studies met the inclusion criteria. Three quality assessments were conducted and
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included: (1) risk of bias, (2) quality of genetic interventions, and (3) consideration of theoretical
underpinnings – primarily the TPB.
Results: Risk of bias in studies was overall rated to be “fair.” Consideration of the TPB was
“poor,” with no study making reference to this validated theory. While some studies (n = 11;
42%) made reference to other behaviour change theories, these theories were generally
mentioned briefly, and were not thoroughly incorporated into the study design or analyses. The
genetic interventions provided to participants were overall of “poor” quality. However, a
separate analysis of studies using controlled intervention research methods demonstrated the use
of higher-quality genetic interventions (overall rated to be “fair”). The provision of actionable
recommendations informed by genetic testing was more likely to facilitate behaviour change
than the provision of genetic information without actionable lifestyle recommendations. Several
studies of good quality demonstrated changes in lifestyle habits arising from the provision of
genetic interventions. The most promising lifestyle changes were changes in nutrition.
Conclusions: It is possible to facilitate behaviour change using genetic testing as the catalyst.
Future research should ensure that high-quality genetic interventions are provided to participants,
and should consider validated theories such as the TPB in their study design and analyses.
Further recommendations for future research are provided.

3.1.2 Background
Since decoding the entire human genome in 2003 (National Institutes of Health 2015),
there have been considerable advances in genetic research and the clinical utility of genetic
testing. The terms nutrigenomics or nutritional genomics describe the study of how genes
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interact with the foods, beverages, and supplements consumed to influence health outcomes
(Gibney and Walsh 2013). Currently, there are no generally accepted or standardized terms
describing the study of how genes interact with physical activity, sleep, or smoking to influence
subsequent health outcomes. These gene-lifestyle interactions can be referred to using the broad
term lifestyle genomics. Despite the lack of a standardized terminology, research pertaining to
nutrigenomics and other emerging genomic sciences continues to advance. Specifically,
behaviour change guided by genetic testing results or other personalized healthcare information
is emerging as a priority area of research, with several reviews on this topic published in recent
years (Hollands et al. 2016; French et al. 2017; O’Donovan et al. 2017).

Genetic testing is increasingly used in clinical practice to provide personalized
information and recommendations about health risks and lifestyle habits at a relatively low cost
(Caulfield and McGuire 2012). However, studies assessing whether or not genetic testing
promotes changes in lifestyle habits have conflicting findings (Egglestone, Morris, and O’Brien
2013; Hietaranta-Luoma et al. 2014; Nielsen and El-Sohemy 2014; Marsaux et al. 2016). Given
that chronic diseases can often be managed through lifestyle interventions alone, or a
combination of lifestyle interventions and medication (Knowler et al. 2002; Roth et al. 2017;
CDC 2016), genetic tests providing personalized lifestyle recommendations hold considerable
promise.

Behaviour change is a multifactorial, complex area of research and clinical practice. The
theory of planned behaviour (TPB) is arguably the most widely accepted behaviour change
theory in academia (Ajzen 2011). This theory posits that attitudes, subjective norms, and
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perceived behavioural control are key constructs that can be used to predict behaviours. Actual
behavioural control, which typically refers to factors such as income, educational level, and other
social determinants of health for the purposes of healthcare research, further contributes to one’s
likelihood of performing a behaviour (Ajzen 2011, 1991). It is important for genetic testing
behaviour change research to consider validated theories in order to control for a number of
confounding factors that could significantly influence the results of a study.

Despite the complexity of behaviour change, genetic testing behaviour change studies do
not often use any theoretical underpinnings to inform their study design, or for the analysis and
interpretation of their data. This is concerning, as it implies that these studies did not report
whether they considered the many confounding factors impacting behaviour change, including
but not limited to attitudes, subjective norms, and perceived and actual behavioural control
(Ajzen 2006). Consideration of such factors could help explain why some studies conclude that
genetic testing facilitates health behaviour change, while others conclude that it does not. For
example, a study may find that genetic testing has a positive influence on attitudes and subjective
norms, but it is only when behavioural control is high (for example, with a higher income or
education level) that genetic testing facilitates health behaviour change. The importance of such
considerations has been highlighted in a recent call to action for personalized healthcare
behaviour change research, which recommended the completion of a systematic review with
perspective from the TPB as an important next step in advancing knowledge in personalized
healthcare behaviour change literature (Horne, Madill, and Gilliland 2017).
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Systematic reviews and meta-analyses are typically considered the highest quality of
scientific evidence and, notably, often guide clinical practice (West et al. 2002). When it comes
to systematic reviews assessing behaviour change as a result of genetic testing interventions, a
simple risk-of-bias assessment is not sufficient to develop the most meaningful conclusions; yet
it is often the only quality assessment conducted in this type of work (Hollands et al. 2016;
French et al. 2017; Li et al. 2016). It is further important to consider the delivery of a
health/genetic intervention (such as considering the provision of disease risk estimates vs.
actionable behaviour change recommendations) and to consider behaviour change theories
(Horne, Madill, and Gilliland 2017). Therefore, the development of more comprehensive
methods for reviewing and compiling the primary research articles conducted to date related to
genetic testing behaviour change is needed.

The present review provides an in-depth analysis and summary of the current body of
knowledge, thus presenting the most robust and comprehensive review of genetic testing
behaviour change research conducted to date. Overall, the purpose of this comprehensive
systematic review is to use these novel perspectives to answer the following research questions:
Are we considering validated behaviour change theory (particularly the TPB) in genetic testing
behaviour change research? Are we using high-quality genetic interventions in genetic testing
behaviour change research? What is the impact of genetic testing on behaviour change pertaining
to four lifestyle factors: nutrition, physical activity, smoking, and/or sleep? These four lifestyle
factors were chosen as they have all been shown to have a significant impact on chronic disease
management (Audrain et al. 1997; Dean and Söderlund 2015; Walker et al. 2010; Zhu et al.
2017; Wu, Zhai, and Zhang 2014). Behaviour change is challenging, and it is important to find
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strategies that effectively facilitate beneficial lifestyle changes related to nutrition, physical
activity, smoking, and/or sleep. Genetic tests may provide information on disease risk, which can
be mitigated through specific alterations in lifestyle habits such as improving nutrition,
optimizing physical activity habits, quitting smoking or smoking less, and engaging in healthful
sleep-related behaviours.

3.1.3 Methods
Search Strategy
The systematic review protocol that was used to guide this review is detailed elsewhere
(Petticrew and Roberts 2006). In brief, the search strategy was guided by the PRISMA Flow
Diagram (Moher et al. 2009). From February to April 2017, the following databases were
searched for relevant articles: PubMed, Scopus, and Nursing and Allied Health. Publications
posted on the Food4Me website (Food4Me n.d.), as well as the reference lists of 4 recent review
articles published on topics similar to those of the present review (Hollands et al. 2016;
O’Donovan et al. 2017; French et al. 2017; Li et al. 2016), were also screened for articles
relevant to the research questions. After the number of records had been condensed through title
and abstract screening, the full-text articles were reviewed to assess each one for eligibility
according to predetermined inclusion and exclusion criteria. The complete search terms and
search strategy were developed and approved by all authors, and they are detailed in Figure 3.1
and Figure 3.2, respectively.
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Selection Criteria
To capture a comprehensive summary of the research conducted to date, the present
review was not limited to a single, specific study design. We included primary research articles
published in English in peer-reviewed journals from all years which assessed the impact of
genetic testing on one or more of the four lifestyle habits of interest (nutrition, physical activity,
smoking, and/or sleep). Both qualitative and quantitative studies were included. Studies were
excluded if there was not at least one group of participants who underwent genetic testing and/or
if the study did not provide follow-up data related to one or more of the lifestyle habits of interest
after the participants had received the results of a genetic test. One author (JH) completed data
extraction using piloted forms (The Cochrane Collaboration 2011), which were tested on 4
studies, reviewed by another author (JG), and modified during the piloting process by two
authors (JH and JG).
Analysis
The National Institutes of Health (NIH) Study Quality Assessment Tools were used to
conduct a risk-of-bias assessment in quantitative research (National Institutes of Health n.d.).
The Critical Appraisal Skills Programme Qualitative Research Checklist (Critical Appraisal
Skills Programme 2017) was used to assess risk of bias in qualitative research. The quality of the
genetic intervention was also assessed. To our knowledge, there currently is no tool available for
assessing the quality of a genetic intervention. As such, we developed the first assessment tool
for evaluating the quality of a genetic intervention provided to subjects (Supplementary Table
3.4). The quality rating and general outline for this new tool was based on the format of the NIH
Study Quality Assessment Tools (National Institutes of Health n.d.). The questions included
were developed from a review of previously identified critiques and concerns related to genetic
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testing and health risk messages (Nielsen and El-Sohemy 2014; Fenech 2008; Katsanis and
Katsanis 2016; Witte, Meyer, and Martell 2001; Hall, Weinman, and Marteau 2004; Legenthal et
al. 1997; Bloss, Schork, and Topol 2011; Bloss et al. 2013; Ferguson and Barnett 2012).
Consideration of the main components of the TPB (attitudes towards a behaviour,
subjective norms, behavioural control, and intention) (Ajzen 2006), as well as consideration of
theory more generally, was assessing using deductive content analysis of the manuscripts (Elo
and Kyngäs 2008). The deductive content analyses of consideration of the TPB and its key
components in each study was then translated into a rating, based on the rating system generated
in the NIH Study Quality Assessment Tools, whereby “good” indicates a robust consideration of
the main components of the TPB, “fair” indicates intermediate consideration of the main TPB
components, and “poor” represents little to no consideration of the main TPB components. An
overall quality score was assigned to each article based on a point system, where “good” ratings
were awarded 3 points, “fair” ratings were awarded 2 points, and “poor” ratings were awarded 1
point. The maximum possible overall quality rating was 9/9, upon consideration of all three
assessments.

3.1.4 Results
The comprehensive electronic literature search returned a total of 32,783 results, with 26
studies meeting the predetermined inclusion criteria. In these 26 studies, the following outcomes
were assessed: nutrition (n = 18), physical activity (n = 16), and smoking (n = 12) (Figure 3.2),
with 14 articles assessing more than one lifestyle habit of interest to this review. The vast
majority of the literature has been published over the past decade, with a large spike in
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publications recently in 2015 (Supplementary Figure 3.3). Consistent with recommendations for
systematic reviews (Petticrew and Roberts 2006), our review was analytic and descriptive in
nature and included: (a) a tabulation of the study characteristics and findings (Table 3.1); (b) a
thorough and robust quality assessment (Table 3.2); and (c) a narrative synthesis. Research
conducted thus far has focused on a variety of genes, as outlined in (Table 3.3). It is concerning
to note that 12 studies (46%) did not report whether or not the authors had a conflict of interest
(COI). The vast majority of the literature has focused on genetic testing for determining the risk
of developing certain diseases or conditions (88%; n = 23), while only a small number of studies
have focused on nutrient metabolism (12%; n = 3), which indirectly affects the risk of
developing diseases or conditions (Siscovick et al. 2017; Cornelis et al. 2006; Hietaranta-Luoma
et al. 2014). The three separate quality assessments completed on each study are summarized in
Table 3.2. Risk of bias was overall rated as “fair.”
Are We Using High-Quality Genetic Interventions?
Although some risk of bias is apparent, the ratings for the quality of the genetic
interventions were more concerning, since overall the ratings were “poor” and only 6 of the 26
studies (23%) received a “good” rating. Thus, it is clear that the studies did not provide highquality interventions to their participants, which helps to explain why the majority of studies did
not report that genetic interventions facilitated lifestyle behaviour change.
Are We Considering Validated Behaviour Change Theory?
Consideration of the TPB and/or one or more of the theory’s three key components had
mode overall ratings of “poor.” The deductive content analyses of the theoretical underpinnings
mentioned in the studies are summarized in Supplementary Table 3.5. Fifteen studies (58%) did
not make reference to any specific behaviour change theory or model within the text. When a
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theory was included, it was generally only briefly mentioned and was not thoroughly
incorporated into the study design, or expanded upon in the discussion. No study specifically
referred to the TPB, suggesting that researchers have yet to consider this important theory in
their study design or interpretation of findings. Several studies incidentally considered certain
aspects of the TPB in the development of their scientific methods or within the text, such as the
consideration of behavioural control by assessing one or more social determinants of health,
such as income (Public Health Agency of Canada 2016). Overall, behaviour change theory is not
being thoroughly incorporated into genetic testing behaviour change research.
Does Genetic Testing Impact Changes in Nutrition, Physical Activity, and/or Smoking
Behaviour?
Overall. Given the heterogeneity of the literature and complexity of genetics-based
behaviour change research, a cause-and-effect relationship between genetic testing and health
behaviour change cannot be identified. Notably, it appears that it is unlikely that genetic testing
has a “fatalistic” or negative impact on health behaviour change related to nutrition, physical
activity, and smoking, since no study found that genetic testing negatively impacted the health
behaviours of interest to the present review. Interestingly, 78% of the studies with healthpromoting lifestyle behaviour change findings provided their participants with a genetics-based
intervention that included actionable health behaviour recommendations. Examples of actionable
recommendations provided to participants for each lifestyle factor included recommendations to
reduce sodium intake (nutrition) (Nielsen and El-Sohemy 2014), incorporate exercise into one’s
daily routine (physical activity) (Meisel et al. 2015), and quit smoking (smoking) (Audrain et al.
1997). Conversely, only 50% of the studies with null findings provided their participants with
actionable health behaviour recommendations. Since an overarching cause-and-effect statement
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about the impact of genetic testing on behaviour change cannot be made, a best evidence
synthesis is provided below.

Nutrition. Of the 18 articles that assessed a nutrition-related outcome, 6 (33%) showed a
positive, health-promoting effect of genetic testing on behaviour change at one or more time
points (both short term and long term, as further outlined in Tables 3.1 and 3.2). While this does
not indicate that the majority of studies positively influenced nutrition, multiple studies of good
quality (n = 6) have demonstrated that it is possible to facilitate healthier nutritional behaviours
through the provision of genetic testing (Egglestone, Morris, and O’Brien 2013; HietarantaLuoma et al. 2014; Nielsen and El-Sohemy 2014; Voils et al. 2015; Kaufman et al. 2012;
Vernarelli et al. 2010).

Physical Activity. The provision of genetic testing to facilitate physical activity behaviour
change does not appear to be as promising as behaviour change related to nutrition. Of the 16
studies that analyzed physical activity-related outcomes independently, only 2 (13%) found
positive influences of genetic testing on physical activity (Egglestone, Morris, and O’Brien 2013;
Kaufman et al. 2012), with follow-up periods ranging from 2 to 8 months in one study (Kaufman
et al. 2012) and the periods not indicated in the other study (follow-up varied for each
participant) (Egglestone, Morris, and O’Brien 2013). However, these articles rated poorly in their
overall quality assessment, with “poor” to “fair” quality ratings of 3 (Egglestone, Morris, and
O’Brien 2013) and 4 (Kaufman et al. 2012).
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Smoking. Similar to nutrition, 4 (33%) of the 12 genetic intervention studies had a
positive influence on smoking-related behaviours. However, improvements in smoking-related
behaviours were generally only sustained over a short-term period. The overall quality of these
studies was “fair.”

Sleep. It is clear that sleep is an understudied area of genetic testing and behaviour change
research, since our comprehensive search did not yield a single study that assessed sleep (sleep
quality, hours of sleep, etc.) as a behaviour change outcome.

Pooled Analyses. Two studies completed pooled analyses of changes in more than one
lifestyle factor. Chao et al. did not find significant changes in nutrition or physical activity on
their own, but when pooled together, there were significantly greater changes to nutrition and
physical activity in the high-risk genetic testing group than in the non-risk and control groups
(Chao et al. 2008). Additionally, in a pooled analysis of changes to nutrition, physical activity, or
smoking, Egglestone et al. (Egglestone, Morris, and O’Brien 2013) found significant changes
between the genetic testing group and the control group. However, their results should be
interpreted with caution, as this study was awarded the lowest overall quality rating of 3 (Table
3.2).
Results from Controlled Intervention Trials
While it is important to be comprehensive and consider all studies conducted on the topic
of interest regardless of the research methods chosen, controlled interventions should be further
highlighted and reviewed separately from other study designs given that this is the highest
possible level of evidence for the original research included in the present review.
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In total, 15 controlled intervention trials have been conducted over the past two decades.
Approximately half of these studies (n = 7; 47%) found significant changes in nutrition and/or
physical activity or in smoking at 1–3 time points included in the study. Consistent with the
overall analysis, the controlled interventions found that nutrition was the most promising area of
behaviour change, followed by smoking (short-term only).

The genetic interventions in the controlled intervention trials overall ranked “fair,”
demonstrating that in comparison to the result of the pooled analysis of all study designs, these
studies provided their participants with higher-quality genetic interventions. This may help
explain why 47% of the controlled intervention studies found significant changes in lifestyle
habits resulting from the genetic intervention, compared to 36% of the studies using other study
designs. The overall ranking of these studies was “fair,” with a mean rating of 5.6 out of the
highest possible score of 9. Risk of bias overall was “fair” and consideration of the TPB was
rated to be “poor,” which is consistent with the results of the analysis of all study designs
combined.

3.1.5 Discussion
Given that decoding the entire human genome was the primary focus of genetic research
until 2003 (National Institutes of Health 2015), it is not surprising to find that the majority of
studies included in the present review were published after this time, with only 2 studies
published before 2003. Since then, much greater focus has been placed on genetic testing
behaviour change research pertaining to nutrition, physical activity, and smoking. However,
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several studies included in the present review (46%) did not include a COI statement. Future
research should ensure the inclusion of a COI statement given this concerning finding and given
the increased emphasis in academia on the importance of considering COI in genetic testing and
other research.

Improving one or more of the four lifestyle behaviours of interest to this review has been
shown to have a beneficial effect on chronic disease management and general health and wellbeing (Dean and Söderlund 2015; Walker et al. 2010; B. Zhu et al. 2017; Wu, Zhai, and Zhang
2014). The present review indicated that improvements to smoking habits were promising in the
short-term. This finding was consistent with that of a previously published systematic review of
the impact of genetic notification on smoking cessation (de Viron et al. 2012).

While nutrition, physical activity, and smoking habits have been researched in multiple
genetic intervention studies, sleep remains an understudied area of genetics and behaviour
change. This is notable considering the substantial impact that sleep has on overall health and
well-being. Current systematic reviews demonstrate a significant impact of sleep on cognition
and emotion (Krause et al. 2017), glycemic control (Zhu et al. 2017), and overweight or obesity
(Wu, Zhai, and Zhang 2014), to name a few. To our knowledge, little is known about the ability
of sleep to modify genetic-associated health risks. Thus, future research should seek to first
determine gene-sleep interactions that may influence health outcomes using methodologies
similar to those of nutrigenomics research, as opposed to a genome-wide association study
approach. Upon determining ways in which sleep may mitigate genetics-associated health risks,

47

future research should then seek to determine if genetic testing helps to motivate healthy sleeprelated behaviours.

The considerable heterogeneity in studies (Tables 3.1 and 3.2) can be explained by a
number of factors. Notably, the variation of statistical analyses between groups (i.e., genetic
testing groups vs. control groups or high-risk genetic result groups vs. non-risk genetic result
groups) would have impacted the findings and subsequent conclusions drawn. Consideration of
theories in general to inform the study design was poor, and consideration of the TPB was
absent, which further helps to explain the heterogeneity of findings, since several possible
confounding factors were missed. Additionally, only 3 studies (Hietaranta-Luoma et al. 2014;
Nielsen and El-Sohemy 2014; Roke et al. 2017) focused on nutrient metabolism. Therefore, a
future focus is needed on genetic interventions related to nutrient metabolism and the subsequent
disease risk through genetic testing of modifier genes (genetic risks that can be mitigated through
specific lifestyle changes), rather than genetics-based disease risk estimates where there may be
no known lifestyle modifications that can alter the genetic risk. It is possible that nutrition was
the most promising lifestyle factor for promoting health behaviour change given that genetic
testing of modifier genes typically leads to the provision of actionable recommendations [e.g.,
the recommendation to reduce sodium intake (Nielsen and El-Sohemy 2014)].

It is important to note that our risk-of-bias results are consistent with the previously
published literature (Hollands et al. 2016; O’Donovan et al. 2017; French et al. 2017; Li et al.
2016), providing validation for the NIH quality assessment process completed in the current
review. Effect sizes were not included in this review due to heterogeneity of the genetic
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interventions and study designs of the included articles that would have introduced potential
flaws in effect size calculations and any conclusions drawn from such calculations. For
randomized controlled trials, effect sizes have recently been presented elsewhere (Hollands et al.
2016, although these should be interpreted with caution due to the significant heterogeneity of
treatments (genetic interventions), measurements of outcomes, and populations studied. To our
knowledge, we have developed and utilized the first quality assessment tool for evaluating and
rating genetic interventions. Future research should seek to utilize this novel tool and significant
contribution to the literature to assess the quality of genetic interventions in both primary
research and systematic reviews. Furthermore, the components of this tool can be used in future
genetic testing behaviour change study designs to improve the quality of genetic interventions
provided to participants (Supplementary Table 3.4). Although the genetic intervention quality
assessment was based on previously published robust research and critical commentaries
(Nielsen and El-Sohemy 2014; Fenech 2008; Katsanis and Katsanis 2016; Witte, Meyer, and
Martell 2001; Hall, Weinman, and Marteau 2004; Legenthal et al. 1997; Bloss, Schork, and
Topol 2011; Bloss et al. 2013; Ferguson and Barnett 2012), assessing the quality of evidence
supporting the genetic tests provided to participants was beyond the scope of the present review.
This is an important area of future research and is a notable ethical concern of genetic testing.

This review provides the most comprehensive analysis of genetic testing behaviour
change research completed to date. However, some limitations to the present review exist. While
this review summarized whether the genetic information was delivered direct to consumer or
through a healthcare provider (Table 3.2), the practice of each provider is inevitably distinct.
Some may incorporate behaviour change theory into their practice in order to maximally
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promote health behaviour change, while others may simply provide an explanation of the genetic
results. This limitation further highlights the complexity of genetic testing behaviour change
research. Additionally, the TPB was chosen as the key theory of interest given that it is one of
the most widely accepted and validated theories of behaviour change, with over 4,500
publications referencing this theory and several meta-analyses finding that the key components
of the TPB can be used to predict behavioural intentions with mean multiple correlations ranging
from 0.59 to 0.67 (Ajzen 2011; Notani 1998; Rivis and Sheeran 2003; Wittmann 2003; Armitage
and Conner 2001; Cheung and Chan 2000; Mceachan et al. 2016). However, a number of other
theories have been validated and are frequently used in behaviour change research, such as the
transtheoretical model (Prochaska and Velicer 1997).

By improving upon genetic testing behaviour change studies, we anticipate the
development of an algorithm that can be used to inform effective genetic testing behaviour
change interventions for individuals who might benefit from this more personalized approach to
healthcare. Indeed the limitations of genetic testing and the possible risk of harm (NIH: Genetics
Home Reference 2018) should be considered prior to an individual’s decision to undergo genetic
testing, especially in situations where one may learn about their risk of developing a disease,
where actionable strategies for mitigating the risk are currently unknown (NIH: Genetics Home
Reference 2018). Given that behaviour change is complex and multifactorial and studies have yet
to robustly incorporate validated theory and high-quality genetic interventions into their
methods, we cannot conclude with a broad statement about the impact of genetic testing on
behaviour change. However, it is clear that it is possible to facilitate behaviour change through
the provision of high-quality genetic interventions. Incorporating behaviour change theory into
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future research is an important consideration to enhance our knowledge in this field. Specific
recommendations for study design have recently been published elsewhere (Horne, Madill, and
Gilliland 2017). An interdisciplinary research team with expertise in genomics as well as
behaviour change may be the optimal approach given the complexities of this field of study.
Considerable future research is needed in this promising and exciting area of lifestyle behaviour
change research.

3.1.6 Conclusion
The use of validated theory to inform a robust study design (Horne, Madill, and Gilliland
2017) and the provision of actionable, high-quality, genetic-based information and advice is
recommended to test a behaviour change hypothesis in genetics research. Rather than using the
traditional systematic review process of assessing solely risk of bias, we have demonstrated that
factors beyond risk of bias influence research outcomes related to genetic testing and behaviour
change. As more robust literature continues to be published, allowing for the determination of
key components of genetic interventions that best facilitate behaviour change, lifestyle genomics
behaviour change research has the potential to make a substantial impact on global health and
well-being through the facilitation of personalized, health-promoting lifestyle behaviour change.
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3.1.7 Tables and Figures
Table 3.1: Summary of study characteristics and behaviour change findings

First
Participants
author et (n baseline;
al. date
n follow-up)

Interven
tion
group(s)

Compar
ison
group(s)

Target diseases/
conditions
(genes tested)

Followup

Lifestyle habits Outcomes (p values);
assessed
conclusions

Ranking of
COI
study design1

Roke et al. Young
2017
female adults
(n = 57;
n = 56)

Genetic
testing

No
genetic
testing

Health effects
related to
omega-3 intake
(FADS1)

3 months

Nutrition
NS change in omega-3
(omega-3: EPA intake in the genetic
and DHA)
testing group compared to
the control group (no
genetic testing)

1

No

Marsaux et Adults
al. 2016
(n = 265;
n = 130)

Highrisk
genetic
result

Non-risk
genetic
result

Overweight/
obesity (FTO)

6 months

Physical activity NS change in subjective or
objective physical activity
with provision of FTO
genotype risk info

3

Yes

Meisel et
al. 2015

Young adults
(n = 1,016;
n = 279)

Genetic
testing

No
genetic
testing

Obesity (FTO)

1 month

Nutrition
NS changes in nutrition
(adherence to a and physical activity
variety of eating (pooled) between groups
behaviours) and
physical activity

1

No

Boeldt et
al. 2015

Adults
working at
health and
technology
companies
(NR;
n = 2,037)

Genetic
testing

None

23 conditions
including heart
attack,
Alzheimer
disease, type 2
diabetes,
obesity, colon
cancer, and
cervical cancer
(NR)

5.6±2.4
months

Nutrition
NS (significance level NR)
(dietary fat) and change in nutrition and
physical activity physical activity following
genetic testing2

4

No

Hietaranta- Adults
Luoma et (n = 122;
al. 2014
n = 113 at
12 months)

Genetic
testing

No
genetic
testing

Cardiovascular
disease (apoE)

2 weeks
6 months
12
months

Nutrition (fat
quality, and
consumption of
vegetables,
berries, fruits,
and fatty and
sugary foods)
and physical
activity

1

No

and
Highrisk
genetic
result

and
Non-risk
genetic
result

Improved dietary fat
quality in the high-risk
genetic result group vs. the
control group at 2 weeks
(p < 0.05) and 6 months of
follow-up (p < 0.05);
decreased intake of highfat, high-sugar foods in the
non-risk genetic result
group vs. the control group
at 12 months (p < 0.05)
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Voils et al. Veterans
2015
(n = 601;
n = 506 at
3 months,
n = 472 at
6 months)

Genetic
testing

No
genetic
testing

Type 2 diabetes
(TCF7L2,
PPARγ, and
KCNJ11)

3 months
6 months

Nutrition
(calories,
carbohydrates,
protein, fat,
saturated fat,
MUFA, and
PUFA) and
physical activity

Marsaux et Adults
Genetic
al. 2016
(n = 1,607;
testing
n = 1,233
with
subjective
data at
6 months,
n = 730 with
objective data
at
6 months)

No
genetic
testing

Overweight/
obesity (FTO)

3 months
6 months

Nielsen et Adults
al. 2014
(n = 138;
n = 130 at
3 months,
n = 123 at
12 months)

No
genetic
testing

Caffeine
metabolism
(CYP1A2),
vitamin C
utilization
(GSTT1 and
GSTM1), sweet
taste perception
(TAS1R2), and
sodium
sensitivity
(ACE)

No
genetic
testing

NR (NR)

Highrisk
genetic
result
and
Non-risk
genetic
result

Egglestone Adults who
Genetic
et al. 2013 had
testing
purchased a
DTC genetic
test or were
considering
purchasing a
test or who
were
awaiting their
results
(n = 275)

Reduced calories and fat
(MUFA and PUFA) in the
genetic testing group vs.
the no-genetic-testing
group (p < 0.05) at 3
months; NS changes in
nutrition between the
groups at 6 months; NS
changes in physical
activity at either time point

1

Yes

Physical activity NS changes in physical
activity with the addition
of genetic information

1

Yes

3 months
12
months

Nutrition
The high-risk genetic
(caffeine,
result group (for the ACE
vitamin C, added gene) had reduced sodium
sugar, and
intake to a greater extent
sodium)
than the control group by
the 12-month follow-up (p
= 0.008); NS changes in
caffeine, vitamin C, and
added sugar intake at each
follow-up time point; NS
changes in sodium intake
at the 3-month follow-up

1

Yes

Varied

Nutrition
(healthier diet,
vitamins/
supplements,
caffeine, fibre,
salt, fat, and
fruits/vegetables
), physical
activity, and
smoking

2

NR

Greater health behaviour
scores in the genetic
testing group vs. the
control group (p = 0.02 for
pooled nutrition, physical
activity, and smoking); the
most common changes
were “healthier diet,”
“more exercise,” and
“taking vitamins or
supplements”; more often
reported “sufficient fruit
and vegetable intake” in
the genetic testing group (p
= 0.03); NS changes in
smoking individually
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Bloss et al. Adults
2013
working at
health and
technology
companies
(n = 3,639;
n = 2,037 at
3 months,
n = 1,325 at
14 ± 1.3
months)

Genetic
testing

None

Deep vein
thrombosis,
melanoma,
sarcoidosis,
haemochromatos
is, lactose
intolerance,
breast cancer,
prostate cancer +
20 other
conditions not
listed (variable)

3 months
14±1.3
months

Nutrition
NS changes in nutrition or
(dietary fat) and physical activity at 3
physical activity months (significance level
NR) or 14±1.3 months

4

No

Kaufman et Adult
al. 2012
customers of
DTC genetic
testing
companies
(n = 3,167;
n = 1,048)

Genetic
testing

Non-risk
genetic
result

Variable
(variable)

2–8
months

Nutrition
(change diet)
and physical
activity

The participants who
considered themselves at
high risk of colon cancer
were significantly more
likely to change their diet
(p = 0.02) and start
exercising more (p = 0.01)
than those who considered
themselves at low risk of
colon cancer; 10% of all
participants reported they
changed a supplement,
33% reported being more
careful about their diet,
and 14% reported
exercising more

2

NR

Hollands et Adults with
al. 2012
1st-degree
relatives with
Crohn’s
disease
(n = 497;
n = 426)

Genetic
testing

No
genetic
testing

Crohn’s disease
(NOD2)

6 months

Smoking

NS changes in smoking
cessation between the
genetic testing and the nogenetic-testing group; NS
changes in smoking
cessation between the
high-risk and the non-risk
genetic result group
(significance level NR)

1

No

Bloss et al. Adults
2011
working at
health and
technology
companies
(n = 3,639;
n = 2,037)

Genetic
testing

None

23 conditions
including breast
and prostate
cancer (NR)

5.6±2.4
months

Nutrition
NS changes in nutrition
(dietary fat) and and/or physical activity
physical activity following genetic testing

4

NR

Vernarelli Adults with
et al. 2010 at least one
parent who
developed
Alzheimer
disease
(n = 279;
n = 272)

Highrisk
genetic
result

Non-risk
genetic
result

Alzheimer
disease (apoE)

6 weeks

Nutrition
(dietary
supplement use)
and physical
activity

3

No

and
Highrisk
genetic
result

and
Highrisk
genetic
result

and
Non-risk
genetic
result

The high-risk genetic
result group was more
likely to take supplements
than the non-risk genetic
result group (p = 0.0001)
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Hishida et Adult
Genetic
al. 2010
smokers (n = testing
562; n = 533)

No
genetic
testing

Lung and
oesophageal
cancer
(L-myc)

12
months

Smoking

NS changes in smoking
cessation between the
genetic testing and the nogenetic-testing group

1

No

Quach et
al. 2009

None

Breast and
ovarian cancer
(BRCA1/2)

6 months

Nutrition
(healthy diet and
vitamin use) and
physical activity

NS changes in nutrition,
vitamin use, or physical
activity after genetic
testing (significance level
NR)

4

NR

Uninfor
mative
genetic
result

Breast cancer
(BRCA1/2)

1 month
6 months

Nutrition
(saturated fat,
fruit/vegetables)
and physical
activity

NS differences between
groups in nutrition or
physical activity at
baseline and 1 month or 6
months following genetic
testing

3

NR

Alzheimer’s
disease (apoE)

12
months

Nutrition
(changes in diet,
changes in
vitamin/
supplement use)
and physical
activity

The high-risk genetic
result group was more
likely to report a nutrition
or physical activity change
than the non-risk genetic
result group (p = 0.003)
and the no-genetic-testing
group (p = 0.03); most
common was a change in
medication/supplement use
(specifically vitamin E)

1

NR

Lung cancer
(GSTM1)

1 week
2 months

Smoking

Fewer cigarettes smoked
(p = 0.009) and greater
quit rates (p = 0.009) at the
1-week follow-up in the
high-risk genetic result
group than in the nogenetic-testing group; NS
differences at the 2-month
follow-up between the
groups for cigarettes
smoked and quit rates

1

No

Breast cancer
(BRCA1/2)

Varied –
up to 18
months

Nutrition
Few women reported a
(dietary
significant impact on
changes),
nutrition, physical activity,
physical activity, and/or smoking as a result
and smoking
of receiving genetic testing
results and counselling
(significance level N/A)

Qualitative

NR

Adults with a Genetic
personal
testing
and/or family
history of
breast and/or
ovarian
cancer
(n = 120;
NR)

O’Neill et Adult
al. 2008
females
(NR;
n = 115 at
1 month and
6 months)

Highrisk
genetic
result

and
Non-risk
genetic
result

Chao et al. Adult with
2008
parent who
developed
Alzheimer
disease
(n =162;
n = 147)

Genetic
testing
and
Highrisk
genetic
result

Sanderson Adult
Genetic
et al. 2008 smokers (NR; testing
n = 61)
and
Highrisk
genetic
result
Rees et al. Adult
2007
females
(n = 23)

Genetic
testing

No
genetic
testing
and
Non-risk
genetic
result
No
genetic
testing
and
Non-risk
genetic
result
None
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Rief et al. Adults
2007
(n = 294)

Genetic
testing
and
consultat
ion

No
genetic
testing –
consultat
ion only

Obesity (NR)

6 months

Nutrition
NS changes to restraint
(restraint eating) eating in the genetic
testing group compared to
the no-genetic-testing
groups

1

No

and
No
genetic
testing
and no
consultat
ion
Carpenter Adult
Highet al. 2007 smokers (n = risk
729; n = 199) genetic
result

Non-risk
genetic
result

Emphysema
(AAT)

3 months

Smoking

Those with high-risk
genetic results made
significantly greater quit
attempts than the non-risk
genetic result group (p =
0.004)

3

NR

Ito et al.
2006

Genetic
testing

No
genetic
testing

Lung and
oesophageal
cancer
(L-myc)

3 months
9 months

Smoking

NS differences in smoking
cessation between groups
at 3 months (significance
level NR) or 9 months

1

NR

Marteau et Adult
Genetic
al. 2004
probands and testing
their adult
relatives with
familial
hypercholeste
rolaemia (n =
341;
n = 275)

No
genetic
testing

Familial
hypercholesterol
aemia (NR)

6 months

Nutrition (total NS impact on nutrition,
fat and
physical activity, or
unsaturated fat), smoking with genetic
physical activity, testing
and smoking

1

NR

Mcbride et Adult
Genetic
al. 2002
smokers (n = testing
557; n = 412
at
6 months,
n = 356 at
12 months,
n = 487 with
data from all
3 time points)

No
genetic
testing

Lung cancer
(GSTM1)

6 months
12
months

Smoking

Greater smoking cessation
in the genetic testing group
than in the no-genetictesting group (p < 0.006) at
6 months; NS smoking
cessation rates at 12
months

1

NR

Audrain et Adult
Genetic
al. 1997
smokers (n = testing
550; n = 426)

No
genetic
testing

Lung cancer
(CYP2D6)

12
months

Smoking

Greater likelihood of quit
attempts in the genetic
testing group than in the
no-genetic-testing group (p
= 0.02); NS change in 30day cessation between
groups

1

NR

Adult
smokers (n =
697; n = 369
with data for
baseline,
3 and 9
months)
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Table 3.1 Legend: COI, conflict of interest; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; NS, not statistically significant (p > 0.05 unless otherwise
stated); NR, not reported; DTC, direct to consumer; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid. 1 The rank of the study design is as
follows, based on the categories of the NIH Quality Assessment Tools (NIH, 2014) in combination with consideration of the hierarchy of evidence (Evans et al.
2003): 1 = controlled intervention study; 2 = observational cohort/cross-sectional study; 3 = case-control study; 4 = pre-post study with no control group. 2 Note:
significance levels for this group of participants are reported in Bloss et al. 2011.

Table 3.2: Summary of quality assessment ratings and impact of genetic testing on lifestyle factor(s) of interest
Ranking of First author,
study
year
design1

Quality assessment rating

Key findings: impact of genetic testing on
lifestyle factor(s) of interest

methods genetic TPB
info

overall
quality
score

nutrition PA smoking nutrition nutrition,
& PA

Source of genetic Specific lifestyle factors with significant
information
improvement

PA, &
smoking

1

Roke et al.
2017

Good

Fair

Fair

7

Δ

Other

N/A

1

HietarantaLuoma et al.
2015

Fair

Good

Poor

6

a
Δ
(2 weeks)
b

(6
months)
c
(12
months)

HCP

Improved dietary fat quality (high-risk
genotype vs. control at 2 weeks and
baseline to 6-month follow-up in high-risk
genotype group); decreased intake of highfat, high-sugar foods (in low-risk genotype
vs. control at 12 months)

1

Marsaux et al. Fair
2015

Fair

Poor

5

Δ

DTC

N/A

1

Meisel et al.
2015

Poor

Fair

Fair

5

Δ

Δ

DTC

N/A

1

Voils et al.
2015

Fair

Good

Poor

6

d
Δ
(3
months)
Δ
(6
months)

HCP

Reduced calories and fat (MUFA and
PUFA)

1

Nielsen et al.
2014

Good

Fair

Poor

6

Δ
(3
months)
a
(12
months)

DTC

Reduced sodium intake

1

Hollands et al. Good
2012

Good

Poor

7

Δ

Other

N/A

1

Hishida et al.
2010

Poor

Poor

3

Δ

HCP

N/A

Poor
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1

Chao et al.
2008

Fair

Poor

Poor

4

1

Sanderson et
al. 2008

Poor

Fair

Fair

5

1

Rief et al. 2007 Fair

Good

Poor

6

1

Ito et al. 2006 Poor

Good

Fair

6

1

Marteau et al. Fair
2004

Fair

Fair

6

1

McBride et al. Poor
2002

Good

Fair

1

Audrain et al. Fair
1997

Fair

Fair

2

2

Δ

Δ

a, e

HCP

General improvements to nutrition and PA;
vitamin E supplementation was the most
common change reported

HCP

Fewer cigarettes smoked and greater
smoking cessation

HCP

N/A

Δ

Other

N/A

Δ

HCP

N/A

6

d
(6
months)
Δ
(12
months)

Other

Greater smoking cessation

Fair

6

d (quit
attempts)
Δ (30-day
cessation)

HCP

Greater likelihood of quit attempts

Fair

Poor

5.6

3/8

0/6 3/7

Egglestone et Poor
al. 2013

Poor

Poor

3

d

d Δ

DTC

Kaufman et al. Fair
2012

Poor

Poor

4

e

e

DTC + optional
HCP

Greater health behaviour scores; the most
common changes were “healthier diet,”
“more exercise,” and “taking vitamins or
supplements”; more often reported
“sufficient fruit and vegetable intake”
“Changed their diet” and “started
exercising more”

Poor

Poor

3.5

2/2

2/2 0/1
Δ

DTC

N/A

Summary2 (n = 15)

Summary2 (n = 2)

Fair –
poor

a
(1 week)
Δ
(2
months)
Δ
Δ

Δ

1/1
d

1/1

3

Marsaux et al. Fair
2016

Fair

Poor

5

3

Vernarelli et al. Good
2010

Poor

Poor

5

e

Δ

HCP

Greater changes in supplement use; vitamin
E, vitamin C, botanicals, multivitamins,
vitamin B, and fish oil/omega were the
most common changes reported

3

O’Neill et al.
2008

Poor

Poor

5

Δ

Δ

HCP

N/A

3

Carpenter et al. Fair
2007

Fair

Poor

5

DTC + optional
HCP

Greater 24-h quit attempts

DTC + optional
HCP

N/A

Good

e

Summary2 (n = 4)

Good – Fair – Poor
fair
poor

5.0

1/2

0/3 1/1

4

Fair

5

Δ

Δ

Boeldt et al.
2015

Poor

Fair
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4

Bloss et al.
2013

Fair

Poor

Fair

5

Δ

Δ

DTC + optional
HCP

N/A

4

Bloss et al.
2011

Fair

Poor

Poor

4

Δ

Δ

DTC + optional
HCP

N/A

4

Quach et al.
2009

Fair

Poor

Fair

5

Δ

Δ

HCP

N/A

Summary2 (n = 4)

Fair

Poor

Fair

4.8

0/4

0/4

Qualitative Rees et al.
2007

Good

Poor

Poor

5

Δ

Δ

HCP

N/A

Summary2 (n = 1)

Good

Poor

Poor

5.0

0/1

0/1

Summary of all studies
(n = 26)

FAIR

POOR POOR 5.2

Nutrition: 6/18 (33%)
PA: 2/16 (13%)
Smoking: 4/12 (33%)

Studies with significant beneficial health behaviour
change(s):
7/93 (78%) provided actionable recommendations
Studies with null findings:
7/14 (50%) provided actionable recommendations

“Other” sources of genetic information: Roke et al. 2017, used a researcher; McBride et al. 2002, used “trained counsellors”; Ito et al. 2006, used a “trained interviewer”;
Hollands et al. 2012, used a “trained research counsellor.” No studies found a detrimental effect of genetic testing on lifestyle change. Statistically significant beneficial behaviour
change(s); Δ, no statistically significant behaviour change(s); blank cells, lifestyle factor(s) of interest was/were not assessed; N/A, not applicable; TPB, theory of planned
behaviour; PA, physical activity; HCP, genetic intervention offered through a healthcare provider; DTC, genetic intervention offered direct to consumer; Other, another method
was used to deliver the genetic intervention to the participants; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid. 1 The rank of the study design is as
follows, based on the National Institutes of Health Quality Assessment Tools (National Institutes of Health n.d.) and the hierarchy of evidence pyramid (Evans 2003): 1 =
controlled intervention study; 2 = observational cohort/cross-sectional study; 3 = case-control study; 4 = pre-post study with no control group. 2 n = x indicates the total number
of studies included in the summary; modes are reported for each of the three quality assessment ratings; x/x indicates the number of beneficial behaviour change findings/the
total number of studies (note: several studies included multiple analyses such as those with more than one follow-up time point, and those assessing more than 1 lifestyle factor
of interest); the overall quality score is represented as a mean. 3 Three studies did not provide information about whether or not actionable recommendations were provided.
a High-risk genotype vs. control group. b Baseline to 6-month follow-up in high-risk genotype group. c Non-risk genotype vs. control group. d Genetic testing group vs. control
group. e High-risk genotype group vs. non-risk genotype group.
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Table 3.3: Frequencies of genes tested in genetic interventions and their reported associated
health outcomes
Gene

Frequency

Health outcomes reported to be
associated with the gene

AAT
ACE
apoE

1
1
3

BRCA1

3

BRCA2

3

CYP1A2
CYP2D6
FADS1
FTO
GSMT1

1
1
1
3
3

GSTT1
KCNJ11
L-myc

1
1
2

NOD2
PPARγ
TAS1R2
TCF7L2

1
1
1
1

Emphysema
Salt sensitivity
Alzheimer disease
Cardiovascular disease
Breast cancer
Ovarian cancer
Breast cancer
Ovarian cancer
Caffeine metabolism
Lung cancer
Omega-3 metabolism
Overweight/obesity
Lung cancer
Vitamin C utilization
Vitamin C utilization
Type 2 diabetes
Lung cancer
Oesophageal cancer
Crohn’s disease
Type 2 diabetes
Sweet taste preference
Type 2 diabetes

Of the studies that reported the specific genes tested in the genetic
intervention, single nucleotide polymorphisms in 16 unique genes were
tested, with apoE, BRCA1/2, FTO, and GSTM1 having the highest
frequencies of use in the genetic intervention.
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Figure 3.1: Search terms

Figure 3.2: Search strategy

*Several articles assessed behaviour change related to >1 lifestyle factor of interest;
therefore, the total number of records included in the systematic review does not match
the total number of articles by lifestyle category.
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Supplementary Table 3.4: Quality assessment tool for genetic interventions
Criteria

Yes

No

Other (CD,
NR, NA)*

1. Were the results of the genetic test interpreted and explained by a trained
healthcare professional?
2. Was a copy of the genetic testing report provided to the participants?
3. Were the results of the genetic test communicated to participants on more than
one occasion (i.e. was there follow-up provided after the initial communication of
the results)?
4. Were the results provided in the report, or discussed in the genetic counselling
session actionable (i.e. did the report contain specific recommendations or did the
genetic counsellor communicate specific recommendations)?
5. Were the participants provided with an opportunity to ask questions about their
results?
Other Comments: ___________________________________________________________________________________
Overall Rating:_____________________________________________________ (Good, Fair, Poor; if Poor state reasons)
*CD, cannot determine; NA, not applicable; NR, not reported
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Supplementary Table 3.5: Summary of behaviour change theories and models included in
genetic intervention behaviour change research manuscripts
Author (Year)

Was reference
made to the TPB?

Roke (2017)
Marsaux (2016)
Meisel (2015)
Boeldt (2015)

No
No
No
No

Hieteranta-Luoma
(2015)
Voils (2015)
Marsaux (2015)
Nielsen (2014)
Egglestone (2013)
Bloss (2013)
Kaufman (2012)
Hollands (2012)

No

Was reference made to another
behaviour change theory or
model?
Yes – Parallel Process Model*
No
No
Yes – Health Belief Model and
Parallel Process Model*
No

No
No
No
No
No
No
No

No
No
No
No
No
No
No

Bloss (2011)
Vernarelli (2010)
Hishida (2010)

No
No
No

Quach (2009)
O’Neil (2008)
Chao (2008)
Sanderson (2008)

No
No
No
No

Rees (2007)

No

No
No
Yes – Transtheoretical Model**,
Extended Parallel Process Model
Yes – Self-Regulation Model
Yes – Transtheoretical Model**
No
Yes – Extended Parallel Process
Model
Yes – Transtheoretical Model**

Rief (2007)
Carpenter (2007)
Ito (2006)
Marteau (2004)

No
No
No
No

No
Yes – Transtheoretical Model**
Yes – Transtheoretical Model**
No

McBride (2002)

No

Audrain (1997)

No

Yes – Transtheoretical Model**
and Social Cognitive Theory
Yes – Transtheoretical Model**

Other Comments

Referred to “behaviour theories” in general

- Referred generally to “theories of attitude
change”

- Discussed that interventions based on
behaviour change theories are more
effective
- Referenced a meta-analysis of Protection
Motivation Theory
- Referenced an article which referred to
several theoretical perspectives including
the TPB and Theory of Reasoned Action

Referenced a meta-analysis of Protection
Motivation Theory

*The Parallel Process Model is often referred to as The Common Sense Model
**The Transtheoretical Model is often referred to as The Stages of Change
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Supplementary Figure 3.3: Number of studies published annually by category
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CHAPTER 4: A CRITICAL, SCOPING REVIEW OF GENETICBASED INTERVENTIONS FOR WEIGHT MANAGEMENT
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4.1 Title: Assessing the effectiveness of actionable nutrigenomics and lifestyle
genomics interventions for weight management: A critical, scoping review with
directions for future research
4.1.1 Abstract
The use of nutrigenomics and lifestyle genomics in clinical practice has the potential to
optimize weight-related outcomes for patients. A scoping review was conducted to summarize
and evaluate the current body of knowledge related to the effectiveness of providing DNA-based
lifestyle advice on weight-related outcomes, with the aim of providing direction for future
research. Primary studies were included if they were written in English, evaluated weight-related
and/or body composition outcomes, and provided participants with an actionable genetic-based
lifestyle intervention. Interventions that only provided information on genetic risk for
diseases/conditions were excluded. Data were extracted from each article meeting inclusion
criteria (n=3) and the studies were critically appraised for methodological quality. Research in
this area is promising, but limited. One study demonstrated that a nutrigenetic intervention
resulted in greater long-term weight loss compared to a standard intervention, while another
found no significant improvements in weight-related outcomes with genetically-tailored advice.
The third study found that individuals with high-risk FTO genotypes had greater changes in
markers of adiposity compared to a group receiving standard/non-personalized advice, but no
differences were observed between the genetic group and groups receiving other levels of
personalization that did not include the provision of genetic information and advice. With limited
existing research, the effectiveness of nutrigenomics and lifestyle genomics interventions for
weight management in clinical practice cannot yet be conclusively determined.
Recommendations for future research are detailed in the present manuscript.
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4.1.2 Background

Consumers have expressed considerable interest in nutrigenetic testing (Vallée Marcotte
et al. 2019; Nielsen and El-Sohemy 2014). As a result, many companies are offering
personalized DNA-based lifestyle advice, most of which provide specific recommendations to
optimize weight management practices (Nutrigenomix Inc., n.d.; MyDNA 2019; Pathway
Genomics, n.d.; 23andMe n.d.). With increasing epidemiological and interventional research
demonstrating relationships between genetics, nutrition and physical activity, and weight-related
outcomes (Garaulet et al. 2011; Phillips et al. 2012; Zhang et al. 2012; Corella et al. 2009),
personalized lifestyle recommendations based on genetics are beginning to be established. For
example, evidence from a 2-year randomized controlled trial (RCT) reported that variation in the
FTO gene at rs9939609 can predict weight loss response to a lower vs. higher protein diet
(Zhang et al. 2012).

Weight loss continues to be a priority for the general public (Sui et al. 2019). As such,
nutrigenomics and lifestyle genomics testing for weight management are attractive tools, as they
promote more personalized strategies for individuals to optimize their weight loss response to a
particular dietary plan (Garaulet et al. 2011; Phillips et al. 2012; Zhang et al. 2012; Corella et al.
2009). While the scientific evidence for personalized weight management strategies continues to
grow, long-term behaviour change and weight management remains a challenge and weight loss
outcomes in clinical practice often do not satisfy the wants or needs of patients (Soleymani,
Daniel, and Garvey 2016; Field, Camargo, and Ogino 2013; Rogerson, Soltani, and Copeland
2016). Moreover, weight loss is often followed by weight regain above and beyond baseline
weight. Research has demonstrated that such weight “yo-yoing” (the constant and recurring
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decrease and increase in weight over time) could be more harmful to health than maintenance of
a higher body mass index (BMI) (Rhee 2017).

Research demonstrates that individual responses to nutritional intake for weight
management differ based on genetic variation (Garaulet et al. 2011; Phillips et al. 2012; Zhang et
al. 2012; Corella et al. 2009). Some studies have also shown that individuals are more motivated
to follow nutrition advice when it is based on their genetics (Nielsen and El-Sohemy 2014;
Horne et al. 2018; Kaufman et al. 2012). Thus, it is possible that the provision of nutrigenomics
and lifestyle genomics interventions could be used as tools to support long-term weight
management. However, multiple factors beyond genetics, nutrition, and physical activity
contribute to the development and management of obesity including the social determinants of
health, built environment, food access and availability, medications, certain diseases/conditions
such as polycystic ovarian syndrome, sleep, stress and others (Moore et al. 2010; Finkelstein,
Ruhm, and Kosa 2005; Seabrook and Avison 2010; Gilliland et al. 2012; Naderpoor et al. 2015;
Maina et al. 2004). Thus, managing overweight and obesity is multi-factorial. Nutritional
genomics and lifestyle genomics are not the only considerations of weight management, but they
remain important components of the overall picture, alongside other factors.

With the robust and growing research foundation on the science of nutrigenomics,
lifestyle genomics, and differing weight loss responses to the same nutrition plans, this review
aims to summarize and evaluate the current body of knowledge related to the effectiveness of
providing DNA-based lifestyle advice on weight-related outcomes, with the aim of providing
direction for future research.

68

4.1.3 Methods
A scoping review was conducted with guidance from Arksey and O’Malley’s
methodological framework (Arksey and O’Malley 2005). The purpose of this review was to
identify, summarize and review the existing literature on the efficacy of using genetic-based
lifestyle interventions to enhance weight loss and/or improve body composition. Furthermore,
we aimed to use these results to provide direction for future research. English articles assessing
the impact of providing genetic-based lifestyle advice on weight-related, BMI and/or body
composition outcomes were included. Non-English articles, and articles assessing the impact of
providing information on genetic risk (i.e. without actionable lifestyle advice) were excluded. To
capture studies only assessing the pragmatic use of genetic-based lifestyle interventions, articles
were also excluded if they aimed to identify or replicate gene-nutrient-health outcome/weight
interactions. PubMed and Google Scholar were searched for relevant studies using different
combinations of the following search terms: nutrigenomics, nutrigenetics, nutritional genomics,
lifestyle genomics, weight, BMI, body composition, intervention, nutrition, lifestyle, and/or
physical activity. Reference lists of included articles were reviewed for relevant articles.

The following data from each study were charted: author(s), year of publication,
intervention type and comparator, duration of intervention, study population, methods, relevant
outcome measures, single nucleotide polymorphisms (SNPs) included in genetic reports, genetic
testing company (where applicable), and relevant results related to the effectiveness of geneticbased weight management interventions. Each article was critically appraised for key limitations
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of the employed scientific methods to determine gaps in the existing literature and provide
direction for future research.

4.1.4 Results

A summary of studies meeting the inclusion criteria (n=3) is presented in Table 4.1. This
review found that overall research in this area is minimal, with only three studies assessing the
practical impact of providing actionable genetic-based lifestyle information on weight-related
and/or body composition outcomes. While two RCTs have been conducted, one was a feasibility
study (Frankwich et al. 2015), which has not yet been followed up with a larger, adequately
powered trial and in the other, change in a weight-related outcome was not the primary outcome
of interest (Celis-Morales et al. 2017; Newcastle University 2016).

The retrospective chart review by Arkadianos et al. (2007) was an informative first step
for this body of knowledge. The authors concluded that individuals receiving the nutrigenomics
intervention were more likely to maintain weight loss and experienced significantly greater BMI
reductions over the long-term, compared to individuals who were advised to follow a low
glycemic-index, Mediterranean diet. However, several methodological limitations should be
noted. First, due to the nature of the study methods (retrospective chart review), cause and effect
relationships cannot be drawn. Furthermore, the nutrition recommendations provided to
participants were not specific to weight management; rather, they provided recommendations for
general health and wellbeing. For example, SNPs in tumor necrosis factor alpha (TNFα),
interleukin 6 (IL6) and nitric oxide synthase 3 (NOS3) were tested to provide nutrition
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recommendations such as “Add supplement Omega 3 (700-1400 mg). Make sure weekly diet
contains portions of oily fish” (Arkadianos et al. 2007). Additionally, intervention durations
were not standardized and therefore varied substantially in both total length and the amount of
follow-up. Of note, income was not considered as a confounding factor, and given that patients
either chose to purchase a nutrigenetic test (out of pocket) or did not purchase a nutrigenetic test
in this study, it is plausible that income levels differed significantly between groups. This is an
important confounding factor to consider given that income is a well-established social
determinant of health (Government of Canada 2019; Seabrook and Avison 2012). The authors
noted several other limitations including the lack of placebo, modest sample (n=93) size, and a
sample consisting of Caucasian individuals from Greece with a history of difficulty losing
weight, thus limiting generalizability (Arkadianos et al. 2007).

Frankwich and colleagues conducted the first RCT in this area (Frankwich et al. 2015).
This was a feasibility RCT. Feasibility trials are distinguished by their focus on assessing the
viability or capability of conducting a larger trial, rather than assessing effectiveness or efficacy
of an intervention with adequate power (Eldridge et al. 2016). The percent of participants
achieving 5% weight loss was the primary outcome, and this study found that there was no
significant difference between groups in the percent of participants achieving 5% weight loss
(Frankwich et al. 2015). However, typically estimates of participant outcomes such as weight
loss would be reported as estimates with 95% confidence intervals (without p-values) given that
feasibility trials are not adequately powered to assess the effectiveness of an intervention
(Eldridge et al. 2016). In fact, the authors noted limitations related to the small sample size
(n=32), and determined that a sufficiently powered trial would require 336 participants per group
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using a sample size calculation with 80% power and an alpha-level of 0.05 (Frankwich et al.
2015).

Finally, Celis-Morales et al. (2017) conducted the second RCT on this topic, which was a
sub-study within the larger Food4Me RCT. This was a significant contribution to the body of
knowledge in this area. In total, participants were provided with information and advice related
to five gene-lifestyle-health outcome interactions (FTO, physical activity and weight; FADS1
omega-3 and cardiovascular health; TCF7L2 dietary fat and weight; ApoE(e4), saturated fat and
cholesterol/cardiovascular health; MTHFR, folate and cardiovascular health). This study
compared weight and waist circumference (WC) outcomes between a control group and different
levels of personalized advice (as outlined in Table 4.1), and further compared risk and non-risk
FTO genotype groups (Celis-Morales et al. 2017). Participants randomized to receive FTO
genetic information/advice were informed that “A specific variation of this gene is associated
with a greater need to maintain a healthy body weight and engage in physical activity. A healthy
weight combined with exercise may provide added health benefits for these individuals.”
Carriers of the high-risk FTO allele were further advised to “[reduce their] body weight and
waist circumference to a healthy normal range because [they] have a genetic variation that can
benefit by reducing these two obesity-related markers.” Furthermore, participants randomized to
receive genetic-based advice were provided with weight-related information and advice
according to a variant within the TCF7L2 gene. They were informed that “a specific variation of
this gene is associated with improved weight loss when consuming a low-fat diet compared with
the effect of other weight-loss diets” and that “reducing dietary fat may enhance weight loss in
these individuals” (Celis-Morales et al. 2017). While the RCT was well-designed and is
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reflective of direct-to-consumer (DTC) lifestyle genomics testing, there are some considerable
limitations to note. First, the height, weight, and waist circumference (WC) data were all selfreported. While the authors point out that these measures are reliable (Celis-Morales et al. 2015),
certainly measured data would still have improved validity and reliability. Another notable
limitation of this study was that the FTO-related advice provided to participants was borderline
actionable. Given the complexity of weight management (Moore et al. 2010; Finkelstein, Ruhm,
and Kosa 2005; Seabrook and Avison 2010; Gilliland et al. 2012; Naderpoor et al. 2015; Maina
et al. 2004), simply advising individuals to “maintain a healthy body weight” does not provide
specific direction on how to achieve this aside from a broad statement advising individuals to
exercise. While the TCF7L2-related advice to consume a low-fat diet was actionable, the exact
amount of dietary fat was not well-defined and only individuals with the high-risk genotype of
TCF7L2 received an actionable recommendation. Therefore, it is not surprising that individuals
provided with genetic-based information/advice did not reduce their weight or WC to a greater
extent than those receiving other forms of personalized advice (Table 4.1). The authors do
mention this as a limitation, stating that the feedback was “only a positive reinforcement” (CelisMorales et al. 2017). Lastly, a weight-related outcome was not the predetermined primary
outcome of this study and therefore it is possible that the statistical power for this study was
inadequate, which is also noted by the authors (Celis-Morales et al. 2017).

Overall, study limitations in the current body of knowledge are related to study design,
the nature of the recommendations provided to participants, small (underpowered) sample sizes,
the use of self-reported weight-related data, and lack of consideration of important confounding
factors.
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Table 4.1: Summary of studies meeting inclusion criteria
Author,
year

Methodology

Intervention
Duration
(data
collection
follow-ups)

Intervention
Type and
Comparator

Study
Population
(number of
participants
completing
study)

Information on Genes, SNPs,
Dietary/Lifestyle Advice
Provided, and Company
(where applicable)

Outcome*

Results Related to the Effectiveness of GeneticBased Interventions for Weight Management

Arkadianos
et al. 2007

Retrospective
Chart Review

90 to >365
days
(duration
differed by
patient)

Nutrigeneticguided diet vs.
low glycemicindex,
Mediterranean
diet

Patients with
history of
unsuccessful
weight loss
attempts
(n=93)

Weight,
BMI

•

RCT
(feasibility
trial)

24 weeks
(follow-up at
8 weeks and
24 weeks)

Nutrigeneticguided diet vs.
standard
balanced diet

U.S. veterans
(n=32)

RCT

6 months
(follow-up at
3 and 6
months)

Diet + phenotype
+ genotype vs.
diet + phenotype
vs. diet vs.
control; and FTO
high-risk
genotype vs.
FTO non-risk
genotype

Overweight/
obese
individuals
from 7
European
countries
(n=583)

24 variants in 19 genes to
provide advice for: folic acid,
vitamin B6, vitamin B12,
cruciferous vegetables, vitamin
A, vitamin C, vitamin E,
caffeine, dairy, vitamin D,
calcium, omega-3, exercise
Balanced, low-carbohydrate,
low-fat or Mediterranean based
on SNPs of 7 genes (APOA2
rs5082, ADIPOQ rs17300539,
FTO rs9939609, KCTD10
rs10850219, LIPC rs1800588,
MMAB rs2241201, and PPARG
rs1801282) used in Pathway
FIT®’s proprietary algorithm
Individuals with high-risk FTO
genotype advised to engage in
physical activity and reduce
weight and waist circumference
to maintain a healthy body
weight; individuals with highrisk TCF7L2 genotype advised
to consume a low-fat diet

Frankwich
et al. 2015

CelisMorales et
al. 2017

•

Weight*,
BMI

•
•

Weight,
WC

•

•

Nutrigenetic diet group was more likely to have
maintained some weight loss
Nutrigenetic diet group had significantly greater
BMI reduction long-term (>300 days)

Nutrigenetic intervention did not enhance weight
loss
Adherence to nutrigenetic intervention was
correlated with weight loss (adherence to standard
diet was not)

High-risk FTO genotype group had greater
reductions in weight and WC compared to the
control group (standard, non-personalized
lifestyle advice)
No significant differences in weight loss and WC
reductions between diet + phenotype + genotype
group and different levels of personalized advice
(i.e. diet + phenotype group that received advice
based on weight, diet, physical activity level,
blood work and WC; and diet only group that
received advice based on weight, diet and
physical activity level)

*denotes primary outcome indicated in manuscript
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4.1.5 Discussion

To our knowledge, this is the first review that summarized and assessed the current body
of knowledge related to the impact of providing patients with genetic-based lifestyle
interventions for managing weight, BMI and/or body composition. It is clear that significant gaps
exist in the literature.

Critically analyzing the level of evidence available to support the genes tested and
subsequent dietary advice provided was beyond the scope of this review. However, it should be
noted that the lack of regulation in the genetic testing industry allows for tests to go to market
without any accountability to base such tests on robust or any level of scientific evidence
(Caulfield and McGuire 2012); as such, guidelines have been developed to assess the scientific
validity and evidence for various nutrigenomics interactions (Grimaldi et al. 2017). It is
interesting to note that one of the three conducted studies provided genetic-based
recommendations for following low-carbohydrate nutrition plans for weight loss, when the
evidence to support such genetic-based advice has been scrutinized. Recent research has assessed
whether genetic-based alignment to low-carbohydrate nutrition plans is effective for predicting
weight loss outcomes. These studies (Coletta et al. 2018; Gardner et al. 2018) do not assess the
effectiveness of providing patients/consumers with genetic-based lifestyle advice and therefore
were not included in the present review. However, based on the results from these two studies, it
is clear that our knowledge of using genetics to predict weight loss response to low-carbohydrate
diets is lacking as both studies concluded that dietary alignment to the particular genetic profiles
did not correlate with greater weight loss outcomes (Coletta et al. 2018; Gardner et al. 2018).
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This simply demonstrates that the genes tested, and genetic-based nutrition advice provided were
not based on robust evidence; it does not necessarily imply that all nutrigenomics interventions
will be ineffective at reducing weight and/or improving body composition. Until further research
provides better insights for tailoring carbohydrate intake based on genetics, it remains
inappropriate to use nutrigenetic testing to provide information in response to low-carbohydrate
nutrition plans for weight loss. While we work towards improving knowledge in this area,
perhaps interventions providing genetically-tailored weight management advice should be
focused on other nutrients such as protein and saturated fat (Zhang et al. 2012; Casas-Agustench
et al. 2013; Corella et al. 2009).

From a consumer genetic testing perspective, with the current lack of industry regulation,
companies are free to provide any genetically-guided advice regardless of the level of scientific
evidence (Caulfield and McGuire 2012). Until regulation catches up with industry practices, the
development of clinical practice guidelines in nutrigenomics would help to provide guidance to
researchers and clinicians for incorporating evidence-based nutrigenomics advice into research
and clinical practice. Ultimately, this would enhance the potential for nutrigenomics to improve
health outcomes for the general public.

Overall, weight management remains a challenging area of clinical practice. Research
evaluating the effectiveness of genetic-based weight management interventions has been
minimal, and results have been variable thus far. While there were some promising findings by
Arkadianos et al. (2007), this study had significant methodological flaws. Similarly, while
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Frankwich et al. (2015) completed the first RCT in this area, this was a feasibility RCT, which
has not yet been followed up with a larger, adequately powered clinical trial. Lastly, CelisMorales (2017) completed a second RCT, but the genetic-based advice provided to participants
was minimal, and borderline actionable, and the study may not have been adequately powered
statistically.

Based on this review, future research should seek to use evidence-based nutrigenetic
interventions, employ an RCT methodology, be adequately powered to detect significant
differences for a predetermined weight-related primary outcome, consider important
confounding factors, be at least 12 months in duration, and follow established processes for
clinical trials such as the SPIRIT and CONSORT guidelines (Chan et al. 2013; Zwarentein et al.
2008). Furthermore, this future work should provide a genetic-based intervention that is likely to
facilitate behaviour change; a quality assessment tool for genetic-based interventions has been
developed and should be used to help researchers design appropriate interventions (Horne et al.
2018). This work should also use previously developed study quality assessment tools to inform
study design and reduce any risk of bias (National Institutes of Health n.d.).

4.1.6 Conclusion
Research assessing the impact of providing genetically-tailored information and advice
on weight management outcomes is minimal. Notable limitations exist in the study methods
employed in the current body of knowledge. Future research should address these limitations
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before we can thoroughly answer the important research question: Can the use of nutrigenomics
and lifestyle genomics interventions enhance weight-related outcomes?
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CHAPTER 5: STUDY DESIGN
As published* in BMC Public Health:
Horne J, Gilliland J, O’Connor C, Seabrook J, Hannaberg P, Madill J. 2019. “Study protocol of
a pragmatic randomized controlled trial incorporated into the Group Lifestyle Balance™
Program: The Nutrigenomics, Overweight/Obesity and Weight Management Trial (The NOW
Trial).” BMC Public Health 19(1): 310.
*Sub-heading numbers, table/figure numbers and reference formatting have been modified for consistency with the
present dissertation.
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5.1 Title: Study Protocol of a pragmatic randomized controlled trial incorporated into the
Group Lifestyle Balance™ Program: The Nutrigenomics, Overweight/Obesity and Weight
Management Trial (The NOW Trial)

5.2 Abstract

Background: The nutrigenomics, overweight/obesity and weight management trial (NOW Trial)
is a pragmatic randomized controlled trial of community-dwelling adults recruited from the
Group Lifestyle Balance™ (GLB) Program. The GLB Program (formerly referred to as the
Diabetes Prevention Program) is an evidence-based, intensive weight management program,
which was offered to overweight/obese patients (BMI ≥ 25.0 kg/m2) in a rural Ontario
community.
Methods: Patients enrolled in the GLB Program were invited to participate in this study. GLB
groups were randomized 1:1 to receive either the standard GLB program + population-based
lifestyle advice for weight management, or a modified GLB program + personalized, geneticbased lifestyle advice for weight management. The purpose of this study is to determine if the
provision of genetic-based lifestyle guidelines is superior to the provision of population-based
guidelines in a pragmatic clinical setting to promote changes in: body composition, weight, body
mass index, dietary and physical activity habits, as well as attitudes, subjective norms, and
behavioural control. The 12-month intervention protocol consists of 23 group-based sessions and
4 one-on-one sessions. Data collection time points include baseline in addition to 3, 6, and 12month follow up. The comprehensive study design is described in the present manuscript, using
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both the extended CONSORT checklist for reporting pragmatic trials and the SPIRIT checklist
as guidance during manuscript development.
Discussion: Overall, this study seeks to pragmatically determine if the provision of DNA-based
lifestyle advice leads to improved health and lifestyle outcomes compared to the provision of
standard, population-based lifestyle advice. The results of this trial can be used to inform clinical
and community nutrition practice guidelines.
Trial Registration: This study was registered with clinicaltrials.gov: NCT03015012 on January
9, 2017.

5.3 Introduction

Lifestyle modification of nutrition and physical activity are often recommended to help
manage overweight and obesity (Jensen et al. 2014). Despite increased knowledge of beneficial
lifestyle strategies for weight management, rates of overweight and obesity continue to climb
among adults in Canada and the United States (Devito, French, and Goldacre 2018; Statistics
Canada 2014). The Group Lifestyle Balance™ (GLB) program is one of the most successful
lifestyle-based weight management programs and is currently offered in over 80 primary care
settings in the United States and is now becoming increasingly prevalent in Canada (University
of Pittsburgh, c2017). The GLB program was originally intended only for individuals with
prediabetes and was formerly referred to as The Diabetes Prevention Program (DPP). In patients
with prediabetes, the DPP lifestyle intervention reduced the risk of progressing to type 2 diabetes
by 58%, while the biguanide antihyperglycemic agent, Metformin, reduced the risk of type 2
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diabetes by 31% when compared to a placebo pill (Diabetes Prevention Program Research Group
2002). Given the documented success of the DPP, the Ontario Ministry of Health and LongTerm Care encouraged program expansion through broader eligibility criteria (Ontario Ministry
of Health and Long-Term Care 2018), and as such some clinics are now offering this program
for general weight management (regardless of receiving a prediabetes diagnosis), since
overweight and obesity are considered risk factors for the development of type 2 diabetes
(Diabetes Canada, c2019).

Although the GLB program has proven to be successful (Kramer et al. 2010; Diabetes
Prevention Program Research Group 2002; Piatt et al. 2012), a “one-size fits all” approach to
weight management has been critiqued by experts, who argue that this generalized approach
yields minimal weight loss outcomes that do not satisfy the wants and needs of clinicians,
researchers and patients alike (Field et al. 2013). Genetic testing is an innovative tool, which has
the potential to facilitate positive lifestyle changes and enhance patient outcomes, though this has
been widely debated in the literature in recent years (Horne et al. 2018; Hollands et al. 2016;
O’Donovan et al. 2017; French et al. 2017). A systematic review found that actionable lifestyle
recommendations (e.g., “reduce your consumption of sodium”) facilitated behaviour change
greater than the provision of simple genetic-based disease-risk estimates, and that nutrition was
the most promising lifestyle habit that could be motivated by lifestyle genomics testing (Horne et
al. 2018).

A few studies have assessed change in weight from the provision of genetic-based
information compared to a standard intervention (Arkadianos et al. 2007; Frankwich et al. 2015;
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Celis-Morales et al. 2017). Two studies reported that genetic testing was superior to a standard
intervention for changes in weight or BMI (Arkadianos et al. 2007; Celis-Morales et al. 2017),
and one study showed that adherence to a genetic-based diet was correlated with greater weight
loss, whereas adherence to a standard diet was not (Frankwich et al. 2015).

There have been considerable scientific advancements in knowledge pertaining to
nutrition and physical activity recommendations, which can be personalized based on an
individual’s genetic variation. Nutrigenomics is a science that explores the interaction between
nutrition, genetics, and health outcomes (Gibney and Walsh 2013). The science exploring how
nutrition and physical activity, alongside other lifestyle components, can impact health outcomes
can be referred to as lifestyle genomics (Horne et al. 2018). Single nucleotide polymorphisms
(SNPs) located within the genes FTO, MC4R, TCF7L2, UCP1, APOA2, and PPARg2 can
impact physical activity and dietary approaches to weight management and/or nutritional habits
(Corella et al. 2010; Nagai et al. 2011; Zhang et al. 2012; Grau et al. 2010; Mattei et al. 2012;
Phillips et al. 2012; Garaulet et al. 2011; Stutzmann et al. 2009; Andreasen et al. 2008).
Furthermore, SNPs located within the genes ACTN3, NFIA-AS2, ADRB3, NRF2 and GSTP1
have been shown to impact genetic predisposition to excel in either endurance or strength-based
activities (Ma et al. 2013; Ahmetov et al. 2015; Zarebska et al. 2014; He et al. 2006; Santiago et
al. 2011). These genetic variants were used in the genetic test provided in the present study as
they are currently offered through commercial genetic testing (Nutrigenomix Inc., n.d.), thus
optimizing the pragmatic nature of this trial.
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While genetics certainly play a role in obesity, there are multiple factors contributing to
the current obesity epidemic, including diminished energy expenditure, increased energy intake,
rising food costs, the built environment, socioeconomic status, and other social determinants of
health (Moore et al. 2010; Eriksson et al. 2003; Finkelstein, Ruhm, and Kosa 2005; Seabrook
and Avison 2010; Gilliland et al. 2012; Sarma et al. 2014). Several of these factors can be
modified such as energy intake and energy expenditure.

The Theory of Planned Behaviour (TPB) posits that attitudes towards a behaviour,
subjective norms, perceived behavioural control and actual behavioural control can be used to
predict intentions and behaviours (Ajzen 1991). Although the TPB is one of the most widelyaccepted behaviour change theories, it has yet to be incorporated into genetic testing behaviour
change research (Horne, Madill, and Gilliland 2017; Horne et al. 2018), despite a recent call to
incorporate this theory into personalized healthcare research (Horne, Madill, and Gilliland 2017).
By considering this theory, we can account for many contributors impacting behaviour change
and therefore account for several confounding factors, which could influence study results. The
present randomized controlled trial is the first study to intentionally incorporate the TPB into
genetic testing behaviour change research.

The proposed extended CONSORT checklist for reporting pragmatic trials (Zwarentein et
al. 2008) was used to guide the development of the current manuscript. The complete checklist
can be reviewed in Supplementary Table 5.2, with items 1 through 16 being relevant for
purposes of this paper.
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5.4 Methods/Design
5.4.1 Objectives
The primary objective of this study is to determine if the provision of genetic-based lifestyle
advice reduces body fat percentage to a greater extent than the provision of population-based
lifestyle advice. Secondary objectives include determining whether the provision of geneticbased lifestyle advice (a) helps to motivate healthful changes to dietary intake and physical
activity, (b) leads to greater improvements in anthropometric measures such as weight, BMI,
lean mass, fat mass (kg), and water weight, and (c) influences attitudes, subjective norms,
behavioural control, and intention to make lifestyle changes. The tertiary objective is to
determine if there is a nutrigenomics interaction between ACE rs4343 genetic variation, sodium
and water intake, and water weight.

5.4.2 Hypotheses
Compared to the provision of population-based lifestyle advice, providing DNA-based
lifestyle advice will lead to significantly greater improvements in: body fat percentage, attitudes
and intentions towards behaviour change, the adoption of healthier dietary and physical activity
habits, as well as improved weight, and BMI. Furthermore, ACE rs4343 genetic variation will
lead to increased water weight when sodium intake is high.

5.4.3 Material and Methods

The flow of the study protocol for this parallel group, superiority randomized controlled
trial is outlined in Figures 5.1, 5.2 and 5.3. Further details are provided below.
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5.4.4 Sample Size Calculation

Seventy-four participants (n = 37 per group) are needed in this study to detect a clinically
meaningful difference of 4% in body fat percentage, assuming 80% power, an alpha of 5%, and a
standard deviation of 6.1% (Smilowitz et al. 2009). We aimed to recruit 88 participants (n = 44
per group) to account for the potential dropout rate of 20%. While minimal research exists
outlining a clinically meaningful change in body fat percentage, a 5% change in weight (which
would come from fat mass, water weight and/or muscle mass) is often reported to be clinically
meaningful (Williamson et al. 2015). Furthermore, clinical experience from the registered
dietitians involved in this study helped to determine the clinically meaningful 4% difference
mentioned above. This difference has also been supported in published reference standards of
body fat percentage in Caucasian adults indicate that a 4% change in body fat percentage is
associated with a 1 – 2 decile change on the reference standards charts (Imboden et al. 2017).

5.4.5 Cohort Randomization

A cohort randomization model was used rather than subject randomization to allow all
participants in a given GLB group to obtain the same intervention. At the time of randomization,
12 cohorts (GLB groups) were randomized 1:1 to either the personalized lifestyle intervention
(PLI) based on genetics, or the standard lifestyle intervention (SLI) based on population-based
guidelines. It was anticipated that 12 groups of approximately 7 participants each would be
needed to obtain the desired sample size of 88 participants. Prior to obtaining informed consent
from participants, randomly permuted blocks were generated using the original generator on an
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internet-based randomization program (Dallal 2017). Since participant recruitment was quicker
than anticipated and there was an even 1:1 split of a PLI and a SLI group in the last two
randomized groups, only 10 of the randomized groups (5 PLI groups, 5 SLI groups) were used,
resulting in a total of N = 140 participants in the study (mean number of study participants per
group ± SD = 14.0 ± 4.1).

5.4.6 Recruitment

Participants were recruited from the GLB program at the East Elgin Family Health Team
(EEFHT). There were two primary methods of recruitment into this program: [1] adults from
Elgin and Middlesex Counties in Ontario, Canada were referred to the GLB program by
healthcare professionals in the area such as registered dietitians (RDs), physicians, nurses, nurse
practitioners, and physical therapists; and [2] adults joined the program through word-of-mouth
referrals from members of the community. Participants expressing interest in joining the GLB
program were invited to the EEFHT for an in-person meeting to learn about the NOW Trial, and
to provide written, informed consent if they decided to take part in the study. Therefore,
participants are highly reflective of typical patients in the GLB program. Recruitment occurred
from April 2017 until September 2018. This study is registered with clinicaltrials.gov
(NCT03015012) and was approved by the Western University Research Ethics Board (108511).

5.4.7 Participants: Screening & Informed Consent

Screening and informed consent were completed in person at The EEFHT during the inperson meeting. Inclusion criteria were as follows: BMI ≥ 25.0 kg/m2, ≥18 years of age, English-
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speaking, willing to undergo genetic testing, having access to a computer with internet at least
one day per week, and not seeing another healthcare provider for weight loss advice outside of
the study. Pregnancy and lactation were considered exclusion criteria.

5.4.8 Run-In

Upon obtaining written, informed consent, participants were scheduled for in-person
baseline data collection, within approximately 14 days (mean ± SD = 9.3 ± 5.7) prior to the
intervention start date. Participants were not given any lifestyle advice during the run-in period.

5.4.9 Baseline Data Collection

All data were entered into the database using unique study codes for each participant and
were securely stored in a locked cabinet, in a locked office. Baseline data consisted of a
combination of in-person, online, and telephone data collection methods.

Trained research assistants collected 3-day food records over the phone using the
validated multiple-pass method (Conway et al. 2003). To reduce participant burden, each
participant chose to have either three separate phone calls (one for each day of intake), or one
phone call (for all three days of intake). One weekend day and two weekdays were collected. In a
few cases where research assistants were unable to reach participants over the phone, the food
records were collected in-person at the EEFHT. The food records were then analyzed using the
Canadian Nutrient File within the nutritional analysis software program ESHA Food Processor
(version 11.1).
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Participants also completed a self-administered past-month, semi-quantitative, online
food frequency questionnaire, the Canadian Diet History Questionnaire II (CDHQII). This
questionnaire is a modified version of the United States Diet History Questionnaire adapted for
Canadian data (National Institutes of Health 2018). Most participants completed this
questionnaire away from the EEFHT, but in cases where participants did not have internet access
at home (n = 3), the CDHQII was self-administered at the EEFHT.

In-person baseline data collection included: measured height and weight (to calculate
BMI), a BIA assessment to obtain body composition data (using the Body Stat 1500MDD; see
further detail in methodological Appendix B), a past-week physical activity recall (to calculate
metabolic equivalents), a baseline demographic questionnaire, a list of medications, and a TPB
questionnaire. To optimize reliability, weight and height measurements were taken on the same
Health O Meter Professional weigh scale and stadiometer, and body composition was assessed
using the same BIA machine. The TPB questionnaire was developed based on Ajzen’s Guide to
Constructing a TPB Questionnaire (Ajzen 2006). The results for weight, body fat percentage,
body fat amount, lean weight, and water weight from the BIA were communicated to participants
during their in-person baseline data collection visit.

To assess possible short-term changes in components of the TPB (e.g., attitudes towards
nutrition, physical activity, genetic testing, etc.), the TPB questionnaire was administered twice
during the baseline assessment period: once during the one-on-one, in-person meeting (pre-
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intervention), and once immediately after the group-based intervention was delivered (postintervention).

5.4.10 Blinding and Allocation Concealment

During informed consent meetings, baseline data collection and the run-in period,
participants were blinded to their group assignment. However, participants were not blinded to
their group assignment during the administration of the second baseline TPB survey (completed
immediately after the first group session in order to assess possible changes short-term in key
components of the TPB upon receiving either population-based advice or genetic-based advice).
Research assistants collecting and analyzing food intake data were also blinded to the study
group of the participants and the statistician will be blinded to the group assignments. Since our
outcomes included changes in attitudes related to genetic testing for personalized lifestyle
advice, as well as change in nutrition and physical activity habits, it was inappropriate to blind
the participants throughout the entire duration of the study. Therefore, participants were
informed of their group assignment during the first group intervention meeting, as further
outlined in section 5.4.12, below. One author (JH) generated the allocation sequence, enrolled
participants, facilitated group and one-on-one interventions, collected data, entered data into the
database and scheduled participants, and therefore could not be blinded. Allocation was
concealed for the other five co-authors.

5.4.11 Staggered Cohorts
Staggered cohorts have been used to reduce the impact of confounding by indication and
have previously been successful in studies comparing active and passive treatment groups
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(Blackburn et al. 2017). In the present study, staggered cohorts were pre-planned in order to
maximize study efficiency and effectiveness. Seasonality and timing of groups were considered
in the planning phase to ensure that there was a similar amount of SLI groups and PLI groups
offered during the day and evening. Three SLI groups were offered during the day, and 2 SLI
groups were offered in the evenings. Likewise, 3 PLI groups were offered during the day, and 2
PLI groups were offered in the evenings. 1 SLI group began in the spring, 2 in the summer, and 2
in the fall. Similarly, 1 PLI group began in the spring, 2 in the summer, 1 in the fall, and 1 in the
winter.

5.4.12 Interventions

Given its previously documented success (Kramer et al. 2010; Diabetes Prevention
Program Research Group 2002; Piatt et al. 2012), the GLB program was chosen as the gold
standard comparator for this RCT. Furthermore, given that this study is taking place within
routine community/clinical practice, it is highly pragmatic with a mean overall PRECIS-2 score
of 4.4 (Table 5.1) (Loudon et al. 2015).

Participants joined the GLB group session that best suited their availability, and were
blinded to the group intervention assignment at this time. As previously detailed, groups were
pre-randomized 1:1 to receive either the standard 12-month GLB Program curriculum + a
summary report of population-based lifestyle recommendations (SLI/Control Group), or a
modified 12-month GLB Program + a summary report of DNA-based lifestyle recommendations
(PLI Group). All participants underwent a group-based weight management program in addition
to four one-on-one sessions (one baseline and three follow-up) with a RD. Group sizes ranged
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from 7 - 20 participants per group at baseline, with a mean group size of 14 participants. At the
three follow-up one-on-one sessions, the RD reviewed the information provided in the summary
report (population-based recommendations for the SLI group and DNA-based recommendations
for the PLI group; refer to Supplementary Tables 5.3 and 5.4, respectively, for sample reports).
One-on-one sessions lasted approximately 30 minutes. The same RD who completed the one-onone sessions was also the lead trained lifestyle coach for the GLB Program group sessions. This
allowed for optimization of intervention reliability in all group and one-on-one sessions. These
sessions were highly standardized as outlined in Supplementary Table 5.5. No additional
healthcare professionals above and beyond standard practice were hired to run the intervention at
the EEFHT. Interventions took place between May 2017 and September 2019.

SLI Group Meetings (Control Group)
The standard GLB Program curriculum involves group-based education on a sustainable
healthy lifestyle and a low-fat, calorie-controlled diet as further detailed elsewhere (University of
Pittsburgh 2017). Standard GLB group sessions were 1 hour long. The EEFHT expanded the
eligibility criteria for this program and offered it to adults with a BMI ≥25 kg/m2. In addition to
the standard GLB Program, participants were provided with an extra 1.5 hour group session (the
first session), where they were given an overview of population-based information and
recommendations for calories, protein, total fat, saturated fat, total unsaturated fat,
monounsaturated fat, polyunsaturated fat, and physical activity. This information is further
detailed in Supplementary Table 5.3. Upon completion of the 12-month study, participants in the
SLI group were given the results of their lifestyle genomics test if they were interested in
receiving it.
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PLI Group Meetings (Intervention Group)
The modified GLB Program curriculum is outlined in Supplementary Table 5.5. The
modifications allowed participants in this group to follow their DNA-based recommendations,
rather than the standard population-based guidelines. For example, if an individual possessed a
genetic variant in the FTO gene whereby a moderately high protein diet can enhance weight loss
(Zhang et al. 2012), they were given a target for protein, and were taught how to count daily
grams of protein (in addition to calories). In comparison, for the standard GLB program, every
participant was provided with a target for total fat intake and were taught how to count daily fat
grams (in addition to calories). Modified GLB group sessions were 1 hour long. In addition to
the modified GLB Program, participants were provided with an extra 1.5 hour group session (the
first session), where they were given an overview of personalized DNA-based information and
recommendations for calories, protein, total fat, saturated fat, total unsaturated fat,
monounsaturated fat, polyunsaturated fat, and physical activity. This information is further
detailed in Supplementary Table 5.4. It should be noted that the genetic intervention is rated to
be high-quality based on a recently developed genetic intervention quality assessment tool
(Horne et al. 2018). The quality assessment is outlined in Supplementary Table 5.6.

5.4.13 Follow-Up Data Collection

Similar to baseline data collection, follow-up data collection involved a combination of
in-person, online and telephone data collection methods. All participants were invited to
complete follow-up data collection, regardless of their compliance to their intervention’s lifestyle
recommendation. Complete follow-up data included: BMI, 3-day food records, the CDHQII
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past-month online food frequency questionnaire, BIA, a past-week physical activity recall, a
follow-up demographic survey and medication list, and a TPB questionnaire. Further details of
these measures are indicated above in section 5.4.9. The TPB questionnaire was administered
once at each follow-up time point during the one-on-one in-person sessions. In addition, at the
12-month follow-up, participants were asked one open-ended question: How has your life
changed since you started participating in this program/study (if at all)? Follow-up data
collection commenced in August 2017 and is ongoing until September 2019.

5.4.14 Statistical Analysis Plan

We plan to use SPSS Version 23.0 to conduct all statistical analyses, and the data will be
analyzed on an intention-to-treat basis. Generalized linear mixed-effects models will be used to
test between group differences from baseline to each follow-up period for each outcome
indicator. If significant mean differences are detected, a Tukey’s post hoc test will be used to
compare differences by group. General linear regression models will be used to assess
interactions between a given genotype of interest and dietary component of interest on BMI and
body composition. General linear regression models will further be used to assess interactions
between TPB components, study group, and anthropometric measures of weight and body
composition. No interim analyses will be completed.

5.4.15 Outcomes

The primary outcome in this study is change in percent body fat. Secondary outcome
measures include changes in: dietary intake (calories, fat, protein, carbohydrates, unsaturated fat
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including mono- and poly-unsaturated fat, saturated fat, and sodium), physical activity, attitudes,
subjective norms, behavioural control, intention to make lifestyle changes, weight and BMI.

5.4.16 Dissemination
We plan to disseminate the findings from this trial through: a community presentation to
the participants involved in the study, presentations at relevant conferences for researchers and
healthcare professionals, as well as in peer-reviewed publications.

5.5 Discussion
The overarching aim of this study is to determine if patients have improved health and
lifestyle outcomes with the provision of DNA-based lifestyle information and recommendations,
compared to the provision of standard, population-based lifestyle advice. Furthermore, it aims to
test the aforementioned hypotheses, based on lifestyle genomics weight management advice
available to consumers globally through commercial genetic testing. This highlights the
pragmatic nature of this trial, and optimizes the potential for knowledge translation on a globalscale.

The NOW Trial protocol differs from previous research in that it was designed
pragmatically, using a knowledge translation approach. Furthermore, the NOW Trial aims to
compare a DNA-based lifestyle change program to the gold standard, population-based lifestyle
change program (the GLB Program), while considering and accounting for major confounding
factors of behaviour change. It is also the first lifestyle genomics weight management and
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behaviour change study to incorporate the TPB into the study design; this may help target a subset of the population that may benefit most from genetic testing for weight management. This
trial is also unique because the genetic information was presented to participants in a group
setting, thus demonstrating the feasibility of this more efficient approach to the delivery of
genetic information.

Pragmatic clinical trials are distinguished by their focus on informing clinical practice
rather than confirming a physiological or clinical hypothesis. Notably, pragmatic trials help to
inform real-world research questions that are applicable to broad patient groups (Ford et al.
2016). Given the novel and pragmatic nature of the study, the NOW Trial provides several
original contributions to the literature. Overall, the NOW Trial will provide important,
innovative health knowledge relevant to researchers, academia, consumers, the genetic testing
industry, clinicians and public health authorities.
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5.6 Tables and Figures
Table 5.1: PRECIS-2 Scoring Tool
PRECIS-2 Domain

Score [Likert scale 1
(very explanatory) 5 (very pragmatic)]

1. Eligibility: To what extent are the participants in the trial similar 5
to those who would receive this intervention if it was part of usual
care?
2. Recruitment: How much extra effort is made to recruit
participants over and above what would be used in the usual care
setting to engage with patients?

5

3. Setting: How different are the settings of the trial from the usual
setting?

5

4. Organization: How different are the resources, provider
expertise, and the organization of care delivery in the intervention
arm of the trial from those available in usual care?

4

5. Flexibility (delivery): How different is the flexibility in how the
intervention is delivered and the flexibility anticipated in usual
care?

4

6. Flexibility (adherence): How different is the flexibility in how
participants are monitored and encouraged to adhere to the
intervention from the flexibility anticipated in usual care?

4

7. Follow-up: How different is the intensity of measurement and
follow-up of participants in the trial from the typical follow-up in
usual care?

3

8. Primary outcome: To what extent is the trial’s primary outcome
directly relevant to participants?

5

9. Primary analysis: To what extent are all data included in the
analysis of the primary outcome?

TBD

Mean score:

4.4
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Figure 5.1: Flow of study protocol
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Figure 5.2: CONSORT 2010 Flow Diagram

Enrollment

Assessed for eligibility (n=141)

Excluded (n=1)
 Not meeting inclusion criteria (n=1)
 Declined to participate (n=0)
 Other reasons (n=0)

Randomized (n=140)

Allocation
Allocated to SLI (n=70)
 Received allocated intervention (n=68)
 Did not receive allocated intervention (n=2,
lost to follow-up during run-in period)

Allocated to PLI (n=70)
 Received allocated intervention (n=69)
 Did not receive allocated intervention (n=1,
lost to follow-up during run-in period)

Follow-Up
Lost to follow-up (give reasons) (TBD)

Lost to follow-up (give reasons) (TBD)

Discontinued intervention (give reasons) (TBD)

Discontinued intervention (give reasons) (TBD)

Analysis
Analysed (TBD)
 Excluded from analysis (give reasons) (TBD)

Analysed (TBD)
 Excluded from analysis (give reasons) (TBD)
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Figure 5.3: SPIRIT flow diagram of the NOW trial study protocol at the EEFHT
STUDY PERIOD

TIMEPOINT

Enrolment

Baseline
Data
Collection

SE

Run-In

Post-allocation
Day 1

3 Mo.

6 Mo.

Close-out
12 Mo.

12 Mo.

ENROLMENT:
Eligibility screen

X

Informed consent

X

Allocation Revealed
to Participants

X

INTERVENTIONS:
Personalized
Lifestyle Intervention
Standard Lifestyle
Intervention
(Control)
Lifestyle Genomics
Results Provided to
Control Group

X

ASSESSMENTS:

Body Composition
Weight/Height/BMI

X

X

X

X

X

X

X

X

X

X

X

TPB Survey

X

Demographic
Questionnaire + Med
List

X

X

X

X

Past-Week Physical
Activity Recall

X

X

X

X

X

X

X

X

X

X

X

X

3-Day Food Records
Past-Month CDHQII
Qualitative
Component

SE: study entry

X

X

Mo: month
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Supplementary Table 5.2: Proposed extended CONSORT checklist of items for reporting
pragmatic trials
Section

Item

Standard CONSORT description

Extension for pragmatic trials

Checklist

1

How participants were allocated to
interventions (eg, “random allocation,”
“randomised,” or “randomly assigned”)



Title and abstract



2

Describe the health or health
service problem that the
Scientific background and explanation of intervention is intended to address
rationale
and other interventions that may
commonly be aimed at this
problem

Introduction

Background

Methods

Participants

Interventions

Objectives

3

4

5

Eligibility criteria for participants;
settings and locations where the data
were collected

Precise details of the interventions
intended for each group and how and
when they were actually administered

Eligibility criteria should be
explicitly framed to show the
degree to which they include
typical participants and/or, where
applicable, typical providers (eg,
nurses), institutions (eg,
hospitals), communities (or
localities eg, towns) and settings
of care (eg, different healthcare
financing systems)



Describe extra resources added to
(or resources removed from)
usual settings in order to
implement intervention. Indicate
if efforts were made to
standardise the intervention or if
the intervention and its delivery
were allowed to vary between
participants, practitioners, or
study sites



Describe the comparator in
similar detail to the intervention





Specific objectives and hypotheses
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Section

Outcomes

Sample size

Randomisation—
sequence
generation

Randomisation—
allocation
concealment

Randomisation—
implementation

Blinding
(masking)

Item

Standard CONSORT description

Extension for pragmatic trials

Checklist

Clearly defined primary and secondary
outcome measures and, when applicable,
any methods used to enhance the quality
of measurements (eg, multiple
observations, training of assessors)

Explain why the chosen outcomes
and, when relevant, the length of
follow-up are considered
important to those who will use
the results of the trial





7

How sample size was determined;
explanation of any interim analyses and
stopping rules when applicable

If calculated using the smallest
difference considered important
by the target decision maker
audience (the minimally
important difference) then report
where this difference was
obtained



8

Method used to generate the random
allocation sequence, including details of
any restriction (eg, blocking,
stratification)



9

Method used to implement the random
allocation sequence (eg, numbered
containers or central telephone),
clarifying whether the sequence was
concealed until interventions were
assigned



10

Who generated the allocation sequence,
who enrolled participants, and who
assigned participants to their groups

11

Whether participants, those
administering the interventions, and
those assessing the outcomes were
blinded to group assignment

6

Statistical methods 12


If blinding was not done, or was
not possible, explain why



Statistical methods used to compare
groups for primary outcomes; methods
for additional analyses, such as subgroup
analyses and adjusted analyses

Results
Participant flow

13

Flow of participants through each stage
(a diagram is strongly recommended)—
specifically, for each group, report the



The number of participants or
units approached to take part in
the trial, the number which were
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Section

Item

Standard CONSORT description
numbers of participants randomly
assigned, receiving intended treatment,
completing the study protocol, and
analysed for the primary outcome;
describe deviations from planned study
protocol, together with reasons

Extension for pragmatic trials

Checklist

eligible, and reasons for nonparticipation should be reported



Recruitment

14

Dates defining the periods of recruitment
and follow-up

Baseline data

15

Baseline demographic and clinical
characteristics of each group

TBD

TBD

Numbers analysed 16

Number of participants (denominator) in
each group included in each analysis and
whether analysis was by “intention-totreat”; state the results in absolute
numbers when feasible (eg, 10/20, not
50%)
For each primary and secondary
outcome, a summary of results for each
group and the estimated effect size and
its precision (eg, 95% CI)

TBD

Outcomes and
estimation

TBD

Ancillary analyses 18

Address multiplicity by reporting any
other analyses performed, including
subgroup analyses and adjusted analyses,
indicating which are prespecified and
which are exploratory

Adverse events

19

All important adverse events or side
effects in each intervention group

TBD

TBD

Interpretation

20

Interpretation of the results, taking into
account study hypotheses, sources of
potential bias or imprecision, and the
dangers associated with multiplicity of
analyses and outcomes

Generalisability

21

Generalisability (external validity) of the Describe key aspects of the
setting which determined the trial
trial findings
results. Discuss possible

TBD

17

Discussion
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Section

Item

Standard CONSORT description

Extension for pragmatic trials

Checklist

differences in other settings where
clinical traditions, health service
organisation, staffing, or
resources may vary from those of
the trial
Overall evidence

22

General interpretation of the results in
the context of current evidence

TBD
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Supplementary Table 5.3: Sample report for standard lifestyle intervention (GLB group)

Lifestyle Component

Population-Based Recommendations

Calories

Aim for a 500 calorie deficit per day for weight loss.

Protein
Total Fat
Saturated Fat
Unsaturated Fat

Consume 10-35% of calories from protein.
Consume 20-35% of calories from fat.
Limit your saturated fat intake to less than 10% of total calories.
Consume a balance of monounsaturated and polyunsaturated fat to meet your total fat
needs.
Monounsaturated Fat Consume a balance of monounsaturated and polyunsaturated fat to meet your total fat
needs.
Polyunsaturated Fat
Sodium
Consume less than 2300 mg sodium daily.
Eating Between
Do not go longer than six hours without eating throughout the day. Ensure snacks and
Meals
meals are calorie-controlled.
Physical Activity
Aim for 150 minutes/week of physical activity with muscle strengthening activities at
least 2 days/week.
Endurance
Find an endurance-based activity that you enjoy – meet the physical activity guidelines
stated above.
Strength and Power
Find a strength/power based activity that you enjoy – meet the physical activity
guidelines stated above.
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Supplementary Table 5.4: Sample report for personalized lifestyle intervention (GLB+NGx)
Lifestyle Component

Gene(s), rs
number(s)

Your
Genetic
Variant

Your
Risk/
Response

DNA-Based Recommendations and Implication

Calories

UCP1, rs1800592

AA

Typical

Your resting metabolism is typical. Aim for a 500 calorie deficit per day for weight
loss.

Protein

FTO, rs9939609

AA

Enhanced

You can enhance your weight loss if you consume 25-35% of calories from
protein.

Total Fat
Saturated Fat

TCF7L2, rs7903146
APOA2, rs5082

TC
CC

Typical
Enhanced

Consume 20-35% of calories from fat.
You can enhance your weight loss if you consume less than 10% of calories from
saturated fat.

Unsaturated Fat

FTO, rs9939609

AA

Enhanced

You can enhance your weight loss if you limit your intake of saturated fat to less
than 10% of calories and consume at least 5% of calories from polyunsaturated
fat.

Monounsaturated Fat

PPARg2, rs1801282

CC

Typical

Sodium
Eating Between Meals

ACE, rs4343
MC4R, rs17782313

GG
TT

Typical
Typical

Consume a balance of monounsaturated and polyunsaturated fat to meet your
total dietary fat intake goal.
Limit your sodium intake to less than 2300 mg per day for heart health.
You have a typical likelihood of eating between meals. Do not go longer than six
hours without eating.

Physical Activity

FTO, rs9939609

AA

Enhanced

Endurance

TT
CA
AA
CC
TC

Typical

Strength and Power

ADRB, rs4994
NRF2, rs12594956
GSTP1, rs1695
NFIA-AS2, rs1572312
ACTN3, rs1815739

Participant Number

X

Enhanced

You can enhance your weight loss if you complete at least 30-60 minutes/day of
cardio activity, 6 days/week and muscle-strengthening activities at least 2
days/week.
You have a typical genetic predisposition to excel in endurance-based physical
activity.

You have an enhanced genetic predisposition to excel in strength and power
based physical activity.
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Supplementary Table 5.5: GLB program/NOW trial curriculum and modifications for genetic
testing intervention groups
Class
Number

Class Topic

Modifications for Genetic Testing Intervention Groups1

1

General
Overview of
Nutrition and
Physical Activity
Targets2

•

Genetic information and recommendations provided to
participants

2

Welcome to the
Group Lifestyle
Balance™
Program3

•

The physical activity goal was verbally modified
whereby participants were asked to refer to their
personalized physical activity goals from their genetic
report.

3

Be a Calorie
Detective

•

Any reference made to counting fat grams was verbally
modified. Participants were reminded about how
response to different diets for weight loss differ from
person to person. Based on their personalized genetic
report, participants were advised and taught how to
count a nutrient that would benefit their personal weight
loss (i.e. some counted protein, others counted saturated
fat, and/or total fat, etc).
The calorie goals remained the same, but participants
with the “diminished” result in their genetic report for
calories were advised to be especially mindful of
meeting their calorie goal, and were advised to aim for a
650 kcal deficit to lose 1 lb per week.

•

4

Healthy Eating

•

When reference was made to a nutrient included in the
genetic report, participants were instructed to refer back
to their genetic report to recall how this nutrient might
be particularly important to them. The information in
the genetic reports was then reviewed.

5

Move Those
Muscles

•

The physical activity goal was verbally modified
whereby participants were asked to refer to their
personalized physical activity goals from their genetic
report.
Genetic predisposition to excel in endurance and/or
strengthening activities (outlined in the genetic report)
was reviewed.

•

6

Tip the Calorie
Balance

•

For the daily calorie deficit for weight loss, participants
were advised to refer to their genetic report to determine
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•

if they should aim for a 500 kcal deficit/day or a 650
kcal deficit/day.
When reference was made to a nutrient included in the
genetic report, participants were instructed to refer back
to their genetic report to recall how this nutrient might
be particularly important to them. The information in
the genetic reports was then reviewed.

7

Take Charge of
What’s Around
You

•

No1 modifications were made. Some participants
discussed components of their genetic report.

8

Problem Solving

•

No1 modifications were made. Some participants
discussed components of their genetic report.

9

Step Up Your
Physical Activity
Plan

•

The physical activity goal was verbally modified
whereby participants were asked to refer to their
personalized physical activity goals from their genetic
report.
Genetic predisposition to excel in endurance and/or
strengthening activities (outlined in the genetic report)
was reviewed.
Participants with the “enhanced” weight loss response
to physical activity (from the genetic report), were
advised to continue working up to 30-60 mins/day, 6
days/week of moderate intensity physical activity.

•

•

10

Manage Slips &
Self-Defeating
Thoughts

•

•

The step goal was verbally modified for individuals
with the “enhanced” weight loss response to physical
activity; these individuals were advised to aim for
10,000 steps/day.
When reference was made to a nutrient included in the
genetic report, participants were instructed to refer back
to their genetic report to recall how this nutrient might
be particularly important to them. The information in
the genetic reports was then reviewed.

11

Four Keys to
Healthy Eating
Out

•

No1 modifications were made. Some participants
discussed components of their genetic report.

12

Make Social
Cues Work for
You

•

No1 modifications were made. Some participants
discussed components of their genetic report.

13

Ways to Stay
Motivated

•

The physical activity goal was verbally modified
whereby participants were asked to refer to their
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•

14

Strengthen Your
Physical Activity
Plan

•

•

personalized physical activity goals from their genetic
report.
The step goal was verbally modified for individuals
with the “enhanced” weight loss response to physical
activity; these individuals were advised to aim for
10,000 steps/day.
The physical activity goal was verbally modified
whereby participants were asked to refer to their
personalized physical activity goals from their genetic
report.
The step goal was verbally modified for individuals
with the “enhanced” weight loss response to physical
activity; these individuals were advised to aim for
10,000 steps/day. Genetic predisposition to excel in
endurance and/or strengthening activities (outlined in
the genetic report) was reviewed.

15

Take Charge of
Your Lifestyle

•

Reference made to fat grams was verbally modified.
Participants were reminded about how response to
different diets for weight loss differ from person to
person. Based on their personalized genetic report,
participants were advised to count a nutrient that would
benefit their personal weight loss (i.e. some counted
protein, others counted saturated fat, and/or total fat,
etc).

16

Mindful Eating,
Mindful
Movement

•

No1 modifications were made. Some participants
discussed components of their genetic report.

17

Manage Your
Stress

•

No1 modifications were made. Some participants
discussed components of their genetic report.

18

Sit Less for Your
Health

•

No1 modifications were made. Some participants
discussed components of their genetic report.

19

More Volume,
Fewer Calories

•

When reference was made to a nutrient included in the
genetic report, participants were instructed to refer back
to their genetic report to recall how this nutrient might
be particularly important to them. The information in
the genetic reports was then reviewed.

20

Stay Active

•

No1 modifications were made. Some participants
discussed components of their genetic report.
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21

Balance Your
Thoughts

•

No1 modifications were made. Some participants
discussed components of their genetic report.

22

Heart Health

•

When reference was made to a nutrient included in the
genetic report, participants were instructed to refer back
to their genetic report to recall how this nutrient might
be particularly important to them. The information in
the genetic reports was then reviewed.
The physical activity goal was verbally modified
whereby participants were asked to refer to their
personalized physical activity goals from their genetic
report.
The step goal was verbally modified for individuals
with the “enhanced” weight loss response to physical
activity; these individuals were advised to aim for
10,000 steps/day. Genetic predisposition to excel in
endurance and/or strengthening activities (outlined in
the genetic report) was reviewed.

•

•

23

Look Back &
Look Forward

•

•

The physical activity goal was verbally modified
whereby participants were asked to refer to their
personalized physical activity goals from their genetic
report.
The step goal was verbally modified for individuals
with the “enhanced” weight loss response to physical
activity; these individuals were advised to aim for
10,000 steps/day. Genetic predisposition to excel in
endurance and/or strengthening activities (outlined in
the genetic report) was reviewed.

1. The physical activity goal and references to fat grams were verbally modified in the “To Do” lists at the end of
sessions. Participants were reminded about how response to different diets and physical activity for weight loss
differ from person to person. Based on their personalized genetic report, participants were advised and taught how to
reach their personal nutrition and physical activity goals. This modification occurred throughout the GLB Program’s
“To Do” lists and is not included in this table.
2. The GLB curriculum begins in class 2. Class 1 allows for an overview of nutrition and physical activity guidelines
either based on 1) the Acceptable Macronutrient Distribution Ranges and population-based health information and
recommendations or 2) genetic-based information and recommendations. Refer to Supplementary Tables 5.3 and 5.4
for sample reports provided in class 1.
3. Participants were informed about how the program is typically used for individuals with pre-diabetes, since our
population consisted of overweight/obese adults who may or may not have pre-diabetes or type 2 diabetes.
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Supplementary Table 5.6: Quality assessment tool for genetic interventions
Criteria

Yes

1. Were the results of the genetic test interpreted and explained by a
trained healthcare professional?
2. Was a copy of the genetic testing report provided to the
participants?
3. Were the results of the genetic test communicated to participants
on more than one occasion (i.e. was there follow-up provided after
the initial communication of the results)?
4. Were the results provided in the report, or discussed in the genetic
counselling session actionable (i.e. did the report contain specific
recommendations or did the genetic counsellor communicate
specific recommendations)?
5. Were the participants provided with an opportunity to ask
questions about their results?



No

Other (CD,
NR, NA)*







Other Comments: N/A ______________________________________________________________
Overall Rating (Good, Fair, Poor; if Poor state reasons): Good
*CD: cannot determine, NR: not reported, NA: not applicable
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CHAPTER 6: DIETARY ADHERENCE AND CHANGE IN
DIETARY INTAKE
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6.1 Title: Enhanced long-term dietary change and adherence in a
nutrigenomics-guided lifestyle intervention program compared to a populationbased (GLB/DPP) lifestyle intervention for weight management: Results from
the NOW randomized controlled trial
6.1.1 Abstract
Background: Adherence to nutritional guidelines for chronic disease prevention and
management remains a challenge in clinical practice. Innovative strategies are needed to help
optimize dietary behaviour change.
Objective: The objective of this study was to determine if a nutrigenomics-guided lifestyle
intervention program could be used to motivate greater dietary adherence and change in dietary
intake short-term, moderate-term, and long-term compared to the gold-standard population-based
weight management intervention [Group Lifestyle Balance™ (GLB)/Diabetes Prevention
Program (DPP)].
Design: The nutrigenomics, overweight/obesity, and weight management randomized controlled
trial is a pragmatic, parallel-group, superiority clinical trial (N=140), which was conducted at the
East Elgin Family Health Team (EEFHT). GLB weight management groups were prerandomized 1:1 to receive either the standard GLB program, or a modified GLB + nutrigenomics
(GLB+NGx) program. Three-day food records were collected at baseline, 3, 6 and 12 months
using the validated multiple pass method. Researcher assistants collecting 3-day food records
were blinded to the participants’ group assignments. Statistical analyses included: split plot
analyses of variance (ANOVAs), two-way ANOVAs, binary logistic regression, chi-square and
Fisher’s exact tests. Using the Theory of Planned Behaviour as guidance, important confounding
factors of behaviour change were considered in the analyses.
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Results: Only the GLB+NGx group significantly reduced their total fat intake from baseline to
12-month follow-up (36.0±4.8%kcal to 30.2±8.7%kcal, p=0.02). Long-term dietary adherence to
total fat and saturated fat guidelines were also significantly (p<0.05) greater in the GLB+NGx
group compared to the standard GLB group.
Conclusions: Nutrigenomics weight management interventions can motivate long-term
improvements in dietary fat intake above and beyond standard guidelines.

6.1.2 Introduction
The science of nutrigenomics, which explores interactions between individual genetic
variation, dietary intake and changes in gene expression, structure and function (Subbiah 2008),
has garnered significant attention in recent years with consumers and healthcare professionals
alike expressing overall positive attitudes towards genetic testing for personalized nutrition
(Valée Marcotte et al. 2019; Nielsen and El-Sohemy 2014; Cormier et al. 2014). As such, a
number of companies are offering nutrigenetic testing for weight management (Saukko 2013;
Drabsch and Holzapfel 2019).
A recent review reported that personalized nutrition recommendations are of great potential
for optimizing outcomes of weight management interventions, while also noting that research in
this area is lacking and human intervention studies are needed (Drabsch and Holzapfel 2019).
The potential value of personalized nutrition for weight management stems from studies
indicating positive consumer attitudes towards genetic-based dietary advice (Nielsen and ElSohemy 2014; Morin 2009), several indications that a one-size-fits all approach to weight
management is not optimal (Drabsch and Holzapfel 2019), and the potential for genetically114

guided, actionable nutrition recommendations to help motivate changes in dietary intake (Horne
et al. 2018).
According to the most recent systematic review on genetic testing behaviour change
research, nutrition was found to be the most promising lifestyle component that could be
motivated as a result of undergoing genetic testing, especially when the genetic intervention
provided actionable recommendations (Horne et al. 2018). Furthermore, this review found that
genetic testing behaviour change research has yet to incorporate the Theory of Planned
Behaviour (TPB), and incorporation of behaviour change theory in general is fundamentally
lacking (Horne et al. 2018). This is concerning given that the TPB is one of the most widely
accepted behaviour change theories. It suggests that attitudes, subjective norms and behavioural
control are the three key factors affecting human behaviour (Ajzen 1991). Furthermore,
researchers in the field of genetic testing behaviour change research have called to action
academia to incorporate this theory into genetic testing behaviour change studies to account for
potential confounding factors; this has been further detailed elsewhere (Horne et al. 2017).
Behaviour change theories provide important guidance for the development of interventions that
are more likely to facilitate changes in lifestyle habits. Thus, failing to consider established
behaviour change theories can lead to findings that do not demonstrate changes in dietary
behaviours. As such, it is not surprising that the current limited knowledge related to change in
dietary intake and eating habits in genetic-based weight management interventions does not
appear to be promising (Horne et al. 2018; Meisel et al. 2015). Overall, the field of
nutrigenomics and behaviour change is highly complex and warrants further investigation.
The purpose of this study was to address the limitations of previous work by considering the
TPB in the dietary intervention and statistical analyses, providing a high-quality, personalized,
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genetic-based lifestyle intervention, and ultimately determining if the provision of a nutrigeneticbased weight management intervention motivates greater dietary changes and adherence
compared to a population-based weight management intervention.

6.1.3 Subjects and Methods
The current study is a sub-study within the nutrigenomics, overweight/obesity and weight
management trial (NOW trial), which is a parallel-group, superiority, randomized, controlled
clinical intervention study (N=140) incorporated into the Group Lifestyle Balance™ (GLB)
program (formerly referred to as the Diabetes Prevention Program). The GLB program is one of
the most effective public health weight management programs (Xiao et al. 2013; Diabetes
Prevention Program Research Group 2002; McTigue et al. 2009; Piatt et al. 2012); it is offered in
numerous clinics in the United States and Canada (University of Pittsburgh c2019) and has been
extensively researched for long-term weight management and diabetes prevention (Xiao et al.
2013; Diabetes Prevention Program Research Group 2002; McTigue et al. 2009; Piatt et al.
2012). Detailed study methods for the NOW trial have been published elsewhere (Horne et al.
2019). One author (JH) conducted 1:1 computer-generated cohort randomization (Dallal 2017)
of 12 GLB groups as this was the anticipated number of groups required to achieve the target
sample size. A cohort randomization model was used rather than subject randomization to ensure
that all participants in each GLB group received the same intervention [standard GLB or GLB +
nutrigenomics (GLB + NGx)]. This study was approved by the Western University Research
Ethics Board and registered with clinicaltrials.gov (NCT03015012).
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Participants
Patients were recruited into the GLB program at the East Elgin Family Health Team
(EEFHT) in Aylmer, Ontario, Canada through healthcare professional referrals and word-ofmouth referrals from members of the community from April 2017 – September 2018. Patients
expressing interest in the GLB program were then invited to participate in the study if they met
the following inclusion criteria: BMI ≥ 25.0 kg/m2, ≥ 18 years of age, English-speaking, willing
to undergo genetic testing, having access to the internet, and not seeing another healthcare
provider for weight loss advice outside of the study. Pregnancy and lactation were exclusion
criteria. The target total sample size was 74 participants (after dropout) in order to detect a 4%
change in body fat percentage (primary outcome), using a standard deviation of 6.1%, with 80%
power and an alpha of 5%. Since recruitment was quicker than anticipated, recruitment ended
after 10 cohorts since there was an even 1:1 split of a GLB and GLB+NGx group in the last two
pre-randomized cohorts as further detailed previously (Horne et al. 2019). Four of the five
researchers (JG, JS, CO, JM) and all research assistants collecting 3-day food records (3DFRs)
were blinded to participant group allocation. It was not possible to blind the researcher
responsible for organizing and facilitating all intervention sessions (JH) and given the nature of
the intervention, it was inappropriate to blind participants to their allocated intervention. The
participants, setting and healthcare provider facilitating the interventions (JH) were all highly
representative of typical/standard care. All interventions were delivered by one healthcare
provider (JH) in order to standardise their delivery and enhance reliability and no additional
resources were required to implement the interventions; the healthcare provider is a registered
dietitian (RD) who has previous training in nutritional genomics.
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Interventions
Staggered cohorts participated in the 12-month intervention and data collection occurred
from May 2017 – September 2019. Participants received specific targets for eight nutrients:
calories, protein, saturated fatty acids (SFAs), monounsaturated fatty acids (MUFAs),
polyunsaturated fatty acids (PUFAs), total unsaturated fat, total fat, and sodium. These targets
were derived from genetics for half of the participants, and were derived from population-based
guidelines (Health Canada 2010) for the other half of participants; the nutrition reports provided
to participants have been previously published (Horne et al. 2019). For the standard GLB
intervention, participants were advised primarily to follow a calorie-controlled, moderately-low
fat (25% kcal) nutrition plan (University of Pittsburgh c2017). Both intervention groups followed
the standard GLB program overall calorie intake targets (University of Pittsburgh c2017). For the
personalized GLB+NGx group, individuals received information related to resting metabolism
and subsequent personalized calorie deficits recommended for weight loss (Horne et al. 2019).
Participants in the GLB+NGx group were advised to focus on the macronutrient
recommendation(s) that was/were highlighted in their genetic report to enhance weight loss
response. For example, an individual with the AA variant of FTO (rs9939609) was advised to
focus on following a higher-protein nutrition plan to optimize weight loss, whereas an individual
with the CC variant of APOA2 (rs5082) was advised to focus on following a low saturated fat
(<10% kcal) nutrition plan to optimize weight loss (rather than all participants following the
standard moderately-low total fat GLB nutrition intervention). Participants randomized to the
GLB+NGx group were also informed of their genetic predisposition to eat more frequently
during the day based on MC4R (rs17782313) genetic variation. If an individual had multiple
genetic variants and genetic-based nutrition recommendations highlighted in their genetic report,
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they were advised to focus on achieving one of the nutrition targets (of their choosing), and then
work on another when they perceived that they were ready to engage in further dietary changes.
A sample NOW trial genetic report has been previously published elsewhere; this report was
selected for the present study based off commercially available nutrigenetic testing accessible by
the general public through healthcare professionals (Horne et al. 2019).
All participants were advised to track their food and beverage intake closely (by completing
food records/journals) for the first two to three months of the intervention while working towards
their nutrition targets. They were further advised to measure their food and beverage intake for at
least the first week of the intervention in order to increase awareness and accuracy of the portion
sizes indicated in their dietary tracking. In the second week of the intervention, participants were
educated on counting and tracking calories and nutrients (total fat for the standard GLB group;
individualized nutrients for the GLB+NGx group). With weekly meetings for the first three
months and meetings approximately once per month for the remainder of the 12-month
intervention, participants had several opportunities to ask questions about their nutrition
recommendations to ensure comprehension. These recommendations were also reviewed at a 3month, 6-month and 12-month one-on-one follow-up appointment with an RD.
Incorporation of the TPB
This is the first study to intentionally incorporate the TPB into a genetic testing behaviour
change study. Both interventions aimed to positively impact key components of the TPB
(attitudes, subjective norms, and behavioural control). The interventions aimed to impact
attitudes by informing individuals of the health benefits associated with engaging in a healthy
lifestyle and providing education on positive mindsets and mindfulness (University of Pittsburgh
c2017). The group-based nature of the intervention aimed to affect subjective norms. A stepwise,
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goal-setting approach was used to help positively impact behavioural control. In the GLB+NGx
group, the intervention aimed to further impact attitudes through the provision of more
personalized dietary guidance. All participants completed a baseline TPB questionnaire. The
TPB was used to guide the analyses of possible attrition bias and subsequently control for
possible confounding factors of behaviour change as further indicated below.
Genotyping
Oragene ON-500 saliva collection kits (DNA Genotek, Ottawa, Ontario, Canada) were
used to collect DNA saliva samples of participants at the EEFHT. The saliva samples were
shipped and stored at -80°C at the University of Toronto until they were analysed. The iPLEX
Gold assay with mass-spectrometry-based detection on the Sequenom MassARRAY® platform
was used for all genotyping. This genotyping method has been utilized in previous research
(Jenkins et al. 2018; Josse et al. 2012; Banks et al. 2019). The following single nucleotide
polymorphisms (SNPs) of interest to the current study were analyzed: UCP1 (rs1800592), FTO
(rs9939609), TCF7L2 (rs7903146), APOA2 (rs5082), PPARγ2 (rs1801282), MC4R
(rs17782313).
Dietary Intake and Adherence
Dietary intake and adherence are important outcomes to address in a pragmatic
randomized controlled trial given that altering nutrition-related behaviour change is a challenge
in clinical practice. As such, dietary intake was a predetermined secondary outcome of the NOW
trial (Madill 2016) and was measured using the validated multiple pass method (Conway et al.
2003) to collect three 24-hour recalls [i.e. three-day food records (3DFRs)] consisting of one
weekend day and two week days. Data collection occurred at baseline (during a 14-day run-in
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period), 3-month, 6-month and 12-month follow-up in order to assess short-term, moderate-term,
and long-term changes. Trained research assistants who were blinded to participants’ group
allocations collected 3DFRs over the phone. In some rare cases where a participant could not be
reached over the phone, 3DFRs were collected in-person at the EEFHT. Dietary adherence was
measured by analyzing the quantity of participants adhering to the calorie, saturated fat, total fat
and protein recommendations. ESHA Food Processor version 11.3.285 (ESHA Research, Salem,
OR, United States) was used to analyze all 3DFRs.
Statistical Analyses
The mean and standard deviation (SD) were used to report continuous variables and
percentages were used for categorical variables. Estimates of the different sources of attrition
bias were conducted using two-way analysis of variance (ANOVA) models. The TPB (Ajzen
1991) was used to guide this analysis with data collected from a baseline TPB survey. The
following possible confounding factors were analyzed to determine if there were significant
differences between drop-outs in each group: attitudes towards changing their intake of calories,
fat, and protein (attitudes); friends eating a healthy diet, family eating a healthy diet (subjective
norms); stage of change/transtheoretical model; perceived difficulty altering calorie, fat, and
protein intake (perceived behavioural control); income and education (actual behavioural
control/social determinants of health).
Chi-square tests were used to analyze categorical variables (dietary adherence). In cases
where there were fewer than five expected counts, Fisher’s exact tests were used. To assess
dietary adherence at 3 months while controlling for income, binary logistic regression was
conducted. Split-plot ANOVAs were used to compare differences between groups (GLB vs.
GLB+NGx) for change in dietary intake from baseline to 3-, 6-, and 12-month follow-up
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(prespecified outcome). Repeated measures ANOVAs were used to assess within-group changes
in dietary intake from baseline to 3-, 6-, and 12-month follow-up (prespecified outcome). SPSS
Version 26.0 (IBM Corporation, Armonk, NY, United States) was used for all statistical
analyses, which took place in October – November 2019. The analyses were by originally
assigned groups.
Hypotheses
It was hypothesized that the GLB+NGx group would engage in greater dietary changes
and better adhere to the dietary advice compared to the standard GLB group.

6.1.4 Results
Overall, mean values from demographic and TPB characteristics (Tables 6.1 and 6.2)
indicated that the study population consisted of highly motivated, college-educated, middle-aged
female subjects with obesity, who had positive attitudes towards changing their dietary intake,
with neutral subjective norms related to friends/family consuming a healthy diet, and neutral
perceived behavioural control for changing their dietary intake. The genetic results of
participants in the GLB+NGx group are summarized in Table 6.3. There was significant attrition
bias for one TPB component, income (p=0.02), at the 3-month follow-up only (Table 6.2) and
therefore this was controlled for as a confounding factor in the 3-month analyses. There were no
differential attrition rates between groups. At baseline, 112 participants completed the 3DFRs,
with 86 completing the 3-month follow-up data collection (77% retention), 74 completing 6month food records (66% retention) and 59 completing the 12-month food records (53%
retention). No adverse events were reported.
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Table 6.1: Baseline demographic and clinical characteristics of participants
GLB Group
Mean ± SD

GLB+NGx Group
Mean ± SD

Age (years)

56.4 ± 12.1

53.5 ± 13.6

Gender

84.3% female

89.9% female

Ethnicity

98.6% Caucasian

97.1% Caucasian

Annual household income (CDN $)

73,943 ± 41,403

71,389 ± 44,301

Weight (lbs)

217.3 ± 49.0

215.4 ± 51.8

BMI (kg/m2)

36.7 ± 7.3

37.3 ± 9.7

Body fat (%)

46.7 ± 7.0

45.7 ± 7.9

N=140 (n=70 participants per group)
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Table 6.2: Baseline scores and values for components of the Theory of Planned Behaviour for dropouts and stayers
TIME
POINT
AND
PARTICIPANT TYPE

3-MONTH
STAYERS
3-MONTH
DROPOUTS
6-MONTH
STAYERS
6-MONTH
DROPOUTS
12-MONTH
STAYERS
12-MONTH
DROPOUTS

TYPE OF
GROUP

ATTITUDES

SUBJECTIVE NORMS

PERCEIVED BEHAVIOURAL CONTROL
(PBC)

Attitudes
(Calories)

Attitudes
(Fat)

Attitudes
(Protein)

Friends Eat a
Healthy Diet

Family Eats a
Healthy Diet

PBC
(Calories)

PBC (Fat)

PBC
(Protein)

Stage of
Change

GLB

6.39 ± 0.75

6.27 ± 0.94

6.30 ± 0.73

4.06 ± 1.69

5.06 ± 1.64

4.45 ± 1.28

4.73 ± 1.38

4.76 ± 1.39

3.70 ± 1.05

GLB+NGx

6.49 ± 0.98

6.23 ± 1.03

6.31 ± 1.05

4.57 ± 1.31

5.06 ± 1.32

4.31 ±1.60

4.37 ± 1.65

4.80 ± 1.57

4.00 ± 1.06

GLB

6.16 ± 0.99

5.89 ± 1.50

5.76 ± 1.28

4.19 ± 1.65

4.65 ±1.58

4.25 ± 1.46

4.31 ± 1.60

4.56 ± 1.48

3.42 ± 1.00

GLB+NGx

6.24 ± 1.10

6.26 ± 0.93

6.29 ± 0.91

4.18 ± 1.31

5.00 ± 1.30

4.50 ± 1.64

4.71 ± 1.51

5.35 ± 1.59

3.67 ± 0.88

GLB

6.50 ± 0.67

6.22 ± 0.97

6.31 ± 0.78

4.31 ± 1.60

5.06 ± 1.61

4.28 ± 1.28

4.63 ± 1.43

4.78 ± 1.39

3.59 ± 1.04

GLB+NGx

6.51 ± 0.95

6.31 ± 1.00

6.41 ± 0.98

4.48 ± 1.30

5.00 ± 1.39

4.38 ± 1.68

4.41 ± 1.57

4.54 ± 1.48

3.93 ± 1.10

GLB

6.01 ± 1.00

5.95 ± 1.49

5.76 ± 1.24

3.97 ± 1.72

4.66 ± 1.62

4.41 ± 1.46

4.52 ± 1.70

5.21 ± 1.66

3.51 ± 1.02

GLB+NGx

6.36 ± 1.04

6.24 ± 0.98

6.23 ± 0.97

4.30 ± 1.34

5.05 ± 1.26

4.43 ± 1.58

4.55 ± 1.50

4.98 ± 1.56

3.78 ± 0.89

GLB

6.57 ± 0.60

6.43 ± 0.87

6.29 ± 0.85

4.43 ± 1.66

5.24 ± 1.44

4.38 ± 1.36

4.57 ± 1.60

4.81 ± 1.50

3.67 ± 1.11

GLB+NGx

6.39 ± 1.10

6.21 ±1.07

6.18 ± 1.12

4.53 ± 1.35

5.07 ± 1.39

4.57 ± 1.73

4.68 ± 1.76

5.18 ± 1.70

4.04 ± 1.10

GLB

6.14 ± 0.96

5.92 ± 1.40

5.90 ± 1.16

4.00 ± 1.66

4.67 ± 1.66

4.33 ± 1.39

4.48 ± 1.47

4.58 ± 1.41

3.50 ± 0.99

GLB+NGx

6.34 ± 1.02

6.27 ± 0.92

6.39 ± 0.86

4.27 ± 1.30

5.00 ± 1.26

4.29 ± 1.54

4.44 ± 1.45

5.00 ± 1.53

3.71 ± 0.87

ACTUAL
BEHAVIOURAL
CONTROL
Income
(CDN$)
70,619 ±
37,561a
85, 059 ±
44,460a
76,806 ±
44,778a
56, 865 ±
39,852a
68,006 ±
33,432
74,893 ±
45,009
79,056 ±
47,079
68,808 ±
44,197
68,760 ±
31,195
81,574 ±
42,411
76,149 ±
45,177
64,338 ±
44,740

Mean scores for attitudes, subjective norms, and PBC (calories, fat, protein) on a Likert scale of 1 (negative attitude/subjective norms/PBC) to 7 (positive
attitude/subjective norms/PBC); Mean scores for stage of change on Likert scale of 1 to 6 (pre-contemplation, contemplation, motivation, action of <3 months,
action of 3-6 months, maintenance of >6 months); Mean scores for highest level of education on a Likert scale of 1 to 5 (elementary school, middle school, high
school, college, university); ‘Stayers’ were defined as individuals completing baseline and 3/6/12 month food records; a. p-interaction < 0.05.

124

Level of
Education
3.97 ± 0.73
4.06 ± 0.79
3.75 ± 0.84
3.97 ± 0.76
3.97 ± 0.65
4.04 ± 0.96
3.76 ± 0.89
4.00 ± 0.82
4.05 ± 0.67
4.00 ± 0.92
3.77 ± 0.83
4.02 ± 0.85

Table 6.3: Nutrition-related genetic variation among participants in the GLB+NGx group
Nutrient, Gene
(rs number)
Calories, UCP1
(rs1800592)
Protein, FTO
(rs9939609)
Total Fat, TCF7L2
(rs7903146)
SFA, APOA2
(rs5082)
PUFA:SFA, FTO
(rs9939609)
MUFA, PPARg2
(rs1801282)
Snacking/Appetite,
MC4R
(rs17782313)

Genotype
Distribution
(n, %)
AA (44, 62.9)
AG (19, 27.1)
GG (7, 10.0)
AA (21, 30.0)
TA (27, 38.6)
TT (22, 31.4)
TT (6, 8.6)
CT (28, 40.0)
CC (36, 51.4)
TT (21, 30.0)
TC (44, 62.9)
CC (5, 7.1)
AA (21, 30.0)
TA (27, 38.6)
TT (22, 31.4)
CC (53, 75.7)
CG (17, 24.3)
GG (0, 0.0)
TT (30, 42.9)
TC (35, 50.0)
CC (5, 7.1)

Participants with Elevated
Risk/Enhanced Response
Genotype (n, %)

Associated
Risk/Response

Elevated Risk (26, 37.1)

Lower resting
metabolic rate

Enhanced Response (21, 30.0)

Weight loss

Enhanced Response (6, 8.6)

Weight loss

Enhanced Response (5, 7.1)

Weight loss

Enhanced Response (48, 68.6)

Weight loss

Enhanced Response (17, 24.3)

Weight loss

Elevated Risk (40, 57.1)

Greater snacking/eating
frequency

n=70

125

Change in Dietary Intake
Change in dietary intake from baseline to 3-, 6-, and 12-month follow-up is detailed in
Table 6.4. For the analysis of overall change in dietary intake throughout the entire duration of
the study, a total of 32 participants completed the food records at all four time points. As further
depicted in Figures 6.1 and 6.2, only the GLB+NGx group significantly reduced total dietary fat
intake from baseline to 12-month follow-up (36.0±4.8%kcal to 30.2±8.7%kcal, p=0.02).
Furthermore, as depicted in Figure 6.3, the GLB+NGx group experienced a clinically meaningful
reduction in SFA intake (11.9±3.3%kcal to 9.3±3.3%kcal, p=0.13) and statistically significant
reduction in grams, but not percent of calories (%kcal), of unsaturated fat. Overall, there were
long-term (12-month) changes in dietary fat intake when participants in the GLB program
received the addition of nutrigenetic information and advice compared to receiving only
population-based dietary information and advice.
Dietary Adherence
As further detailed in Table 6.5, with more broad %kcal ranges, participants in the standard
GLB group had significantly (p<0.01) greater adherence to the group-specific target for protein
intake at all four time points (baseline, 3, 6 and 12 months) indicating that the group-specific
targets in the GLB+NGx group were more difficult to achieve from the beginning. Similarly,
with more broad %kcal ranges for total fat intake in the GLB+NGx ‘typical response’ group,
participants in the GLB+NGx group had significantly (p<0.01) greater adherence to the groupbased targets for total fat at all four time points, indicating that the target for total fat intake in the
standard GLB group was more difficult to achieve. Interestingly, the GLB+NGx group had
significantly greater long-term (12-month) adherence to the targets of <25%kcal from total fat
(p<0.01) and <10%kcal from saturated fat (p=0.02), compared to the standard GLB group.
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Table 6.4: Overall change in dietary intake from baseline to 3-, 6- and 12-month follow-up
Baseline
NUTRIENT

GLB

GLB+NGx

3-Months
GLB

GLB+NGx

6-Months
GLB

GLB+NGx

12-Months
GLB

GLB+NGx

Calories (kcal
1709.2±502.9
1873.9±528.2
1473.2±358.5
1662.9±543.4
1566.2±394.1
1713.2±602.6 1473.5±339.6 1639.1±680.8
± SD)
Calories (%
0.0 ± 0.0
0.0 ± 0.0
-9.9±2.3
-7.7±3.2
-1.8±4.3
-6.7±2.6
-8.5±2.7
-12.9±3.1
change ± SD)
Protein (g ±
70.7±23.3
86.6±23.5
73.6±26.7
77.1±25.8
75.1±28.4
80.6±29.3
68.6±29.0
72.3±24.2
SD)
Protein (%kcal
16.7±2.8
19.1±5.3
20.3±6.1
19.1±4.8
19.2±5.0
19.7±7.1
18.6±5.8
18.6±5.8
± SD)
Total Fat (g ±
74.1±33.6
75.0±22.6
53.3±20.8
61.2±28.3
62.8±27.9
60.6±28.3
59.7±19.1
55.4±29.4
SD)
Total Fat
37.7±8.2
36.0±4.8
31.2±8.3
31.9±7.4
35.5±10.1
31.4±9.2
36.2±7.2
30.2±8.7
(%kcal ± SD)
SFA (g ± SD)
24.6±12.3
24.4±8.1
18.6±9.7
19.7±11.1
21.1±8.8
21.3±12.8
19.7±6.5
17.6±10.8
SFA (%kcal ±
12.2±3.1
11.9±3.3
10.8±4.4
10.2±3.7
11.7±3.9
10.8±4.6
11.9±3.1
9.3±3.3
SD)
Total UnSFA
48.7±22.4
49.6±17.2
33.7±13.0
40.5±18.7
41.1±23.1
38.2±16.4
38.6±14.7
36.8±19.2
(g ± SD)
Total UnSFA
24.5±6.1
23.3±3.8
20.2±5.7
20.8±5.6
22.7±8.4
19.7±5.4
22.8±5.2
19.7±6.0
(%kcal ± SD)
GLB Group: n=16, GLB+NGx Group: n=18 (total n=32). Bold values are significant at p<0.05. Effect sizes: a. 0.190; b. 0.187; c. 0.191

RMANOVA
p-value
GLB

RMANOVA
p-value
GLB+NGx

Split-Plot
ANOVA
p-

0.17

0.30

0.99

0.49

0.39

0.22

0.63

0.20

0.44

0.11

0.91

0.35

0.14

0.01a

0.63

0.12

0.02b

0.24

0.22

0.08

0.85

0.64

0.13

0.45

0.17

0.02c

0.56

0.23

0.05

0.35

127

interaction

Table 6.5: Differences between groups for dietary adherence at baseline, 3, 6 and 12 months

NUTRIENT
Individualized
Calorie Target1
<25% kcal from
total fat
Group-based
total fat target2
10-35% kcal
from protein
Group-based
protein target3
<10% kcal from
saturated fat

Baseline (n, %
achieving target)
GLB+NGx
GLB
20,
26, 44.8%
37.7%

Significance
p-value
0.45

6, 11.3%

5, 8.4%

0.61

6, 11.3%

23, 39.0%

<0.01b

52,
98.1%
52,
98.1%

59,
100.0%

0.47

44, 74.6%

<0.01f

14, 23.7%

0.74

14,
26.4%

3-Months (n, %
achieving target)
GLB+NGx
GLB
22,
22, 52.4%
50.0%
6,
7, 16.7%
13.6%
6,
27, 64.3%
13.6%
43,
42,
97.7%
100.0%
43,
31, 70.5%
97.7%
21,
22, 52.4%
47.7%

Significance
p-value*
0.86
0.87
<0.01c
0.99
0.01g
0.57

6-Months (n, %
achieving target)
GLB+NGx
GLB
23,
15, 44.1%
57.5%
6,
6, 17.6%
15.0%
6,
19, 55.9%
15.0%
40,
34,
100.0%
100.0%
40,
25, 73.5%
100.0%
15,
37.5%

15, 44.1%

Significance
p-value

12-Months (n, %
achieving target)
GLB+NGx
GLB

Significance
p-value

0.25

16, 57.1%

17, 56.7%

0.97

0.76

0, 0.0%

8, 25.8%

<0.01a

<0.01d

0, 0.0%

18, 58.1%

<0.01e

1.00

25, 89.3%

31,
100.0%

0.10

<0.01h

27, 96.4%

22, 71.0%

0.01i

0.56

8, 28.6%

18, 58.1%

0.02j

1. Calorie targets were individualized based on baseline weight as outlined in the GLB Program curriculum (University of Pittsburgh, c2017)
2. Group-based total fat targets were: ≤25% of calories from total fat in the standard GLB group, 20-35% of calories from total fat in the GLB+NGx ‘typical
response’ group and 20-25% of calories in the GLB+NGx ‘enhanced response’ group
3. Group-based protein targets were: 10-35% if calories in the standard GLB group and in the GLB+NGx ‘typical response’ group and 25-35% of calories in the
GLB+NGx ‘enhanced response’ group
Odds ratios: a. NA; b. 5.00; c. 11.40; d. 7.18; e. NA; f. 17.727; g. 15.258; h. NA; i. 11.045; j. 3.46
*binary logistic regression, controlling for income
Baseline: GLB Group: n=53, GLB+NGx Group: n=59 (total n=112; n=111 for calories analysis as baseline weight data missing for n=1)
3-Months: GLB Group: n=44, GLB+NGx Group: n=42 (total n=86)
6-Months: GLB Group: n=40, GLB+NGx Group: n=34 (total n=74)
12-Months: GLB Group: n=28, GLB+NGx Group: n=31 (total n=59; n=58 for calories analysis as baseline weight data missing for n=1)
Fisher’s exact test used when expected counts were less than 5
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Figure 6.1: Flow diagram of participants from baseline to 3-, 6- and 12-month follow-up
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Figure 6.2: Change in percent of calories from total fat
GLB

GLB+NGx

38
37

36

%kcal

35
34
33
32
31

*

30
29
28
B A S E LIN E

3-MONTHS

6-MONTHS

12-MONTHS

Timepoint
p = 0.02
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%kcal

Figure 6.3: Change in percent of calories from saturated fat

Timepoint
p > 0.05
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6.1.5 Discussion
This study demonstrates that a nutrigenomics weight management intervention can
motivate greater long-term dietary change compared to population-based recommendations in
one of the most effective public health weight management and diabetes prevention programs.
Notably, this is the first genetic testing behaviour change study to incorporate the TPB and thus
control for important confounding factors of behaviour change and is the first study to assess
changes in calorie and macronutrient intake resulting from a genetic-based weight management
intervention. It is also the first study to assess change in dietary intake when the GLB/DPP
program is extended to patients with overweight/obesity, regardless of having a prediabetes
diagnosis - a recommended program expansion by public health officials (Ontario Ministry of
Health and Long-Term Care 2018).
Previous research has assessed change in dietary intake in participants diagnosed with
prediabetes enrolled in the GLB/DPP program. Over the course of 12 months, it appears that the
participants with prediabetes made greater overall dietary changes (-452 calories and -6.6% total
fat) compared to the population of adults with overweight/obesity in the NOW trial who received
the standard GLB program (-236 calories and -1.5% total fat), although different tools were used
to measure dietary intake, therefore the results cannot be compared with complete accuracy
(Mayer-Davis et al. 2004). Theoretical concepts of behaviour change support this finding; the
extended parallel process model suggests that if individuals’ perceptions about susceptibility to a
threat (e.g., developing type 2 diabetes) and the magnitude of the threat are high, they are more
likely to take action to control the threat (e.g., improve their nutrition) (Popova 2012).
Interestingly, the NOW trial GLB+NGx group (with overweight/obesity but not necessarily a
prediabetes diagnosis) changed their dietary intake to a similar extent as those in the original
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GLB/DPP cohort, all of whom had a diagnosis of prediabetes, whereas the NOW trial standard
GLB group made fewer changes to their diet (Mayer-Davis et al. 2004). In comparing these
findings to the extended parallel process model, it is possible that the addition of genetic-based
nutrition information and advice positively impacted response efficacy (beliefs about the
effectiveness of the advice to improve weight management), and elicited greater danger control
responses (beliefs, attitudes, intentions, and behaviours to manage weight) (Popova 2012).
Future research should explore this concept further. Future research should also assess change in
dietary intake in the GLB program (with and without the addition of nutrigenomics
information/advice) in various locations across North America, and with a more ethnically
diverse study sample in order to improve generalizability. The current study is primarily
generalizable to Caucasian females with overweight and obesity enrolled in a weight
management program. Notably, given the highly pragmatic nature of the NOW trial (Table 6.6),
overall, this study has strong external validity.
In terms of the dietary analyses, while both grams and %kcal are reported in the present
study, %kcal is a more accurate comparison between groups given that calorie intakes between
groups were not identical. As such, differences in %kcal from macronutrients should be
weighted more highly in the interpretation of the overall results compared to grams of nutrients.
Given that the %kcal from protein recommendations for the GLB+NGx ‘enhanced response’
group proved to be challenging to achieve, and that a large proportion of the GLB+NGx group
were advised to limit their SFA intake to <10%kcal to enhance weight loss (Table 6.3), it is not
surprising that there was significantly greater dietary adherence to the SFA recommendations in
the GLB+NGx group as many participants were focusing on reducing their SFA intake. This
would also contribute to the significant reduction in total fat intake in the GLB+NGx group only
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(in addition to a reduction in unsaturated fat). It was, however, surprising to see minimal change
in total fat intake and poor dietary adherence to the total fat recommendations in the standard
GLB group at 12-month follow-up since this was the focus of the standard program. While
clinically meaningful (though not statistically significant) reductions in total fat intake occurred
from baseline to 3-, and 6-month follow-up, these were not sustained after 12-months. As
further explained above, it appears individuals with overweight/obesity, but not necessarily
having a prediabetes diagnosis, have a more difficult time maintaining long-term dietary changes
in the standard GLB program compared to those diagnosed with prediabetes (Mayer-Davis et al.
2004). According to the NOW trial findings, the addition of genetic-based dietary advice could
help to mitigate this. Indeed, previous research has indicated that weight control is a motivator
for the intention to adopt personalized nutrition strategies (Rankin et al. 2018).
Our finding that GLB+NGx group participants who dropped out at 3 months had a
significantly lower income, on average, compared to 3-months dropouts from the standard GLB
group was interesting. It is possible that purchasing food in order to adhere to the nutrigenomics
intervention was perceived as, or in reality was, more expensive (e.g. 30% of participants were
advised to follow a higher protein nutrition plan) and cost may have been prohibitive to
following the dietary advice. Studies have reported cost is a barrier to consumption of higher
protein foods (Appleton 2016; Best and Appleton 2013). However, the finding that dropouts
from the GLB+NGx group tended to have lower incomes was not consistent after 6 and 12
months, and therefore, future research should explore this phenomenon further.

134

Table 6.6: PRECIS-2 Scoring Tool
PRECIS-2 Domain

Score [Likert scale 1
(very explanatory) - 5
(very pragmatic)]

1. Eligibility: To what extent are the participants in the trial similar to
those who would receive this intervention if it was part of usual care?

5

2. Recruitment: How much extra effort is made to recruit participants
over and above what would be used in the usual care setting to engage
with patients?

5

3. Setting: How different are the settings of the trial from the usual
setting?

5

4. Organization: How different are the resources, provider expertise,
and the organization of care delivery in the intervention arm of the trial
from those available in usual care?

4

5. Flexibility (delivery): How different is the flexibility in how the
intervention is delivered and the flexibility anticipated in usual care?

4

6. Flexibility (adherence): How different is the flexibility in how
participants are monitored and encouraged to adhere to the intervention
from the flexibility anticipated in usual care?

4

7. Follow-up: How different is the intensity of measurement and followup of participants in the trial from the typical follow-up in usual care?

3

8. Primary outcome: To what extent is the trial’s primary outcome
directly relevant to participants?

5

9. Primary analysis: To what extent are all data included in the analysis
of the primary outcome?

N/A (the present study
provides an analysis of
secondary outcome
data)

Mean score:

4.4
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Strengths and Limitations
There are several specific strengths and limitations of the present work that should be
noted. This was novel to the field, as it was one of only four randomized controlled trials (RCTs)
to assess change in dietary intake resulting from a nutrigenetic intervention over a 12-month
period. Previously, Hietaranta-Luoma et al. (2014) similarly found that a nutrigenetic
cardiovascular disease intervention motivated greater long-term changes in dietary intake, and
further motivated greater short-term and moderate-term changes compared to a control group.
Nielsen and El-Sohemy’s (2014) and Chao et al.’s (2008) 12-month RCTs also found that
nutrigenomics interventions motivated greater long-term (12-month) changes in dietary intake.
There have been no RCTs demonstrating that nutrigenomics is ineffective at motivating changes
in dietary intake after 12-month follow-up (Horne et al. 2018). Thus, taken together, the body of
evidence highly suggests that nutrigenomics is a useful tool for motivating positive nutritional
intake over the long-term.
Consistent with the vast majority of nutrition research, there were limitations related to
the methods used to collect dietary intake data such as possible recall bias and underreporting of
intake (Shim, Oh, and Kim 2014). However, 3DFRs were collected using the multiple-pass
method, which has been validated against direct observation in a similar population (Conway et
al. 2003). Additionally, these food records provided highly detailed nutritional intake data, which
is a strength of this dietary collection method (Shim, Oh, and Kim 2014). Nonetheless, 3DFRs
are time consuming leading to respondent burden (Shim, Oh, and Kim 2014), which helps to
explain why a smaller subset of the NOW trial sample participated in 3DFR collection
throughout the entire duration of the study. In addition, 3DFRs were collected over the phone,
whereas other NOW trial outcome data (e.g. weight and body composition) were collected in-
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person (Horne et al. 2019; Madill 2016), leading to slightly different samples as some
participants completed only the 3DFRs, while others completed only the in-person data
collection, and others completed both.
Since the dietary analysis was a secondary outcome of the NOW trial, the sample size
may not have been large enough to detect statistical significance in some cases. For example,
while adherence to SFA was significantly greater (p=0.02) in the GLB+NGx group compared to
the standard GLB group, a 12-month clinically meaningful reduction in SFA was observed in the
GLB+NGx group only (11.9±3.3%kcal to 9.3±3.3%kcal), but this change was not statistically
significant (p=0.13). Nonetheless, this was a notable observation given that in addition to
possible weight-related outcomes resulting from a decrease in SFA to <10% kcal from saturated
fat (Corella et al. 2009), achieving <10% kcal from SFA can have further beneficial effects on
LDL-cholesterol and other cardiovascular disease risk factors (Anderson et al. 2016). Future
research should seek to replicate this study in a RCT adequately powered to detect significant
differences in %kcal from SFA. Nonetheless, this long-term 22% reduction in SFA observed in
the GLB+NGx group is notable, and relates to the statistically significant greater adherence to
the SFA guidelines after 12 months in the GLB+NGx group compared to the standard GLB
group.
Lastly, baseline portion sizes were likely underreported given that baseline data
collection occurred during the run-in period and participants learned how to measure their food
and beverage intake in the first week of the intervention. This may have affected results for
calories and grams of nutrients (but not percent of intake from macronutrients). However, since
participants were advised to measure all food and beverages for one week and track their intake
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for two to three months, this likely improved the accuracy of the follow-up 3DFRs. Thus, the
actual change in dietary intake may in fact have been greater than the data suggest.

6.1.6 Conclusion

Overall, the NOW trial provides important, novel insights into genetic testing behaviour
change research, grounded in fundamental theoretical concepts. The results of this study provide
convincing evidence that the addition of nutrigenomics to one of the most effective public health
weight management and diabetes prevention programs can help motivate and optimize longterm, clinically meaningful differences in nutritional intake and adherence to dietary guidelines.
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CHAPTER 7: CHANGE IN WEIGHT, BMI AND BODY
COMPOSITION
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7.1 Title: Change in weight, BMI and body composition after 3, 6 and 12 months
in a population-based intervention vs. genetic-based intervention: Results from
the NOW randomized controlled trial
7.1.1 Abstract
Importance: Nutrigenomics testing for weight management is widely available to the general
public through direct-to-consumer testing and via healthcare professionals, but limited research
has assessed its effectiveness.
Objective: To compare changes in body fat percentage (BFP), weight and body mass index
(BMI) between a standard intervention and a nutrigenomics intervention.
Design: The nutrigenomics, overweight/obesity and weight management (NOW) trial is a
parallel group, pragmatic, randomized, controlled clinical trial incorporated into the Group
Lifestyle Balance (GLB)/Diabetes Prevention Program. Participants were followed from baseline
to 3, 6, and 12 months through staggered cohorts occurring between April 2017 and September
2019. Statistical analyses included two-way analyses of variance (ANOVAs) for analyses of
potential attrition bias, and split plot ANOVAs to assess between-group differences from
baseline to 3-, 6-, and 12-month follow-up.
Setting: This study took place at the East Elgin Family Health Team in Aylmer, Ontario,
Canada.
Participants: Participants enrolled in the GLB/Diabetes Prevention Program were invited to
participate if they had a BMI ≥25.0 kg/m2, were ≥18 years of age, English-speaking, willing to
undergo genetic testing, had internet access and were not seeing another healthcare provider for
weight loss advice outside of the study. Pregnancy and lactation were exclusion criteria. Only
one participant declined study participation, with a total of 140 enrolling.
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Interventions: GLB groups were randomized 1:1 to receive either the standard 12-month GLB
program or a modified 12-month program (GLB+NGx), which included the provision of
nutrigenomics information and advice for weight management.
Main Outcome(s) and Measure(s): The primary study outcome was change in BFP. Change in
weight and BMI were secondary outcomes.
Results: The sample consisted primarily of middle-aged Caucasian females with class II obesity
(n=75). The GLB+NGx group experienced significantly (p<0.05) greater reductions in percent
and absolute BFP at the 3-month follow-up (percent BFP change: -4.95±5.52%, 95% CI: -3.3 to
-6.6; absolute BFP change: -2.12±1.96%, 95% CI: -1.5 to -2.8) and percent BFP at 6-month
follow-up (-7.76±6.33%, 95% CI: -5.8 to -9.6) compared to the standard GLB group (3-month
percent BFP change: -2.24±4.13%, 95% CI: -0.5 to -3.9; 3-month absolute BFP change: 1.02±1.89, 95% CI: -0.4 to -1.7; 6-month percent BFP change: -4.80±4.85%, 95% CI: -2.8 to 6.8, respectively).
Conclusions and Relevance: The nutrigenomics intervention used in the NOW trial is a valuable
intervention for optimizing body composition, especially over the short- and moderate-term.
Trial Registration: This trial is registered with clinicaltrials.gov (NCT03015012).

7.1.2 Introduction

Weight management is an ongoing challenge for a substantial proportion of the
population. It is estimated that two-fifths of the adult population worldwide are attempting to
lose weight, with another quarter of the population attempting to maintain weight (Santos et al.
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2017). Patients’ motivations for weight control are broad and include desires to improve health,
well-being, physical appearance, fitness, and self-esteem (Santos et al. 2017).

The most current American Heart Association/American College of Cardiology/Task
Force on Practice Guidelines and the Obesity Society (AHA/ACC/TOS) clinical practice
guidelines for overweight and obesity management state that there is “strong evidence” (NHLBI
Grade A) for the effectiveness of several interventions in achieving sustained weight loss (Jensen
et al. 2014). Despite this knowledge, successful long-term weight loss still proves to be
challenging, with many interventions demonstrating weight regain after long-term follow-up
(Aller et al. 2014; Miura et al. 1989; Brock et al. 2010; Wadden and Sarwer 1999). While there
are numerous weight management programs available to the public, the Group Lifestyle
Balance™ (GLB) program (formerly referred to as the Diabetes Prevention Program) can be
considered the gold standard weight management intervention for long-term, sustainable weight
loss and diabetes prevention (Diabetes Prevention Program Research Group 2002; McTigue et
al. 2009; Piatt et al. 2012; Xiao et al. 2013). This program meets all of the criteria from the
AHA/ACC/TOS clinical practice guidelines, while addressing various modifiable health and
lifestyle behaviours (Jensen, Ryan, Apovian, et al. 2014).

Complex factors affect weight and body composition. Factors contributing to the
development and management of overweight/obesity include stress, sleep, nutrition, physical
activity (PA), social determinants of health, the built environment, medications, certain
diseases/conditions and genetics (Moore et al. 2010; Eriksson et al. 2003; Finkelstein, Ruhm, and
Kosa 2005; Seabrook and Avison 2010; Gilliland et al. 2012; Sarma et al. 2014). With increasing
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knowledge of how individual genetic variation affects nutrient metabolism, absorption, and other
physiological processes, genetics are an important factor to consider in weight management
interventions. The science of nutrigenomics explores interactions between nutrition, genetics,
and health outcomes (Subbiah 2008). The science of lifestyle genomics is broader, and explores
interactions between various lifestyle components (such as smoking, PA, sleep, and nutrition),
genetics, and health outcomes (Horne et al. 2018).

Consumers have demonstrated consistently positive attitudes towards nutrigenetic testing
(Vallée Marcotte et al. 2019; Morin 2009; Stewart-Knox et al. 2009; Nielsen and El-Sohemy
2012). As such, many consumer nutrigenomics and lifestyle genomics tests are available to the
general public, often including personalized weight management lifestyle advice. While primary
research has demonstrated several relationships between genetic variation, weight/body
composition and specific dietary and PA strategies (Zhang et al. 2012; Eller et al. 2008; Paniagua
et al. 2007; Corella et al. 2010; Corella et al. 2011; De Luis, Aller, and Pacheco 2015; Phillips et
al. 2012; Memisoglu et al. 2003; Garaulet et al. 2011; Sonestedt et al. 2011; J. Zhu et al. 2014;
Xi et al. 2011; Rampersaud et al. 2008), the efficacy of the practical application of this science in
a clinical setting has yet to be thoroughly explored. To date, only three studies have assessed the
efficacy of using nutrigenomics and lifestyle genomics to optimize weight management
(Arkadianos et al. 2007; Frankwich et al. 2015; Celis-Morales et al. 2017). These studies
provided a solid starting point for enhancing our knowledge on this topic, but exhibit notable
limitations related to statistical power, methodology and the quality of the interventions
delivered to study participants. Nonetheless, findings have been variable (Arkadianos et al.
2007; Frankwich et al. 2015; Celis-Morales et al. 2017) with some promise for the use of
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genetic-based advice to optimize weight management (Arkadianos et al. 2007). The present
randomized controlled trial (RCT) aimed to address the limitations of the current body of
knowledge in order to answer the important research question, does the provision of
personalized genetic-based lifestyle information and advice enhance weight loss and improve
body composition to a greater extent than the gold-standard, population-based weight
management program?

7.1.3 Methods

The nutrigenomics, overweight/obesity and weight management (NOW) trial is a
pragmatic, parallel-group, superiority randomized controlled trial. Complete details of the study
methods for this clinical trial, including a SPIRIT flow diagram, have been published elsewhere
(Horne et al. 2019). Briefly, a personalized genetic-based lifestyle intervention program was
compared (1:1) to the gold standard, population-based lifestyle intervention program (GLB) for
weight management. Inclusion criteria consisted of having a BMI ≥25.0 kg/m2, being ≥18 years
of age, English-speaking, willing to undergo genetic testing, having internet access, and not
seeing another healthcare provider for weight loss advice outside of the study. Pregnancy and
lactation were considered exclusion criteria. This study took place at the East Elgin Family
Health Team (EEFHT) in Aylmer, Ontario, Canada and was registered with clinicaltrials.gov
(NCT03015012) (Madill 2016).
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Recruitment

Adults from Elgin and Middlesex Counties in Ontario, Canada were either referred to the
GLB program by healthcare professionals in the area, or signed up for the program through
word-of-mouth referrals from members of the community. Participants expressing interest in
joining the GLB program were invited to the EEFHT for an in-person NOW trial information
meeting, and provided written, informed consent if they decided to take part in the study.

Primary and Secondary Outcomes

The primary outcome of this RCT was percent change in body fat percentage (BFP).
Changes in weight and body mass index (BMI) were secondary outcomes as indicated on
clinicaltrials.gov (Madill 2016).

Sample Size

As indicated in the study protocol (Horne et al. 2019), in order to detect a 4% change in
BFP, using a standard deviation of 6.1%, the sample size calculation indicated that a total of 74
participants (37 participants per group) were needed to test the primary outcome of this trial with
80% power and an alpha of 5%.
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Randomization and Blinding

For the cohort randomization, randomly permuted blocks were generated by one author
(JH) using the original generator on an internet-based randomization program (Dallal 2017). This
allowed for pre-randomization of GLB groups in order to determine if the group intervention
sessions would be population-based, or genetic-based as further detailed in ‘Interventions and
Data Collection,’ below. Participants selected a GLB group that best suited their schedule and
were blinded to the group assignment at this time. Four authors were blinded throughout the
duration of the study, with one author unblinded (JH) for logistical reasons as this investigator
was responsible for scheduling participants, arranging the genetic testing, facilitating all group
and one-on-one sessions and completing data collection.

Run-In
Baseline data collection occurred within approximately 14 days (mean ± SD = 9.3 ± 5.7)
prior to the intervention start date. No lifestyle advice was provided to participants during this
run-in period.

Interventions and Data Collection

Participant recruitment took place between April 2017 and September 2018. Recruitment
ended in September 2018 given the allocated timeline for this project and given that the target
recruitment sample number had been achieved. One author (JH) was responsible for enrolling
participants and assigning them to interventions (based on their availability and the GLB group
times/dates selected by the blinded participants). Data collection and lifestyle interventions
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occurred between May 2017 and September 2019, with staggered cohorts throughout this period.
Group allocation was concealed for the participants until the first group intervention session
(after baseline data collection). Those randomized to the population-based lifestyle intervention
(GLB) group participated in the standard 22-session, 12-month GLB program (University of
Pittsburgh, c2017). They also received an additional information session detailing populationbased guidelines for 11 nutrition and PA-related items: calories, protein, total fat, saturated fat,
monounsaturated fat, polyunsaturated fat, sodium, snacking, overall PA, endurance and
strength/power as previously published (Horne et al. 2019). Individuals randomized to the
standard GLB program received their nutrigenomics/lifestyle genomics report after the 12-month
study was complete.

Individuals randomized to the personalized, genetic-based nutrition and PA-intervention
(GLB+NGx) received information/advice on the 11 nutrition and PA-related items listed above,
with their advice based on individual genetic variation in 12 unique genetic variants: FTO
(rs9939609), UCP1 (rs1800592), TCF7L2 (rs7903146), APOA2 (rs5082), PPARg2 (rs1801282),
ACE (rs4343), MC4R (rs17782313), ADRB (rs4994), NRF2 (rs12594956), GSTP (rs1695),
NFIA-AS2 (rs1572312), and ACTN3 (rs1815739). These genetic variants were chosen as they
are reflective of currently available consumer nutrigenetic testing. Participants were also
involved in the 12-month GLB program, which was modified by the program facilitator (JH)
throughout its duration to highlight nutrition and PA guidelines that may differ according to
genetic variation (Horne et al. 2019). In addition to the 22 GLB program group sessions, a
supplementary group session occurred at the beginning of the program, which consisted of an
overview of the nutrition and PA advice, based on genetics. Furthermore, all participants’
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nutrition and PA guidelines (for both the GLB and GLB+NGx groups) were reviewed during
their three follow-up data collection appointments (occurring at months 3, 6, and 12) with a
registered dietitian (RD).

Baseline and follow-up anthropometric data included weight and height (used to calculate
BMI) and body composition conducted using the Bodystat 1500MDD (Bodystat, Douglas, Isle of
Man, United Kingdom) bioelectrical impedance analysis (BIA) device.

Genotyping

Oragene ON-500 saliva collection kits (DNA Genotek, Ottawa, Ontario, Canada) were
used to collect DNA saliva samples of participants at the EEFHT. The saliva samples were
shipped to the University of Toronto and stored at -80°C. The iPLEX Gold assay with massspectrometry-based detection on the Sequenom MassARRAY® platform was used for
genotyping of the 12 single nucleotide polymorphisms (SNPs) listed above. This method of
genotype analysis has been used in previous research (Jenkins et al. 2018; Josse et al. 2012;
Banks et al. 2019).

Statistical Analysis

All statistical analyses were completed using IBM SPSS Statistics version 26.0 (Armonk,
NY: IBM Corp.). Two-way analyses of variance (ANOVAs) facilitated the analysis of potential
attrition bias for the following participant characteristics: level of education, annual household
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income (CDN dollars), age (years), baseline stage of change (transtheoretical model), and
perceived difficulty managing weight (behavioural control construct of the theory of planned
behaviour [TPB]) (Ajzen 2011). To account for potential BIA equipment error, descriptive
statistics were used to identify far-out outliers, which were then removed from the final analyses
(Figure 7.1). Split plot ANOVAs were used to assess between-group changes in anthropometric
data from baseline to 3-, 6-, and 12-month follow-up. Hypothesis tests were 2-sided and a pvalue < 0.05 was considered statistically significant.

7.1.4 Results

Baseline participant demographic and clinical characteristics were outlined in Chapter 6,
Table 6.1. A total of 140 participants enrolled in the study with 75 participants completing
anthropometric data collection for all four time points (Figure 7.1). No statistically significant
sources of attrition bias were revealed for level of education, annual household income (CDN
dollars), age (years), baseline stage of change (transtheoretical model), and perceived difficulty
managing weight (TPB). There were no reported harms or unintended consequences reported in
either group.

Far-out (extreme) outliers (n=2) were removed from the body composition data (one in
the standard GLB group and one in the personalized GLB+NGx group). Results from the
analyses of changes in anthropometric characteristics are outlined in Tables 7.1 and 7.2, as well
as Figure 7.2. After 3- and 6-month follow-up, the GLB+NGx group had significantly (p<0.05)
greater reductions in percent BFP change compared to the standard GLB group. The GLB+NGx
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group additionally had significantly (p<0.05) greater reductions in absolute BFP change after 3
months. There were no significant interactions between group and BFP (percent and absolute)
after 12-month follow-up (p>0.05). Furthermore, while the GLB+NGx group had clinically
meaningful, greater reductions in weight and BMI after 3 and 6 months (percent and absolute)
compared to the standard GLB group, there were no significant interactions between group and
weight or BMI at 3-,6-, and 12-month follow-up (p>0.05).
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Table 7.1: Anthropometric measurements at baseline, 3, 6, and 12 months
Anthropometric
Measures
GLB Group:
Body Fat (%)
Weight (lbs)
BMI (kg/m2)
GLB+NGx Group:
Body Fat (%)
Weight (lbs)
BMI (kg/m2)

Baseline
(Mean ± SD,
95% CI)

3 Months
(Mean ± SD,
95% CI)

6 Months
(Mean ± SD,
95% CI)

12 Months
(Mean ± SD,
95% CI)

48.18 ± 6.60,
45.6 to 50.7
219.83±49.71,
206.1 to 233.5
37.82 ± 7.70,
35.6 to 40.1

47.16 ± 7.18,a
44.5 to 49.9
212.97±49.36,
199.4 to 226.6
36.65 ± 7.91,
34.3 to 39.0

45.91 ± 6.97,b
43.3 to 48.9
211.72±51.41,
197.7 to 225.8
36.38 ± 8.12,
34.0 to 38.7

44.70 ± 7.02,
42.1 to 47.4
213.51±51.64,
199.2 to 227.8
36.68 ± 8.07,
34.2 to 39.1

44.93 ± 7.95,
42.5 to 47.4
203.34±32.29,
189.8 to 216.9
35.22 ± 6.06,
33.0 to 37.5

42.77 ± 8.29,a
40.2 to 45.4
194.56±32.10,
181.1 to 208.0
33.72 ± 6.13,
31.4 to 36.0

41.55 ± 8.24,b
39.0 to 44.1
192.48 ± 32.60,
178.6 to 206.4
33.36 ± 6.20,
31.0 to 35.7

42.32 ± 8.15,
39.7 to 44.9
196.85±34.16,
182.7 to 211.0
34.11 ± 6.46,
31.8 to 36.5

p-interaction for body fat (%) = 0.002, effect size = 0.087; a. p = 0.023; b. p = 0.022
Standard GLB Group: Weight and BMI, n=37; Body Fat, n=33
GLB+NGx Group: Weight and BMI, n=38; Body Fat, n=35
Analyses were all by originally assigned groups.
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Table 7.2: Change in anthropometric measurements at 3, 6, and 12 months
Anthropometric
Measure
GLB Group:
Body Fat (%)
Weight (lbs)
BMI (kg/m2)
GLB+NGx Group:
Body Fat (%)
Weight (lbs)
BMI (kg/m2)

3-Month
(Absolute ∆ ±
SD, 95% CI)

3-Month
(Percent ∆ ± SD,
95% CI)

6-Month
(Absolute ∆ ±
SD, 95% CI)

6-Month
(Percent ∆ ± SD,
95% CI)

12-Month
(Absolute ∆ ±
SD, 95% CI)

12-Month
(Percent ∆ ±
SD, 95% CI)

-1.02 ± 1.89,a
-0.4 to -1.7
-6.86 ± 7.36,
-4.5 to -9.2
-1.12 ± 1.28,
-0.8 to -1.6

-2.24 ± 4.13,b
-0.5 to -3.9
-3.23 ± 3.57,
-2.1 to -4.4
-3.27 ± 3.60,
-2.1 to -4.4

-2.27 ± 2.26,
-1.4 to -3.2
-8.11 ± 9.11,
-4.7 to -11.5
-1.44 ± 1.64,
-0.9 to -2.0

-4.80 ± 4.85,c
-2.8 to -6.8
-3.96 ± 4.70,
-2.3 to -5.7
-4.06 ± 4.70,
-2.4 to -5.8

-3.48 ± 2.55,
-2.6 to -4.4
-6.32 ± 9.25,
-2.6 to -10.0
-1.14 ± 1.67,
-0.5 to -1.8

-7.31 ± 5.35,
-5.4 to -9.2
-3.13 ± 4.81,
-1.3 to -4.9
-3.22 ± 4.79,
-1.4 to -5.0

-2.12 ± 1.96,a
-1.5 to -2.8
-8.77 ± 7.04,
-6.4 to -11.1
-1.50 ± 1.19,
-1.1 to -1.9

-4.95 ± 5.52,b
-3.3 to -6.6
-4.37 ± 3.44,
-3.2 to -5.5
-4.35 ± 3.45,
-3.2 to -5.5

-3.38 ± 2.83,
-2.5 to -4.2
-10.86 ± 11.48,
-7.5 to -14.2
-1.86 ± 1.97,
-1.3 to -2.4

-7.74 ± 6.33,c
-5.8 to -9.6
-5.38 ± 5.57,
-3.7 to -7.0
-5.35 ± 5.62,
-3.7 to -7.0

-2.61 ± 2.66,
-1.7 to -3.5
-6.48 ± 12.91,
-2.8 to -10.1
-1.11 ± 2.24,
-0.5 to -1.7

-6.00 ± 5.76,
-4.1 to -7.9
-3.26 ± 6.03,
-1.5 to -5.0
-3.24 ± 6.06,
-1.5 to -5.0

∆: change
p-interaction for absolute BFP∆ = 0.002, effect size = 0.087; a. p = 0.018
p-interaction for percent BFP∆ = 0.003; effect size = 0.076; b. p = 0.026; c. 0.036
Standard GLB Group: Weight and BMI, n=37; Body Fat, n=33
GLB+NGx Group: Weight and BMI, n=38; Body Fat, n=35
Note: Differences is percent weight and BMI change are due to rounding.
Analyses were all by originally assigned groups.
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Figure 7. 1: CONSORT 2010 Flow Diagram

Enrollment

Assessed for eligibility (n=141)

Excluded (n=1)
 Not meeting inclusion criteria (n=1)
 Declined to participate (n=0)
 Other reasons (n=0)

Randomized (n=140)

Allocation
Allocated to standard GLB (n=70)
 Received allocated intervention (n=68)
 Did not receive allocated intervention (lost to
follow-up during run-in period, n=2)

Allocated to GLB+NGx (n=70)
 Received allocated intervention (n=69)
 Did not receive allocated intervention (lost to
follow-up during run-in period, n=1)

Follow-Up (3, 6 and 12 Month)
Lost to follow-up (n=21) (busy
schedule/participant burden, n=3; could not
reach participant, n=18)

Lost to follow-up (n=24) (busy
schedule/participant burden, n=7; could not
reach participant, n=17)

Discontinued intervention (total, n=10)
(schedule changed, n=1; family member
became ill or deceased, n=3; participant
became ill, n=3, participant reported losing
interest in program, n=3)

Discontinued intervention (total, n=7)
(schedule changed, n=3; participant moved to
different city or country, n=2; family member
became ill or deceased, n=2)

Analysis
Analyzed (n=37)
 Excluded from analysis (participant had
spinal stimulator placed and therefore could
not conduct BIA to measure body fat
percentage, n=1; extreme outlier due to BIA
machine error, n=1; weight and BMI were still
measured for both participants therefore both
remain included in the total number analysed)

Analyzed (n=38)
 Excluded from analysis (participant had
pacemaker and therefore could not conduct
BIA to measure body fat percentage, n=1;
extreme outlier due to BIA machine error, n=1;
weight and BMI were still measured for
153both
participants therefore both remain included in
the total number analysed)

Figure 7.2: Change in anthropometric measures after 3-, 6-, and 12-month follow-up
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7.1.5 Discussion

This study provides several notable, novel contributions to the literature. From a public
health perspective, it is the first study to explore short-, moderate- and long-term anthropometric
changes resulting from the standard GLB program in a population of adults with a baseline BMI
≥ 25.0 kg/m2 regardless of having a prediabetes diagnosis. While originally piloted and intended
for diabetes prevention in individuals diagnosed with prediabetes (Diabetes Prevention Program
Research Group 2002), public health officials have since encouraged the GLB program
expansion to more broad patient populations such as those with a BMI ≥ 25.0 kg/m2 (Ontario
Ministry of Health and Long-Term Care 2018). This study demonstrates that a clinically
meaningful 3-5% sustained weight loss (Jensen et al. 2014) can be achieved with program
expansion to this broader population, thus supporting public health authority recommendations.
However, it should be noted that weight-related outcomes in patients with prediabetes appear to
be even greater (Diabetes Prevention Program Research Group 2002). Additionally, to our
knowledge this is the first study to explore body composition changes within the GLB program.
Measures of body composition are superior to weight and BMI given that body composition
accounts for changes in fat, water and muscle mass as opposed to overall weight changes (Nuttall
2015).

Gold-standard clinical practice guidelines for weight management interventions indicate
that such interventions should include: calorie restriction; participation in a comprehensive
lifestyle program for ≥6 months with at least 14 sessions in 6 months; counselling on the
cardiovascular benefits associated with ≥3-5% weight loss; participation in long-term (≥12month) weight loss maintenance programs; and regular contact with an ‘interventionist’ who
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assists with engagement in PA and monitoring body weight regularly (Jensen et al. 2014). Both
the standard GLB and GLB+NGx interventions adhered to these guidelines. A minimum of 35% sustained weight loss is clinically meaningful in order to produce several health benefits
including reduced triglycerides, reduced blood glucose and hemoglobin-A1C, as well as a
reduced risk of developing type 2 diabetes; higher weight loss is associated with greater benefits
(Jensen et al. 2014). Both the standard GLB and GLB+NGx groups achieved such sustained
weight loss over a 12-month period demonstrating the success of both the standard and modified
(personalized) versions of the GLB program. Clinically meaningful changes in BFP are not as
well-established as changes in weight, but population reference standard charts of BFP have been
published (Imboden et al. 2017). Women tend to experience an approximate 2% absolute
increase in BFP per decade from ages 20-29 until ages 50-59. From ages 60-69 to 70-79, less
than a 1% absolute BFP increase is observed (Imboden et al. 2017). In comparing the percentiles
for reference standards of women’s BFP (given that the current study consisted primarily of
female participants) to the current study, the NOW trial participants exhibited a 1-2 decile
change in BFP throughout the GLB and GLB+NGx programs across various study time points
(3, 6, and 12 months) and long-term reductions of approximately 3% absolute BFP. Given that
overall, BFP tends to increase with time (Imboden et al. 2017), this 3% reduction represents a
clinically meaningful change. Moreover, as there were clinically meaningful changes observed
for weight at all time points, this further demonstrates that the overall change in BFP would also
be considered clinically meaningful. Furthermore, with body fat mass specifically having major
impacts on health outcomes (Nuttall 2015), a 3-5% change in BFP is likely of greater clinical
benefit than a 3-5% change in overall weight, which may also include reductions in muscle
and/or fat mass.
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Notably, the GLB+NGx group experienced significantly greater reductions in BFP after 3
and 6 months compared to the standard GLB group. This speaks to the scientific validity and/or
clinical utility of the nutrigenetic and lifestyle genomics information and advice provided to
participants. The precise details of the genetic information provided, including a sample genetic
report, have been previously detailed elsewhere (Horne et al. 2019). There are many clinical
cases where short- and moderate-term weight loss and/or achieving a specific BMI cut-off have
demonstrated positive impacts on major and critical patient outcomes. Examples include: pretransplant weight loss to reduce the risk of organ rejection, reduce the risk of wound
complications, reduce hospital length-of-stay and increase chances of survival (Clausen et al.
2018; Knoll et al. 2005); pre-surgery to reduce the risk of complications after hernia repair
(Menzo et al. 2018); in kidney, heart, liver, and lung disease patients for transplant listing
(Mehra et al. 2006; Knoll et al. 2005; Martin et al. 2014); to be eligible as a living organ donor at
most transplant centres (UNOS Transplant Living c2019); improvement in pregnancy rates in
patients with infertility (Best, Avenell, and Bhattacharya 2017); prior to total joint arthroplasty to
increase chances of implant survivorship and postoperative functional scores (Bookman et al.
2018); and pre-surgery weight loss to reduce the risk of dislocation following total hip
replacement (Annan et al. 2018). With this in mind, studying the effectiveness of nutrigenomics
and lifestyle genomics interventions for these specific clinical cases, and others where short-tomoderate-term reductions in weight-related outcomes are beneficial, is an important
recommended next step for the field of precision nutrition. Interestingly, a recent study found
that only 6% of clinical dietitians working in the public health setting participated in
nutrigenomics training, as opposed to 33% of industry dietitians and 14% of private practice
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dietitians (Cormier et al. 2014). This suggests that there is likely minimal uptake of
nutrigenomics in acute-care settings, such as hospitals, where the abovementioned cases are
more prevalent; perhaps these are the clinical settings in which patients could benefit most from
nutrigenomics and lifestyle genomics weight management interventions?

Our finding of significant differences in BFP between groups diminishing at the 12month follow-up is intriguing, especially given that the GLB+NGx group made significantly
greater dietary changes and better adhered to specific dietary advice compared to the standard
GLB group at 12 months. There are multiple possible explanations for these findings. First,
biological mechanisms promote weight regain after periods of weight loss. Over time,
physiological mechanisms including adipose cellularity, endocrine function, energy metabolism,
neural responsivity and addiction-like neural mechanisms promote weight regain after a period
of weight loss (Ochner et al. 2013). Decades of research have demonstrated that increased energy
(calorie) intake can lead to increased fat cell size and fat cell number (Martinsson 1969; Hirsch
and Batchelor 1976; Tchoukalova et al. 2010), and while weight loss may reduce the size of fat
cells, it may not reduce the number of fat cells (Martinsson 1969; Björntorp et al. 1975; Hirsch
and Han 1969; Arner and Spalding 2010; Gurr et al. 1982; Löfgren et al. 2005). Furthermore,
preliminary research has demonstrated that this could encourage weight regain following periods
of weight loss due to a reduction in the rate of fat oxidation and increased retention of ingested
energy (MacLean et al. 2006; Jackman et al. 2008; Knittle and Hirsch 1968; Kelley et al. 1999;
Berggren et al. 2008). In addition, some research has demonstrated a decrease in thyroid function
(and thus, a decrease in metabolic rate) after weight loss in individuals with obesity (Rosenbaum
et al. 2000; Kozłowska and Rosołowska-Huszcz 2004; Moreno et al. 2008). Moreover, the
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activity of the hypothalamic-pituitary-adrenal axis, which regulates cortisol levels, is heightened
following weight loss and this can lead to increased appetite and fat accumulation (Björntorp
2001). In terms of changes in metabolic rate, a decrease in fat mass and lean mass will both lead
to reductions in energy output/expenditure (Gallagher et al. 1996; Leibel, Rosenbaum, and
Hirsch 1995). While a reduction in metabolic rate is normal and expected, studies have
demonstrated that weight loss occurring from lifestyle interventions results in ‘metabolic
adaptation.’ Metabolic adaptation refers to the concept that following weight loss, individuals
experience a greater reduction in metabolic rate than would be expected based on an individual’s
body composition (Leibel, Rosenbaum, and Hirsch 1995; Gallagher et al. 1996; Astrup et al.
1999; Rosenbaum and Leibel 2010; Johannsen et al. 2012; Camps, Verhoef, and Westerterp
2013; Tremblay and Chaput 2009). This decrease in resting metabolic rate following weight loss
leads to biological challenges with weight loss maintenance. The classic Minnesota semistarvation experiment was one of the first studies to demonstrate a reduced resting metabolic rate
during a period of weight regain following weight loss (Keys 1950), with several later studies
corroborating these findings (Leibel, Rosenbaum, and Hirsch 1995; Astrup et al. 1999;
Rosenbaum and Leibel 2010; Johannsen et al. 2012; Camps, Verhoef, and Westerterp 2013;
Tremblay and Chaput 2009). Ultimately, there are a number of biological mechanisms leading
the body to resist weight loss, and drive weight regain. This could explain why results from the
NOW trial demonstrated weight regain occurring from 6-month to 12-month follow-up in both
the GLB and GLB+NGx groups. It is further interesting to notice the continued trend towards
decreasing BFP (but not weight) in the standard GLB group only. Although differences were not
significant between groups for BFP at 12-months, it is possible that the faster rate of BFP loss
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experienced in the GLB+NGx group led to an earlier onset of the biological responses promoting
weight regain. Indeed, research supports this idea (MacLean et al. 2011).

Second, while the abovementioned biological mechanisms promoting weight regain
provide a plausible explanation for our findings, it is also possible that participants noticed some
weight regain occurring between 6 and 12 months, and thus at 12 months became increasingly
motivated to follow the genetically-guided advice. Given that weight and BFP losses take time, if
participants were followed beyond 12 months, it is plausible that we would, again, observe
significant differences between the standard GLB and GLB+NGx groups for BFP changes, as we
observed at 3 and 6 months. Indeed, this is an important future research endeavour. Since data
collection did not occur between 6- and 12-months, it is not possible to comprehend how well
participants were following the dietary guidelines in between these two time points.

There are some limitations of the present work that should be noted. Difficulty with
participant retention and thus reduced statistical power may have limited the ability to detect
statistical significance for the secondary outcomes, weight and BMI. Additionally, while the
target dropout rate for an RCT is <20% (National Institutes of Health n.d.), studies demonstrate
that this is typically challenging for long-term weight loss studies (Hillmer et al. 2017; Truby et
al. 2006; Jebb et al. 2011; Wadden et al. 2004; Gill et al. 2012; Foster et al. 2003). Thus, the
dropout rate for the NOW trial was not remarkable. Reasons for reduced participant retention can
include scheduling conflicts, dissatisfaction with treatment, and lack of time to meet the study
requirements (Wadden et al. 2004). Having a lower education level (less than university level),
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and higher level of obesity are also risk factors for dropping out of weight loss programs/studies
(Michelini et al. 2014; Hadžiabdić et al. 2015). These factors contributed to participant dropout
in the NOW trial as further indicated in Figure 7.1, Table 7.1 and Chapter 6, Table 6.2. Given the
higher dropout rate, a modified intention-to-treat (ITT) analysis was performed. Dropouts were
not treated as treatment failures and last observation carried forward methods of imputing
missing data were not conducted. However, participants were not excluded based on adherence.
ITT can be beneficial for increasing statistical power, improving generalizability and minimizing
the risk of a type 1 error (Gupta 2011). However, when there is considerable variability in the
endpoint data, it becomes difficult to predict outcomes (Gupta 2011). Furthermore, ITT can
increase the susceptibility to type 2 errors, especially with higher dropout rates (Gupta 2011). In
addition, the research question should be carefully considered prior to conducting an ITT
analysis (Feinman 2009). In the NOW trial, we aimed to determine if individuals enrolled in a
genetically tailored weight management program reduced their weight and body fat percentage
and improved their dietary intake to a greater extent than those enrolled in population-based
weight management program. Therefore, a modified ITT approach was more appropriate given
that dropouts were no longer enrolled in the weight management programs.

Previous research has been conducted within the GLB program at the EEFHT and five
other Ontario primary care locations. In this previous study, the GLB program was offered
during a 9-month period, and dropout rates throughout the study were 26.8% at 3-months, 46.8%
at 6-months, and 63.0% at 9-months (Hillmer et al. 2017). This is the most comparable study to
the NOW trial given the direct similarities in the intervention (GLB program) and setting
(EEFHT in Aylmer, Ontario). With a longer intervention and study duration of 12 months, the
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NOW trial still had an overall retention rate approximately 17% higher than previous research in
the GLB program, which ran for only 9 months (Hillmer et al. 2017). We suspect that the
provision of genetic information (at baseline for the GLB+NGx group and after 12-months for
the standard GLB group) enhanced overall interest in the intervention/study, therefore helping to
improve retention. This participant interest is further highlighted in Figure 7.1, whereby 140
participants enrolled in the NOW trial out of the 141 patients who were invited to join the study.
Nonetheless, although not statistically significant, there were notable clinically meaningful
differences in percent weight change, whereby only the GLB+NGx group achieved >5% weight
loss (at 6-months follow-up) and both the GLB and GLB+NGx group achieved 3-5% weight loss
after 12-months (Jensen et al. 2014). Thus, both interventions were overall effective.

The results of this study are primarily generalizable to populations of middle-aged,
middle socio-economic status, Caucasian women with obesity (class II) enrolled in a lifestyle
change weight management program. Given that participants who were enrolled in the GLB
program were invited to participate in the study, this appears to be a representative sample of
individuals interested in this weight management program. Furthermore, the NOW trial study
population is similar to other reported GLB study populations (Alva 2019; Alva, Romaire, and
Acquah 2019; Jeffers et al. 2019; McTigue et al. 2009).

This study further demonstrated the feasibility of communicating genetic-based nutrition
and PA information and advice in a group setting. The literature supports that group-based
nutrition education can be more effective in motivating nutrition behaviour change and can be
more meaningful for patients (Siero 2000; Abusabha, Peacock, and Achterberg 1999). However,
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since this type of personalized nutrition advice is typically communicated in one-on-one patient
settings, future research should seek to compare a nutrigenetic and/or lifestyle genomics
intervention to standard of care, rather than gold-standard care as we have studied here. While
the GLB program is the ‘gold-standard,’ it is only currently offered in nine primary care facilities
in Canada (University of Pittsburgh, c2017). In the United States, this program is currently
offered to the general public in over 50 facilities (University of Pittsburgh, c2017). As such,
standard of care for weight management in dietetics typically consists of individual lifestyle
counselling.

7.1.6 Conclusion
Nutrigenomics interventions can produce clinically meaningful health-related outcomes
for patients over the short-term, moderate-term and long-term, with additional benefits observed
above those achieved with gold-standard care over the short-term and moderate-term. Clinicians
should consider implementing the GLB+NGx intervention for patients. As research continues to
advance with the hopes of nutrigenetic tests becoming increasingly accurate, genetic-based
lifestyle interventions hold considerable promise for improving health and wellbeing in a manner
that is innovative and exciting for patients and healthcare professionals alike. It is certainly a
science worth exploring further.
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CHAPTER 8: DISCUSSION
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This dissertation investigated the practical application of nutrigenomics in primary care
for improving weight management, body composition, dietary intake, and adherence to specific
dietary guidelines. The results indicated that the nutrigenetic-guided intervention was effective at
improving body composition to a greater extent than standard advice after 3- and 6-month
follow-up. Furthermore, the nutrigenetic-guided intervention motivated long-term changes in
dietary fat intake and enhanced adherence to recommendations for total fat and saturated fat
intake after 12-month follow-up. The results of this dissertation are generalizable primarily to
college-educated, middle-aged women with overweight and obesity who are enrolled in a weight
management program. Participants involved in the nutrigenomics, overweight/obesity and
weight management (NOW) trial had positive attitudes towards improving their dietary intake
and towards weight management, with neutral lifestyle-related subjective norms and perceived
behavioural control, based on the TPB.

8.1 Novel Research Contributions
8.1.1 Overall
This randomized controlled trial (RCT) provided a number of novel research
contributions, building on previous work in the field (Arkadianos et al. 2007; Frankwich et al.
2015; Celis-Morales et al. 2017). The NOW trial was the first adequately powered RCT to assess
the pragmatic delivery of a nutrigenomics intervention with a weight-related primary outcome.
Furthermore, the measurement of body fat percentage (BFP) provided a more informative healthrelated outcome compared to the measurement of weight and body mass index (BMI). With the
study taking place within the East Elgin Family Health Team’s (EEFHT’s) Group Lifestyle
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Balance™ (GLB) program, the research proved to be highly pragmatic. This is further detailed in
the PRECIS-2 scoring tool (Chapter 6, Table 6.6). Overall, this trial provided a robust
exploration of the impact of nutrigenomics testing on nutritional habits and weight-related
(including body composition) outcomes.
8.1.2 Methodological Contributions

Cohort randomization was used in the NOW trial to allow all participants in each GLB
group to receive the same intervention – either personalized based on genetics, or populationbased. Thus, the feasibility of cohort randomization in personalized nutrition research has been
demonstrated.
8.1.3 Theoretical Contributions
This was the first genetic testing behaviour change study to intentionally incorporate the
TPB into the study methods, including the statistical analyses. Interestingly, we found that
income (a sub-component of behavioural control) was an important confounding factor to
consider in the 3-month analysis of dietary adherence. Furthermore, the interventions (standard
GLB and GLB+NGx) aimed to positively affect the key components of the TPB, in order to
promote optimal health behaviour change.
8.1.4 Clinical and Public Health Contributions
With nutrigenomics typically offered through direct-to-consumer (DTC) genetic testing
or through a one-on-one session with a healthcare professional, the NOW trial demonstrated the
feasibility of incorporating personalized nutrition into a group-based public health program. This
is a more efficient method of delivering nutrition information given that nutrition education can
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be communicated to multiple patients at one time. Furthermore, the NOW trial provided novel
insights into the clinical utility of the only nutrigenetic test currently offered to Canadian
consumers exclusively through healthcare providers. Specifically, this was the first study to
assess changes in calories, dietary fat and protein as well as weight-related (including body
composition) outcomes resulting from the provision of this nutrigenetic test.

8.2 Body Composition: An Overview
8.2.1 Adiposity and Health
Body fat percentage was selected as the primary outcome of this study given its
association with health, and its importance to patients enrolled in weight management programs.
Total adiposity is a more accurate measure of metabolic phenotypes when compared to measures
of BMI (Goossens 2017). Body fat is positively correlated with insulin resistance and
cardiometabolic disease (Goossens 2017). It has also been cross-sectionally associated with joint
pain (Walsh et al. 2018), and linked to cancer and cognitive disfunction (Guo et al. 1999; Lutz et
al. 2008). In addition to total adiposity, body fat distribution is further important given that
adipose accumulation in the abdominal region is associated with comorbidities and all-cause
mortality, whereas adipose accumulation in the gluteofemoral region has been shown to have a
protective effect on cardiometabolic diseases (Snijder et al. 2004; Yusuf et al. 2005).
8.2.2 Body Composition Tools and Techniques
Various tools and techniques are available to assess body composition. Skinfold
measurements provide the least expensive method of measuring body composition, but this
method is also the least accurate (Lee and Nieman 2013). Calipers are used to measure a double
fold of skin and subcutaneous adipose tissue, without muscle tissue. A tape measure is needed to
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measure the appropriate skinfold locations, which can include chest, triceps, subscapular,
midaxillary, suprailiac, abdomen, thigh and calf (Lee and Nieman 2013).
Bioelectrical impedance analysis (BIA) is more accurate than skinfold measurements for
assessing body composition. It involves the use of a low-frequency electrical current to measure
impedance throughout the body. This is then used to estimate measures of body composition
using regression equations (Nelms, Sucher and Lacey 2016).
Hydrostatic (underwater) weighing is known to be a highly accurate method of body
composition measurement, though it is also the least readily available tool. This method is based
on the Archimedes Principle, which states that the buoyancy of an object submersed in water
equals the weight of the displaced fluid of that object. This Principle can be used in hydrostatic
weighing given that lean tissue (bone and muscle) are denser than water, and water is denser than
fat tissue (Lee and Gallagher 2008). While highly accurate, this method is often not well
tolerated by participants as it requires the participant to be completely submerged in water
(Fosbol and Zerahn 2015).
Dual energy X-ray absorptiometry (DXA) is another accurate method, and uses two
different energy levels of X-rays, which pass through the body. The absorption of photons is
measured and used to determine whole body bone mass and soft tissue composition (Shepherd et
al. 2017). According to 2020 Clinical Practice Guidelines, DXA is considered a valid method of
assessing fat mass in patients with various clinical conditions (Sheean et al. 2020). Notably,
some newer DXA technologies can measure abdominal (visceral) fat mass in addition to total
body fat.
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Air displacement plethysmography is another body composition method that uses a
measurement of the air displaced in a sealed chamber to estimate body composition. This method
measures changes in pressure between two chambers: the test chamber and reference chamber.
The equation used to measure body composition involves the measurement of volume and
pressure prior to and while the subject enters the test chamber (Fields, Higgins and Hunter 2004).
Air displacement plethysmography, DXA and hydrostatic weighing are generally considered to
be comparably accurate for measuring body composition across the lifespan, including measures
in infants, children and adults (Heds and Allison 2012; Bedogni et al. 2013; Edwards et al.
2011).
Lastly, computed tomography (CT) and magnetic resonance imaging (MRI) are generally
considered the most accurate methods of measuring body composition, and can be used to
measure total adipose tissue, visceral adipose tissue, subcutaneous adipose tissue, and interstitial
adipose tissue (Ross and Janssen, 2005; Fosbol and Zerahn 2015). CT scans use an X-ray beam,
which passes through tissues to construct images using mathematical techniques. One of the
major downfalls of CT scans is the substantial radiation dosage needed to create the images.
This is especially a concern in studies with multiple follow-ups (Fosbol and Zerahn 2015). MRIs
do not expose participants to radiation, but rather determine body composition based on the
interaction between hydrogen nuclei. Hydrogen nuclei align themselves with a magnetic field. In
MRIs, a radio frequency signal is used to generate images based on energy released from the
hydrogen nuclei (Edelman et al. 2006).
These more accurate tools were not available or feasible in our research setting, therefore
we used BIA given that it is more accurate that skinfold thickness, which was another option
available for use in the NOW trial. Furthermore, BIA is safe (except in patients with electrical
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devices such as pacemakers), inexpensive, low-maintenance, portable, rapid, and requires only
minimal operator training (Buchholz, Bartok and Schoeller, 2004; Fosbol and Zerahn 2015).
8.2.3 BIA Theory

The link between bioimpedance and blood flow was first discovered in the 1950’s
(Nyboer et al. 1959). Later, it was determined that bioimpedance could be used to predict body
composition, based on the underlying theory that the impedance of a cylindrical conductor is
related to its length, cross-sectional area, and the signal of the frequency that’s applied (Mulasi et
al. 2015). Impedance, a measure of current obstruction, is calculated using resistance and
reactance. Resistance refers to the resistive effect exhibited on the current (or current flow
opposition). Thus, water and ionic substances provide a low-resistance pathway. Since water is
contained in fat-free (lean) mass, lower fat-free (lean) mass results in more resistance; higher
lean mass leads to lower resistance. Reactance refers to the conduction delay, which occurs when
the current passes through cell membranes, tissues and non-ionic substances (Mulasi et al. 2015).
The tetrapolar electrode approach that is commonly used today was first validated several
decades ago by Hoffer et al. (1969). This approach involves the administration of electrical
currents via leads attached to electrodes, typically placed on the hand and foot of the subject,
which then differentiates the conductive and nonconductive tissues and fluids of the body
(Mulasi et al. 2015). Tissues containing water and electrolytes (e.g. blood and muscle) conduct
current well. Tissues that resist current include fat, bone and air-filled spaces. Predictions are
then used, based on these measures, to predict body composition (Buchholz, Bartok and
Schoeller, 2004; Mulasi et al. 2015).
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Overall, BIA uses a low amperage current, which passes through the body, to estimate
the amount of water contained in various biological tissues such as skeletal muscle, adipose
tissue and bone. Distal (current injection) electrodes pass an alternating current through the body,
and this current is returned to the proximal (voltage detection) electrodes. The amount of
electricity conducted is proportionate to the concentration of ions in the conductor; thus, when
the concentration of ions decreases, resistance increases. Furthermore, when body fluid viscosity
increases, height increases or the cross-sectional area of the body decreases, resistance
subsequently increases. It is well-established that skeletal muscles are more highly conductive
compared to adipose tissue, which contains less water (Scharfetter et al. 2001; Lukaski et al.
1985). In fact, body fat is considered a non-conducting material, thus providing resistance to
electrical current flowing through the body. Skeletal muscle is more conductive than bone
(Buchholz, Bartok and Schoeller, 2004).
8.2.4 BIA Device and Equation

Body impedance refers to a bodily conductor opposing the flow of an alternating current.
It is made up of resistance and reactance, which are measured using the unit, ohms. Higher
frequency electrical currents can be used to determine total body water, while lower frequencies
can be used to determine extracellular fluid. Extracellular fluid is then calculated based off these
two measures. From there, fat-free mass is derived using proprietary equations that are based on
the assumption that this mass is 73.2% hydrated. Then, fat mass can be determined by
subtracting fat-free mass from total weight. There are also other methods of calculating body
composition using various regression equations (Mulasi et al. 2015). Segmental BIA tends to be
more accurate than whole body BIA given that segmental BIA equations are derived from the
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segmentation of the body into five cylindrical compartments (2 arms, 1 trunk, 2 legs) as opposed
to a single cylindrical compartment (Mulasi et al. 2015).
The relationship between resistance and/or reactance and body fat is indirect. BIA
devices use regression equations to estimate body composition, including BFP. These equations
take into consideration age, gender, weight, height, resistance and reactance (National Institutes
of Health, 1994).
The literature suggests that a midrange frequency current of 50 kHz, used to measure
total body water, will incompletely penetrate intracellular water and therefore detects primarily
extracellular fluid with some intracellular fluid. This can lead to inaccuracies in patients with
altered body water compartmentalization for both intracellular water and extracellular water
(Buchholz, Bartok and Schoeller, 2004; Mulasi et al. 2015). Thus, the addition of a low
frequency, 5 kHz current, helps to more accurately predict extracellular water given that this low
current negligibly penetrates the intracellular water (Gudivaka et al. 1999). The BodyStat
MDD1500 device used in the NOW trial measures resistance and reactance using dual frequency
currents of 5 and 50 kHz. This whole body BIA device measures resistance and reactance, and
based on this impedance measurement, body fat percentage is indirectly derived using a
proprietary equation (BodyStat, 2017).
8.2.5 Contraindications to BIA Use
BIA is more accurate for the measurement of changes in body composition over time, as
opposed to a single, cross-sectional measurement of body composition that may be taken in a
clinical setting (Buchholz, Bartok and Schoeller, 2004). Importantly, BIA should not be used in
individuals who have a pacemaker as the electrical signal from the BIA could alter the function
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of the pacemaker device. Additionally, the safety of BIA has not been assessed in patients with
other implanted electrical devices (e.g. spinal stimulators), and therefore it is recommended that
the device not be used with these patients (BodyStat, 2017).
8.2.6 BIA Limitations
It is normal for fluid shifts to occur throughout the day, which can impact the BIA results.
Asking participants to void prior to conducting the BIA can help to standardize total body fluid.
In addition, repeating the BIA test at the same time of day throughout the duration of a study is
additionally important (Most et al. 2018). However, due to logistical considerations, we were
unable to standardize the time of day that the BIA assessments were conducted in the NOW trial;
this was a limitation of the study.
8.2.7 BIA Data Interpretation
While body mass index (BMI) can be used to classify individuals into categories of
underweight, normal weight, overweight and obese, established categories do not exist for body
composition. This complicates the interpretation of body composition results, but some research
groups have attempted to provide preliminary methods for data interpretation. Ozenoglu and
colleagues (2009) compared body composition measured using BIA to established BMI
categories in 327 adult females residing in Istanbul and found the following mean values for BFP
within each BMI category, with significant differences (p=0.0001) in BFP between categories:
•

Normal Weight: 22.8±4.6%

•

Overweight: 29.7±3.3%

•

Obese: 35.0±3.3%

•

Morbid Obese: 40.2±3.6%
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More recently, Sladjana et al. (2019) profiled BFP stratified by age in a sample of adult
females from the Republic of Serbia. The results are as follows:
•

18.0-19.9 years: 23.8±6.8%

•

20.0-29.9 years: 24.8±7.4%

•

30.0-39.9 years: 28.1±9.3%

•

40.0-49.9 years: 32.4±8.3%

•

50.0-59.9 years: 36.3±7.9%

•

60.0-69.9 years: 39.9±7.9%

To our knowledge, these are the only established interpretations of BIA for female adults.
Reference standards, stratified using percentiles, for BIA-measured BFP in adults are not
available. However, DXA-measured BFP reference standards for Caucasian adults have been
recently published by Imboden and colleagues (2017), with decile cut-offs established for both
male and female Caucasian adults in the United States. These are further detailed elsewhere
(Imboden et al. 2017).
The lack of available reference standards for BIA-measured BFP in samples of Canadian
women poses challenges for the interpretation of the NOW trial results. In comparing the NOW
trial results to the abovementioned studies (Sladjana et al. 2019; Ozenoglu et al. 2009; Imboden
et al. 2017), the GLB group (mean age 56 years, 84% female, 99% Caucasian) exhibited a mean
BFP higher than the mean reported BFP for this age group in Sladjana et al.’s (2019) study. At
baseline, they were between the 20th and 30th percentile for BFP and at 12-months, were
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between the 40th and 50th percentiles (with BFP and percentile values being inversely related).
The GLB+NGx group (mean age 54 years, 90% female, 97% Caucasian) also exhibited a mean
BFP higher than the mean reported BFP for this age group in Sladjana et al.’s (2019) study.
According to Imboden et al.’s (2017) reference standard charts, this group was between the 40th
and 50th percentiles for BFP at baseline, and was between the 50th and 60th percentiles for BFP
at 12 months. Both the GLB and GLB+NGx group fell within the ‘Morbid Obese’ category
according to Ozenoglu et al’s (2009) study. However, these interpretations should be cautioned
given the differences in study samples (Sladjana et al. 2019; Ozenoglu et al. 2009) and body
composition devices (Imboden et al. 2017). Future research should seek to develop reference
standard charts for BIA using a variety of devices and populations. In addition, future research
should aim to explore associations between health outcomes such as blood pressure, cholesterol,
blood glucose and other measures, and these reference standards of BFP.

8.3 Challenges Associated with Long-Term Lifestyle Behaviour Change
Altering lifestyle habits established over the course of an individual’s lifespan is a highly
complex and challenging endeavour. This is referred to in the literature as “the adherence
problem” and is a notable concern given that individuals who do not adhere to a lifestyle
intervention experience fewer health benefits (Dimatteo et al. 2002). Adherence to weight
management programs have demonstrated particularly low rates of long-term adherence
(Middleton, Anton, and Perri 2013). Typically, lifestyle interventions (both weight-related and
non-weight-related) experience short-term initial adherence, followed by reduced adherence over
the long-term (Middleton, Anton, and Perri 2013). Consequently, it is of great interest to find
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that a nutrigenetic-guided intervention was able to motivate long-term dietary adherence to a
significantly greater extent than a population-based lifestyle intervention. The discussion below
provides greater detail on the challenges of long-term behavioural adherence, while linking this
previous knowledge to the results of the NOW trial.
A variety of factors contribute to challenges with long-term behavioural adherence. The
obesogenic food environment makes high-calorie, high-fat foods easily accessible at a low cost
(Brownell 2005). Technological innovation has led to highly sedentary lifestyles, with workers
spending at least 6-8 hours daily sitting at a desk (Lakdawalla and Philipson 2009). In terms of
fitting planned, moderate-intensity physical activity into one’s day, lack of time as well as
feelings of stress and fatigue after work are commonly reported as perceived barriers to
completing physical activity (Schutzer and Graves 2004; Heesch, Brown, and Blanton 2000).
Furthermore, individuals tend to struggle with long-term adherence to lifestyle changes without
ongoing support from a healthcare provider. Following initial treatment, which should include
regular healthcare provider contact, long-term adherence to lifestyle changes can be optimized
through meetings once or twice monthly (Perri et al. 2008; Wing et al. 2006; Svetkey et al.
2008). The NOW trial was designed to provide ongoing support with a healthcare provider by
including meetings approximately monthly between 3- and 12-month follow-up (with weekly
meetings occurring in the first three months). Reported barriers to healthy eating include a lack
of cooking skills, taste preferences, frequency of eating foods away from home, calorically-dense
and large portion sizes served at family meals, perceived cost, the built environment, food
availability, and behaviours of friends and family (social norms) (McMorrow et al. 2017;
Scherme et al. 2014; Seguin et al. 2014). Therefore, individualized factors as well as the social
and built environment can significantly impact dietary intake and adherence. While not
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specifically assessed in the NOW trial, it is suspected that these challenges were similar between
the GLB and the GLB+NGx groups, given that participant groups were randomized.
From a theoretical perspective, the TPB can be used to demonstrate the impact of
attitudes, subjective norms and behavioural control on health behaviours. Given that the
GLB+NGx group had greater behaviour change outcomes with respect to nutrition over the longterm, it is possible that the more personalized lifestyle intervention had a greater impact on
attitudes and/or subjective norms than the standard, population-based lifestyle intervention. This
is an important future research endeavour, which can be completed using the NOW trial data.
Other theories can further our comprehension of human behaviour in the context of lifestyle
changes. The social cognitive theory, for example, suggests that personal factors (i.e. cognitions
and emotions), as well as environmental factors (both social and physical environments)
contribute to one’s behaviour, and that one’s behaviour can also impact personal and
environmental factors (Bandura 1991). The social cognitive theory can be further broken down
into four key constructs: health knowledge, self-efficacy beliefs and outcome expectations, selfregulatory skills, and barriers to change (Bandura 1991). The standard GLB intervention
promoted health knowledge through the 23 group-based and three one-on-one educational
sessions about lifestyle guidelines and their importance for optimal health and weight
management. This intervention encouraged positive self-efficacy beliefs and outcome
expectations through weekly goal setting leading to successful experiences altering lifestyle
habits. It promoted self-regulatory skills using goal setting, food and beverage tracking, and
positive reinforcement from the facilitator and GLB group members alike. Lastly, the program
educated participants on problem-solving and included participant-guided discussions related to
problem-solving, thus positively impacting barriers to change. The GLB+NGx program also
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affected the abovementioned components of the social cognitive theory, but may have further
affected health knowledge and outcome expectations through the provision of personalized,
genetic-based lifestyle information and advice. These theoretical perspectives demonstrate the
complexities and multifactorial nature of behaviour change, while also helping to explain why
the provision of genetic-based nutrition information resulted in greater nutrition-related
behaviour change.

8.4 Comparison to Outcomes of Previous Research on Nutrigenomics and
Change in Nutrition-Related Behaviours

With respect to behaviour change, the NOW trial adds promise to the body of literature by
demonstrating that genetic-based nutrition information can better motivate individuals to change
their nutritional habits. The NOW trial results also support literature demonstrating that the
provision of actionable genetic-based recommendations is more likely to facilitate health
behaviour change compared to the provision of non-actionable genetic-based information such as
disease risk estimates (Horne et al. 2018). Examples of previous, related research are detailed
below.
A RCT conducted by Hieteranta-Luoma et al. (2014) found that when individuals were
given genetic-based information related cardiovascular disease, they improved the quality of
their diet to a greater extent than the control group. Similarly, in Nielsen and El-Sohemy’s RCT
(2014), DNA-based nutrition advice motivated participants with high-risk genetic variants to
reduce their sodium intake over the long-term (12-months), more so than the control group.
These studies, and several others, were conducted in samples of participants who received the
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genetic testing free of charge or at a reduced rate. Thus, it is interesting and important to also
review the results of studies conducted in real-world genetic testing consumers. Kaufman et al.
(2012) surveyed consumers of DTC genetic testing and found that one third of participants
reported being more careful with their diet, 10% reported changing a nutritional supplement, and
14% reported exercising more. Egglestone et al. (2013) surveyed consumers who had purchased
DTC genetic tests and compared them to consumers considering purchasing a test or waiting for
their results (control group). Of the consumers who had purchased DTC genetic tests and
received their results, 27% reported changing health behaviours. The most commonly reported
changes were “healthier diet,” “more exercise” and “taking vitamins or supplements”
(Egglestone, Morris, and O’Brien 2013). With DTC genetic testing, consumers typically receive
a substantial amount of health-related information. Therefore, there may be one or two specific
components of the genetic report that stand out to an individual, and this is likely where the
individual will focus their efforts in improving health behaviours. By assessing health behaviour
change through asking more broad, open-ended questions, Egglestone et al. (2013) and Kaufman
et al. (2012) provided an important assessment of overall behaviour change. With differing
health priorities for different people, the focus of health behaviour change in genetic testing
consumers can be highly variable.
Many studies have, conversely, found a lack of health behaviour change resulting from
genetic testing, as further detailed in Chapter 3. The first study to assess change in nutritional
habits from genetic testing focused on changes in dietary fat intake as a result of receiving a
routine clinical diagnosis of familial hypercholesterolemia, or receiving a routine clinical
diagnosis in addition to genetic testing. This was a randomized trial and found no significant
differences in nutritional intake over the 6-month follow-up (Marteau et al. 2004). Another of the
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earlier studies randomized participants with obesity to receive a 1-session consult on how to
manage obesity, which either included or excluded genetic information. They measured dietary
restraint and found no significant differences between groups after 6-month follow-up (Rief et al.
2007). Roke and colleagues’ (2017) RCT of young female adults found no significant differences
in omega-3 intake after 12-week follow-up in a group receiving genetic-based information about
FADS1 genotype and omega-3 compared to those receiving non-genetic-based information about
omega-3. Another RCT of over 1200 young adults followed up after one month found no
significant differences in nutrition and physical activity habits in a group receiving standard
weight management advice, compared to a group receiving standard weight management advice
in addition to information about FTO genotype (general information about the FTO gene,
personal FTO genotype, mode of inheritance, and impact on weight) (Meisel et al. 2015). With
respect to the weight-related interventional studies (Meisel et al. 2015; Rief et al. 2007), given
the complexities of weight management discussed throughout the present dissertation, it is
perhaps not surprising to find that the abovementioned weight management behaviour change
research found no significant nutrition-related changes stemming from genetic-based
interventions after 1-, 3-, or 6-month follow-up. It is also possible that participants were not
followed up for long enough to exhibit substantial lifestyle behaviour changes, which can take
time to develop and become habits. Following participants for at least 12-months appears to be a
warranted endeavour. Notably, there are now four completed 12-month RCTs (including the
NOW trial) assessing dietary change resulting from genetically-tailored advice, all of which
demonstrated positive dietary changes after 12-month follow-up (Nielsen and El-Sohemy 2014;
Chao et al. 2008; Hietaranta-Luoma et al. 2014).
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Overall, research in the area of nutrigenomics interventions and lifestyle behaviour change is
highly variable regarding the follow-up time points, methods, intervention strategies,
participants, and therefore nutrition-related outcomes. Perhaps the truly important research
question is not broadly “does genetic testing motivate improvements in health behaviours?” with
a simple ‘yes’ or ‘no’ answer, but rather, “how can we use genetic testing to motivate
improvements in health behaviours?” Indeed, the former has been the focus of more recent
systematic reviews (Hollands et al. 2016; French et al. 2017).
In terms of weight-related outcomes, further detailed in Chapter 4, previous research
exploring the impact of nutrigenomics interventions on weight management have had mixed
findings. Some research demonstrated effectiveness, while others reported no effect (Arkadianos
et al. 2007; Celis-Morales et al. 2017; Frankwich et al. 2015). Study designs and nutrigenomics
interventions have both been highly variable in the research that has been conducted to date. The
NOW trial demonstrated that an actionable nutrigenomics-guided weight management
intervention was effective at significantly reducing BFP after 3 and 6 months (Chapter 7). The
first study assessing weight loss outcomes stemming from nutrigenomics interventions
demonstrated an increased likelihood of maintaining some weight loss, with varying follow-up
time points between 90 days and >365 days (Arkadianos et al. 2007). Later research in a sample
of U.S. veterans, followed for 24 weeks, found that a nutrigenomics intervention had no impact
on weight compared to general advice, but adherence to the nutrigenomics intervention was
correlated with weight loss, whereas adherence to the standard diet was not (Frankwich et al.
2015). More recently, Celis-Morales et al. (2017) found that, compared to the provision of other
levels of personalization, there was no beneficial impact of communicating genotype-related
information and advice on weight and waist circumference in a 6-month follow-up study.
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Therefore, the NOW trial adds promise to the body of literature with respect to short-term and
moderate-term reductions in BFP in a nutrigenomics-guided intervention, above and beyond BFP
changes demonstrated in a highly regarded public health weight management program. However,
over the long-term there were no significant differences in weight-related outcomes between
groups (Chapter 7). This is curious, given the long-term significant differences in dietary change
and adherence, whereby the nutrigenomics-guided intervention group made greater dietary
changes and better adhered to the dietary guidelines compared to the standard intervention group.
There are some plausible explanations for this, as discussed previously in Chapter 7. It is
possible that participants noticed weight regain occurring from 6 until 12 months, and thus at 12
months, became increasingly motivated to follow their genetic-based dietary guidelines. It is also
possible that established biological adaptations occurring with weight loss could help to explain
these diverging findings. This topic warrants further discussion, below.

8.5 Biological Challenges of Long-Term Weight Loss and Maintenance
Over time, physiological mechanisms including adipose cellularity, endocrine function,
energy metabolism and neural responsivity promote weight regain after a period of weight loss
(Ochner et al. 2013). Decades of research have demonstrated that increased energy (calorie)
intake can lead to increased fat cell size and fat cell number (Martinsson 1969; Hirsch and
Batchelor 1976; Tchoukalova et al. 2010), and while weight loss may reduce the size of fat cells,
it is unlikely to reduce the number of fat cells (Martinsson 1969; Björntorp et al. 1975; Hirsch
and Han 1969; Arner and Spalding 2010; Gurr et al. 1982; Löfgren et al. 2005). Furthermore,
while not well-established, preliminary research has demonstrated that this could encourage
weight regain following periods of weight loss due to a reduction in the rate of fat oxidation and
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increased retention of ingested energy (MacLean et al. 2006; Jackman et al. 2008; Knittle and
Hirsch 1968; Kelley et al. 1999; Berggren et al. 2008). Changes in leptin (the satiety hormone)
levels can also impact weight regain with research indicating that compared to a control,
formerly obese individuals who had lost weight had reduced serum leptin levels despite having
the same BFP (Löfgren et al. 2005). Several studies have shown a greater reduction in leptin
levels following weight loss than one would expect (Arner and Spalding 2010; Löfgren et al.
2005; Rosenbaum et al. 1997). Leptin depletion can lead to decreased metabolic rate (energy
expenditure) and physical activity (Rosenbaum et al. 2010) as well as increased hunger and
energy (calorie) intake (Kissileff et al. 2012). Peptide YY and cholecystokinin are other satietypromoting hormones, while ghrelin is a hunger-inducing hormone and changes in levels of these
hormones have also been observed following periods of weight loss (Wren et al. 2001;
Batterham et al. 2002; Sumithran et al. 2011; Lien et al. 2009). Therefore, weight loss could lead
to both reduced satiety, and increased hunger, resulting in overeating and thus weight regain
(Rosenbaum et al. 1997). Additionally, research has demonstrated a decrease in thyroid function
(and thus, a decrease in metabolic rate) after weight loss in individuals with obesity (Rosenbaum
et al. 2000; Kozłowska and Rosołowska-Huszcz 2004; Moreno et al. 2008). Moreover, the
activity of hypothalamic-pituitary-adrenal axis, which regulates cortisol levels, is heightened
following weight loss and this can lead to increased appetite and fat accumulation (Björntorp
2001).
In terms of changes in metabolic rate, a decrease in fat mass and lean mass will both lead
to reductions in energy output/expenditure (Leibel, Rosenbaum, and Hirsch 1995; Gallagher et
al. 1996). While a reduction in metabolic rate is normal and expected, studies have demonstrated
that weight loss occurring from lifestyle interventions (behavioural weight loss) results in
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‘metabolic adaptation’ (Leibel, Rosenbaum, and Hirsch 1995; Gallagher et al. 1996; Astrup et al.
1999; Rosenbaum and Leibel 2010; Johannsen et al. 2012; Camps, Verhoef, and Westerterp
2013; Tremblay and Chaput 2009). Metabolic adaptation refers to a greater reduction in
metabolic rate than would be expected based on an individual’s body composition (Leibel,
Rosenbaum, and Hirsch 1995; Gallagher et al. 1996; Astrup et al. 1999; Rosenbaum and Leibel
2010; Johannsen et al. 2012; Camps, Verhoef, and Westerterp 2013; Tremblay and Chaput
2009). This decrease in resting metabolic rate following weight loss leads to biological
challenges with weight maintenance. The classic Minnesota semi-starvation experiment was one
of the first studies to demonstrate a reduced resting metabolic rate during a period of weight
regain following weight loss (Keys 1950). A number of studies have corroborated these findings
following the publication of the Minnesota semi-starvation experiment (Leibel, Rosenbaum, and
Hirsch 1995; Astrup et al. 1999; Rosenbaum and Leibel 2010; Johannsen et al. 2012; Camps,
Verhoef, and Westerterp 2013; Tremblay and Chaput 2009). Weight cycling can also negatively
affect resting metabolic rate, with research demonstrating that the fat-to-lean mass ratio of
weight regained is greater than the fat-to-lean mass ratio of weight lost. Therefore, weight
cycling can result in the body favouring fat mass over lean mass (Lahti-Koski et al. 2005). With
lean mass having a greater contribution to energy expenditure compared to fat mass, over time
multiple bouts of weight cycling can have a considerable impact on metabolic rate (Prentice et al.
1992).
Long-term weight loss is further challenged by neural responsivity. Specifically, neural
systems include: the homeostatic system, which functions to respond to caloric needs to maintain
energy balance; the reward-related system, which functions to promote eating based on
dopamine signalling, thus driving the perception of the reward-value of food; and the inhibitory
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system, which functions to inhibit excessive food intake (Le et al. 2006). With caloric restriction,
the homeostatic system upregulates the reward-related system, thus leading to greater
consumption of high-calorie foods compared to low-calorie foods. This upregulation appears to
persist during the period following weight loss (Kissileff et al. 2012; Murdaugh et al. 2012),
which can result in weight regain (LaBar et al. 2001; Berthoud 2011). Indeed, research
demonstrates that individuals crave “forbidden foods” during periods of dietary restriction
(Soetens et al. 2008).
Ultimately, there are several biological mechanisms leading the body to resist weight
loss, and drive weight regain. This could explain why results from the NOW trial demonstrated
weight regain trends occurring from 6-month to 12-month follow-up in both the GLB and
GLB+NGx groups (Chapter 7). It is intriguing to notice the continued trend towards decreasing
BFP (but not weight) in the GLB group only. It is hypothesized that the faster rate of BFP loss
experienced in the GLB+NGx group led to an earlier onset of the biological responses promoting
weight regain. Indeed, research supports this notion (MacLean et al. 2011). Additionally,
considering the nutrition-related findings presented in Chapter 6, taken together with the weightrelated findings from Chapter 7, it is likely that the drivers of weight and fat mass regain in the
GLB+NGx group were related more to metabolic adaptation, endocrine function, energy
metabolism and adipose cellularity than to neural responsivity and hormonal changes associated
with increased energy intake, such as changes in peptide YY, cholecystokinin and ghrelin.
Overall, biological adaptations to weight loss will remain a challenge for researchers in the field
of pragmatic nutrigenomics for weight loss.
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8.6 Participant Retention in Weight Loss Research
With these biological and behavioural challenges associated with sustaining weight loss
long-term, it is not surprising to find higher dropout rates in weight loss studies compared to
studies of other health-related outcomes. While the target dropout rate for an RCT is <20%
(National Institutes of Health n.d.), studies demonstrate that this is typically challenging for longterm weight loss studies (Hillmer et al. 2017; Truby et al. 2006; Jebb et al. 2011; Wadden et al.
2004; Gill et al. 2012; Foster et al. 2003). Thus, the dropout rate of 46% in the NOW trial was
not remarkable. Reasons for reduced participant retention could include scheduling conflicts,
dissatisfaction with treatment, and lack of time to meet the study requirements (Wadden et al.
2004). Having a lower education level, a higher level of obesity, and higher stress levels are also
risk factors for dropping out of weight loss programs/studies (Michelini et al. 2014; Ortner
Hadžiabdić et al. 2015). Many of these factors contributed to participant dropout in the NOW
trial as further indicated in Chapter 7: Figure 7.1 and Table 7.1, and Chapter 6: Table 6.2.
Notably, research has previously been conducted within the GLB program at the EEFHT and
five other Ontario primary care locations. In this previous study, the program was offered during
a 9-month period, and dropout rates throughout the study were 26.8% at 3-months, 46.8% at 6months, and 63.0% at 9-months (Hillmer et al. 2017). This is the most comparable study to the
NOW trial, in terms of dropout rate, given the similarities in the intervention and setting. The
addition of nutrigenetic information in the NOW trial may have helped achieve a higher retention
rate (over a longer period of time) than this previous research.
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8.7 Future Directions
Future research evaluating the impact of genetic testing on health behaviours should
consider validated behaviour change theory, such as the TPB. Not only would this help to ensure
important possible confounders of behaviour change are considered, but it would also help to
inform high-quality, detailed results from future systematic reviews on this topic. Perhaps
genetic testing for personalized nutrition helps to motivate health behaviour change only when
attitudes and/or subjective norms and/or behavioural control and/or behavioural intentions are
high? For example, participants in the NOW trial had highly positive attitudes towards changing
their nutritional habits, with neutral subjective norms and behavioural control, and strong
intentions to make changes to their nutritional intake. These participants successfully made longterm changes to their total fat and saturated fat intake. If this study was repeated in a sample of
participants with negative attitudes and weak intentions towards changing their nutritional habits,
results may demonstrate no changes in nutritional intake even if behavioural control and/or
subjective norms are positive in terms of encouraging behaviour change. Future studies should
seek to test this concept. Additional TPB research should determine if, over time, genetic testing
for personalized nutrition and physical activity positively affects one or more of the
intermediates of behaviour change: attitudes, subjective norms, and/or perceived behavioural
control. Overall, our understanding of the impact of genetic testing on health behaviour change is
complex and knowledge is only in its infancy.
Future research should further seek to evaluate the impact of pragmatic nutrigenomics
interventions on other indicators of health such as blood pressure, cholesterol, blood glucose,
insulin, and others. In terms of weight management, assessing the impact of nutrigenomics
interventions in samples of patients who may benefit from short-term and moderate-term
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reductions in BFP would be beneficial. These specific patient populations are further outlined in
Chapter 7. Ideally, an RCT methodology should be employed, with the consideration of
validated behaviour change theory to guide both the genetic-based and the standard interventions
as well as the statistical analyses. Given the established difficulties associated with long-term
weight loss including biological adaptations to adipose cellularity, endocrine function, energy
metabolism, and neural responsivity (Ochner et al. 2013), it appears to be of great importance for
researchers to focus on obesity-prevention. Nonetheless, the present work did not seek to
specifically explore if biological mechanisms were responsible for long-term challenges with
maintaining weight loss and fat mass loss from a genetic-based intervention, and thus future
research should aim to replicate the NOW trial while exploring this phenomenon.
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CHAPTER 9: CONCLUSION
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In the areas of nutrigenomics, health behaviour change, overweight/obesity and their
interrelations, there is much that remains to be understood. The NOW trial provided an intriguing
and insightful analysis of these topics, contributing to our overall understanding of the interplay
between nutrition, genetics, health behaviours and health-related outcomes. The findings from
the present dissertation generated strong insights for the focus of future research. As we continue
to gain knowledge in the fields of nutrigenomics, health behaviour change, overweight/obesity
and their interrelations, we are not only contributing greatly to the scientific community, but
more importantly, to the health and wellbeing of individuals through the development of more
precise and personalized health strategies.
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APPENDIX A:
Selected TPB Survey Questions Included in Attrition Analysis
Attitudes/Behavioural Beliefs/Outcome Evaluations

Meeting the recommendation for physical activity outlined in my 1-page report will help me to better
manage my weight.
Unlikely 1

2

3

4

5

6

7

Likely

Meeting the recommendation for calories outlined in my 1-page report will help me to better manage my
weight.
Unlikely 1

2

3

4

5

6

7

Likely

Meeting the recommendation(s) for fat (either total fat and/or different types of fat) outlined in my 1page report will help me to better manage my weight.
Unlikely 1

2

3

4

5

6

7

Likely

Meeting the recommendation for protein outlined in my 1-page report will help me to better manage my
weight.
Unlikely 1

2

3

4

5

6

7

Likely

Subjective (Perceived) Norms/Injunctive Normative Beliefs/Motivation to Comply

My friends eat a generally healthy diet.
Disagree 1

2

3

4

5

6

7

Agree
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My family eats a generally healthy diet.
Disagree 1

2

3

4

5

6

7

Agree

Perceived Behavioural Control/Control Beliefs/Power of Control Factors
For me, making beneficial changes to my calorie intake over the next three months will be:
Extremely Difficult

1

2

3

4

5

6

7

Extremely Easy

For me, making beneficial changes to my fat intake (either total fat and/or different types of fat) over
the next three months will be:
Extremely Difficult

1

2

3

4

5

6

7

Extremely Easy

For me, making beneficial changes to my protein intake over the next three months will be:
Extremely Difficult

1

2

3

4

5

6

7

Extremely Easy

When it comes to making changes to your lifestyle (diet or physical activity), which sentence best
describes your attitude:
a. I do not believe that I need to make any changes to my lifestyle
b. I might need to make some changes to my lifestyle
c. I am determined to make changes to my lifestyle but haven’t started to make any changes yet
d. I have started making positive changes to my lifestyle over the past three months
e. I have started making positive changes to my lifestyle, which I have sustained over the past 3-6
months
f. I have started making positive changes to my lifestyle, which I have sustained for over 6
months
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Actual Behavioural Control

What is your highest level of education?
1.
2.
3.
4.
5.

Elementary School
Middle School (Grade 7/8)
High School
College
University

[Annual household income (CDN$) taken from participant demographic questionnaire]

224

APPENDIX B:
BIA Data Collection Methods
The data collection methods detailed below were adapted with guidance from the
National Institute for Health Research Biomedical Research Centre (National Institute for Health
Research, 2014) and the BodyStat 1500MDD instruction manual (BodyStat, 2017). One
researcher (JH) completed all BIA assessments with participants and therefore inter-rater
reliability assessments were not needed. Before each BIA assessment, safety screening was
conducted. Participants were asked if they had a pacemaker or any other implanted electrical
device and if so, the BIA was not conducted (n=2). Participants were asked to remove all rightsided jewellery and were given the opportunity to void prior to the BIA assessment. They were
then asked to remove their right shoe and sock and lay in a supine position while the researcher
set up the BIA machine and input patient-specific data. The data that was input into the BIA
device included: measured height and weight, age, gender, and physical activity level. Physical
activity level was determined based on the participant’s self-reported 7-day physical activity
recall, which they completed immediately prior to completing the BIA assessment. Alcohol
wipes were used to thoroughly clean the area of the skin where the electrodes would be attached.
Two electrode pads were placed on the right foot, and two on the right hand and wrist as
indicated in Image 1 and Image 2, below. Specifically, the current injection (red) electrodes were
placed proximally to the phalangeal joints and the voltage detection (black) electrodes were
placed at the pisiform prominence of the wrist and on the ankle, in between the medial and
lateral malleoli. The process of setting up the BIA device took approximately 5 minutes, and this
was completed while the patient was laying in the supine position.
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Image 1

Image 2

Images taken from: National Institute for Health Research, 2014

It should be noted that some test violations occurred since dietary intake and physical
activity data collection occurred at the same time period as body composition data collection.
Participants were not asked: to avoid eating 4-5 hours before the test, to avoid caffeine and
alcohol 24 hours before the test or to avoid exercise for 12 hours before the test.
There was one unexpected deviation from the protocol above, in the case of a participant
who experienced extreme pain in the supine position and therefore the participant’s BIA
assessment was conducted in a seated position. This participant, however, only completed the
baseline assessment and therefore their data was not included in the final analysis.

226

Curriculum Vitae

Justine Horne, MScFN, RD, PhD
Profile
• Registered dietitian experienced in clinical, community, industry and research settings
with a passion for knowledge translation, research and teaching
• Proficient in both English (first language) and French (second language)

Education
• Doctor of Philosophy (PhD) in Health and Aging: September 2016 – March 2020, Western
University, Health and Rehabilitation Sciences
o Supervisors: Jason Gilliland, PhD; Janet Madill, PhD, RD
o Major Project: The Nutrigenomics, Overweight/Obesity and Weight
Management Trial (The NOW Trial): A pragmatic randomized controlled trial of
personalized, genetic-based lifestyle advice
o CIHR Frederick Banting and Charles Best Canada Graduate Scholarship Doctoral
Research Award recipient ($105,000)
• Master of Science in Food and Nutrition (MScFN) with Distinction: June 2015, Western
University (Brescia University College)
o Supervisor: Colleen O’Connor, PhD, RD
o Major Project: Exploring knowledge and attitudes of personal nutrigenomics
testing among dietetic students and its value as a component of dietetic
education & practice.
o MScFN Leadership Award recipient
• Bachelor of Science (BSc) in Food and Nutrition – Honours Specialization in Nutrition
and Dietetics with Distinction: June 2013, Western University
o Western Gold Medal recipient
• Certificate in Practical French: June 2013, Western University
o Sir Wilfrid Laurier Memorial Prize recipient

Student Mentorship
•

Preceptor: Diploma in Dietetic Education and Practical Training, Brescia University
College (BUC), 2017 – present
o Supervised 5 dietetic interns for their research placements
o Supervised 3 dietetic interns for their community nutrition/public health
placement
o Supervised 1 dietetic intern for their clinical nutrition placement

227

•

•
•

Lead Coordinator: The NOW Trial Experiential Learning Group, BUC, 2016 – January
2020
o Oversee 50+ student volunteers involved in data collection for The NOW Trial
Undergraduate Independent Study Co-Advisor: BUC Honours BScFN Program, 2019 –
present
o Co-advising undergraduate student with Janet Madill, PhD, RD
Preceptor: MScFN Program, Brescia University College, 2015 – 2017
o Supervised 4 dietetic interns for their clinical nutrition placements

Awards and Recognitions
• Top Scoring Abstract, ASPEN Nutrition Science and Practice Conference: March 2020
(complimentary conference registration)
• CNS Graduate Student and Trainee Award – Poster Competition Finalist: May 2019
• Campus Collaboration Award (the NOW Experiential Learning Group): April 2019
• Canadian Institutes of Health Research (CIHR) – Frederick Banting and Charles Best
Canada Graduate Scholarship Doctoral Research Award: 2018 – present, CIHR
($105,000)
• Ontario Graduate Scholarship: 2017-2018 (2018-2019: offered & declined), Government
of Ontario ($15,000)
• Ontario Respiratory Care Society (ORCS) Fellowship Award: 2017-2018, ORCS ($9200)
• Dean’s Honour List with Distinction: 2009 – 2020, Western University
• Dean’s Honour Roll of Teaching: 2015 – 2018, Western University (Brescia University
College)
• TalentEdge Internship Grant: 2015, Ontario Centres for Excellence ($20,000)
• MScFN Leadership Award: 2015, Brescia University College
• CIS Academic All-Canadian: 2010-2014, Western University
• Sir Wilfrid Laurier Memorial Prize: 2013, Western University ($375)
• A.K. Knill Award: 2013, Western University (Residence Staff)
• Western Gold Medal: 2013, Western University
• Excellence in Leadership Award: 2010-2011, Western University

Certifications
• Registered Dietitian: May 2015 – present, College of Dietitians of Ontario
• Certified Lifestyle Coach: May 2017 – present, Group Lifestyle Balance™/Diabetes
Prevention Program
• DELF Level B2 and DALF Level C1 French Bilingual Certification: May 2013, French
Ministry of Education
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Professional Dietetics Experience
East Elgin Family Health Team: Registered Dietitian, and Health Programs & Research Coordinator, January 2017 – March 2020
Justine the RD & Associates - Personalized Nutrition Consulting: Owner, January 2016 –
October 2018
Nutrigenomix Inc: Manager of Research & Education, May 2015 – Dec 2017
Nutrition Professionals of Canada: Consulting Dietitian, April 2016 – November 2016
Kitchener Downtown Community Health Centre: Registered Dietitian and Diabetes Educator,
May 2015 – September 2015
Brescia University College: Dietetic Intern, May 2014 – April 2015

Teaching Experience
Brescia University College: Adjunct Faculty, January – April 2018
• Nutrition Through the Human Life Cycle, FN2241B
• Dean’s Honour Roll of Teaching
Brescia University College: Adjunct Faculty, September 2015 – December 2016
• Clinical Nutrition 1, FN3351A
• Dean’s Honour Roll of Teaching
Western University: Guest Lecturer, January 2014 – April 2018
• Health Policy, Law & Equity: MPH9009, Lecture Topic: Nutrigenomics: Genetic Testing
for Personalized Nutrition (Graduate Level), April 2018
• Musculoskeletal Disorders in Rehabilitation Science: RS3360, Lecture Topic:
Rehabilitation from the Nutrition Perspective (Undergraduate Level), March 2018
• Guidelines for Physical Activity and Exercise in Older Adults: KIN4474, Lecture Topic:
Nutrition for Healthy Aging and Participation in Physical Activity (Undergraduate Level),
February 2018
• Advances in Clinical Nutrition: FN9444B, Lecture Topics: 1. Long-Term Care; 2.
Nutrigenomics: Genetic Testing for Personalized Nutrition (Graduate Level), January
2015
• Clinical Nutrition 1: FN3351A, Lecture Topic: Disordered Eating (Undergraduate Level),
January 2014
• Nutrition Through the Human Life Cycle: FN2242, Lecture Topics: 1. Nutrition During
Pregnancy; 2. Early Childhood Nutrition; 3. Adult Nutrition (Undergraduate Level),
March - April 2014
• Clinical Nutrition III: FN4453A, Lecture Topic: Nutrigenomics: Genetic Testing for
Personalized Nutrition (Undergraduate Level), January 2014/2015/2016/2017/2018
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Western University: Teaching Assistant, September – December 2016
• Foundations of Mental Health, HS4620F: Supervisor – Louis Charland, PhD
• Population Health Interventions, HS4250A: Supervisor – Jean Samuel, PhD
Self-Employed: Private Tutor, April – June 2014
Brescia University College: Course Assistant, October 2013 – April 2014
• Clinical Nutrition 1, FN3351A and Nutrition Through the Human Life Cycle, FN2242:
Supervisors – Colleen O’Connor, PhD, RD and Janet Madill, PhD, RD

Peer-Reviewed Publications
1. Horne J, Gilliland J, Madill J, Shelley J. A critical examination of legal and ethical
considerations of nutrigenetic testing with recommendations for improving regulation in
Canada: From science to consumer. Journal of Law and the Biosciences. 2020 [in press].
2. Horne J. Are we losing sight of the true meaning of “evidence-based nutrition?” International
Journal of Public Health. 2020 [in press].
3. Guest NS, Horne J, Vanderhout S, El-Sohemy A. Sport nutrigenomics: Personalized nutrition
for athletic performance. Frontiers in Nutrition. 2019;6:8.
4. Toth J, O'Connor C, Hartman B, Dworatzek P, Horne J. "Detoxify or Die": Qualitative
assessments of Ontario nutritionists' and dietitians' blog posts related to detoxification diets.
Canadian Journal of Dietetic Practice and Research. 2019;1-6.
5. Horne J, Gilliland J, O’Connor C, Seabrook J, Hannaberg P, Madill J. Study Protocol of a
pragmatic randomized controlled trial incorporated into the Group Lifestyle Balance™ Program:
The Nutrigenomics, Overweight/Obesity and Weight Management Trial (The NOW Trial). BMC
Public Health. 2019;19(1):310.
6. Horne J, Madill J, O ’Connor C, Shelley J, Gilliland J. A Systematic Review of Genetic Testing
and Lifestyle Behaviour Change: Are We Using High-Quality Genetic Interventions and
Considering Behaviour Change Theory? Lifestyle Genomics. 2018;11(1):49-63.
7. Horne J, Madill J, Gilliland J. Incorporating the ‘Theory of Planned Behaviour’ into
personalized healthcare behavior change research: a call to action. Personalized Medicine.
2017;14(6):521–9.
8. Rinaldi S, Horne J, Madill J. An evolving understanding of modifiable risk factors for posttransplant mortality. [Letter to the Editor] Transplant International. 2017;30(5): 533-534.
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9. Horne J, O’Connor C, Madill J, Rinaldi S, Gilliland J. Re: Polymorphisms of three genes (ACE,
AGT andCYP11B2) in the renin-angiotensin-aldosterone system are not associated with blood
pressure salt sensitivity: A systematic meta-analysis. [Letter to the Editor] Blood Pressure.
2016;26(4): 255-256.
10. Horne J, Madill J, O’Connor C. Exploring knowledge and attitudes of personal nutrigenomics
testing among dietetic students and its value as a component of dietetic education and
practice. Canadian Journal of Clinical Nutrition. 2016;4(1): 50-62.

Abstracts and Poster Presentations
1. Horne J, Gilliland J, Seabrook J, O’Connor C, Madill J. Change in weight, BMI, and body
composition after 3, 6, and 12 months in a population-based intervention vs. genetic-based
intervention: Results from the NOW randomized controlled trial. ASPEN Nutrition Science and
Practice Conference. Tampa, United States. March 29, 2019 (Top Scoring Abstract).
[International]
2. Horne J, Gilliland J, Seabrook J, O’Connor C, Madill J. Exploring the Canadian general public’s
attitudes towards genetic-based lifestyle advice for weight management: Results from the
NOW randomized controlled trial. ASPEN Nutrition Science and Practice Conference. Tampa,
United States. March 30, 2019. [International]
3. Horne J, Gilliland J, Seabrook J, O’Connor C, Madill J. Genetic-based lifestyle information and
recommendations are superior to population-based guidelines for improving body composition
after 3-month follow-up: Results from the NOW trial. European Conference on Personalized
Nutrition and Health. Wageningen, Netherlands. October 8, 2019. [International]
4. Horne J, Gilliland J, Seabrook J, O’Connor C, Madill J. Exploring the Canadian general public’s
attitudes towards genetic-based lifestyle advice for weight management: Results from the
NOW randomized controlled trial. European Conference on Personalized Nutrition and
Health. Wageningen, Netherlands. October 8, 2019. [International]
5. Horne J, Gilliland J, Seabrook J, O’Connor C, Madill J. Genetic-based lifestyle information and
recommendations are superior to population-based guidelines for improving body composition
after 3-month follow-up: Results from the NOW trial. Canadian Nutrition Society Annual
Conference. May 3-4, 2019 (Poster Competition Finalist). [National]
6. Veloce D, Fisher M, O’Connor C, Hartman B, Horne J. Does the Ontario public understand the
difference between registered dietitians and nutritionists? A cross-sectional mixed methods
study assessing public awareness and experiences with different nutrition providers. Canadian
Nutrition Society Annual Conference. May 3-4, 2019. [National]
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7. Hannaberg P, Horne J, Rinaldi S, Gilliland J, Madill J. Phase angle and malnutrition in Canadian
community-dwelling adults: Preliminary results. Dietitians of Canada National Conference.
Vancouver, BC. June 8, 2018. [National]
8. Rinaldi S, Kurowski C, Horne J, Hannaberg P, Brown C, Mura M, Mehta S, Madill J. Vitamin D
intake and status in three patient populations: Interstitial lung disease, pulmonary hypertension
and patients participating in the Group Lifestyle Balance™ weight management program. ASPEN
2018: Nutrition Science & Practice Conference. 2018:53-4. [International]
9. Horne J, Madill J, O’Connor C. Nutrigenomics: An evident need for education in the field of
dietetics. Canadian Journal of Dietetic Practice and Research. 2015;76(3):9. [Oral Presentation
by O’Connor C; National]
10. Horne J, Madill J, O’Connor C. Exploring knowledge and attitudes of personal nutrigenomics
testing among dietetic students and its value as a component of dietetic education and
practice. Journal of Parenteral and Enteral Nutrition. 2015:95. ASPEN’s Clinical Nutrition Week,
Long Beach, United States. [International]

Conference Presentations
Horne J. Change in weight, BMI, and body composition after 3, 6, and 12 months in a
population-based intervention vs. genetic-based intervention: Results from the NOW
randomized controlled trial. ASPEN Nutrition Science and Practice Conference. Tampa, United
States. March 29, 2019. [Oral Presentation]
Horne J. Nutritional genomics: Where are we now and where do we go from here? Hamilton
Health Sciences Annual Dietetics Meeting. Hamilton, Canada. June 11, 2019 [Invited Keynote]
Horne J and El-Sohemy A. Are we ready for nutritional genomics in clinical practice? Canadian
Nutrition Society Annual Conference. Niagara Falls, Canada. May 4, 2019 [Invited Talk]
Horne J and Buccino J. Finding your advocacy passion and taking the first step. Dietitians of
Canada: Ontario RD Networking Meeting. London, Canada. October 10, 2019 [Invited Keynote]
Caulfield T, El-Sohemy A, Horne J, MacKay D. Debate forum - Are we ready for personalized
nutrition? International Society of Nutrigenetics and Nutrigenomics Annual Meeting, Winnipeg,
Canada. October 3, 2018 [Invited Talk]
Horne J. Lifestyle genomics testing for obesity management in Canada: A critical review with
implications for policy and legislation. Canadian Obesity Network: Student Meeting, London,
Canada. June 22, 2018 [Oral Presentation]
Horne J. Nutrigenomics, behaviour change and The NOW Trial. Dietitians of Canada FHT
Registered Dietitians and Primary Care Conference, Barrie, Canada. September 28, 2017
[Invited Talk]
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Community Outreach (Oral Presentations)
Horne J. The NOW Trial Results. East Elgin Family Health Team Physician and Healthcare
Professionals Meeting. Aylmer, Canada. February 13, 2020
Horne J. The NOW Trial Results. East Elgin Family Health Team Patients Meeting. Aylmer,
Canada. February 13, 2020
Horne J. Nutrigenomics and the NOW Trial. SW Regional Diabetes Educators’ Meeting. London,
ON. June 7, 2019. [Keynote]
Veloce D, Buccino J, Sauvé A, Horne J. Protect “Nutritionist.” Protect “Registered.” Protect the
Public. College of Dietitians of Ontario. Toronto, Canada. October 26, 2018.
Horne J. Nutrigenomics, Behaviour Change and The Nutrigenomics, Overweight/Obesity and
Weight Management Trial. London Primary Care Dietitians' Meeting. London, Canada.
December 7, 2017.
Horne J. The Group Lifestyle Balance Program and The Nutrigenomics, Overweight/Obesity and
Weight Management Trial. Thames Valley FHT Quarterly Meeting. Canada. November 24, 2017.
Horne J and Madill J. The Nutrigenomics, Overweight/Obesity and Weight Management Trial.
Canadian Society of Transplantation: Patient Meeting. Toronto, Canada. April 8, 2017.
Horne J. Nutrigenomics and Personalized Nutrition. Southwestern Ontario Regional Dietitians’
Meeting. Woolwich, Canada. May 6, 2016.
Horne J. The Science of Nutrigenomics. RD Appreciation Day. Stratford, Canada. April 13, 2016.

Other Publications
Horne J. Nutrigenomics and weight management. Dietitians in Integrative and Functional
Medicine Newsletter (Academy of Nutrition and Dietetics). Invited.
Horne J and O’Connor C. The truth about detox diets [guest blog post]. Weighty Matters Blog
(Yoni Freedhoff). [2019]. Invited.
Horne J. Nutritional genomics: Genetic testing for personalized nutrition. Nutrition Nibbles
(Hamilton Family Health Team). [2019]. Invited.
Horne J. What RDs Do. Something Nutrishus Blog. [2017]. Available from:
http://nutrishus.blogspot.com/2017/04/what-rds-do-justine-horne-msc-rd-phd.html
Horne J and Cianfrini L. Integrating nutrigenomics into undergraduate dietetic education.
Dietetic Educators’ Network Newsletter (Dietitians of Canada). 2013. Invited.
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Affiliations/Memberships
•
•
•
•
•

Canadian Nutrition Society: 2018 – present
Dietitians of Canada: 2013-2016, 2018 - present
Ontario Respiratory Care Society: 2017 – present
College of Dietitians of Ontario: 2015 – present
Collegiate and Professional Sports Dietitians’ Association: 2016 – 2017

Academic Conference Attendance
•
•
•
•
•
•
•
•
•
•
•
•

ASPEN Nutrition Science and Practice Conference, Tampa, United States: March 2020
European Conference on Personalized Nutrition and Health, Wageningen, Netherlands:
October 2019
Canadian Society of Nutrition Annual Conference, Niagara, Canada: May 2019
International Society for Nutrigenetics and Nutrigenomics, Winnipeg, Canada:
September 2018
Canadian Obesity Network: Student Meeting, London, Canada: May 2018
Association of Family Health Teams of Ontario Conference, Toronto, Canada: October
2017
Dietitians of Canada Family Health Team and Primary Care RD Conference, Barrie,
Canada: September 2017
Low German Mennonite Networking Conference, Aylmer, Canada: May 2017
Canadian Nutrition Society: Advances in Nutrition, Gut Health and the Microbiome,
Toronto, Canada: January 2017
Food and Nutrition Conference and Expo (Exhibitor), Nashville, United States:
September 2015
Canadian Association of Nephrology Dietitians National Meeting, Toronto, Canada:
September 2015
APSEN’s Clinical Nutrition Week, Long Beach, United States: February 2015

Other Professional Development Activities
•
•
•
•
•
•

Speaker, Dietitians of Canada Webinar, Nutrigenomics: Impact on Weight and Body
Composition, 2020
Intuitive Eating PRO Skills Training Course, 2019
Speaker, Dietitians of Canada Learning on Demand course: The NOW Trial:
Nutrigenomics, Overweight/Obesity and Weight Management, 2017
Diabetes Prevention Program training, March 2017
ASPEN pre-conference course: ‘Taste Signaling – Impact on Food Selection, Intake, and
Health,’ February 2015
Dietitians of Canada online courses completed:
234

•
•
•

o Critical Care Nutrition, 2015
o Population and Public Health Needs Assessment, 2014
o Herbal Supplements, 2013
o World Health Organization Growth Charts, 2012
Crisis Prevention Institute’s non-violent crisis intervention training, 2014
Bridges Out of Poverty training, 2014
Hope’s Garden Eating Disorders Awareness Breakfast attendee, 2014

Journal Article Reviews
•
•
•
•
•
•

BMJ Open, 2020: Number of works reviewed/refereed: 1
Medicine, 2019: Number of works reviewed/refereed: 1
Lifestyle Genomics, 2018, 2019: Number of works reviewed/refereed: 3
PLoS One, 2018: Number of works reviewed/refereed: 1
Nutrition and Health, 2017, 2019: Number of works reviewed/refereed: 2
Annals of Behavioural Medicine, 2017: Number of works reviewed/refereed: 1
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